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Acute Graft-versus-Host Disease (aGvHD) is a severe complication of 
allogeneic hematopoietic stem cell transplantation, which is induced by donor T 
cells that become stimulated after recognizing recipient proteins as foreign. 
Glucocorticoids (GCs) are the standard first-line therapy of aGvHD due to their 
strong immunosuppressive effects mediated via the ubiquitously expressed 
glucocorticoid receptor (GR). While GC therapy is believed to mainly target T 
cells, our results show that radioresistant recipient myeloid cells are also crucial. 
This was demonstrated by using genetically engineered mice lacking the GR in 
myeloid cells and thus being refractory to GCs. These GRlysM mice were unable 
to limit systemic cytokine secretion during aGvHD leading to a premature death 
of the mice. Considering the importance of myeloid cells, we tested the potential 
of a targeted delivery of GCs to this cell type by using inorganic-organic hybrid 
nanoparticles (IOH-NPs). Our results demonstrate that IOH-NPs were 
preferentially taken up by macrophages, internalized via macropinocytosis, and 
localized to the lysosomal compartment. Magnetic resonance imaging and 
analysis by Inductive Coupled Plasma-Mass Spectrometry further revealed that 
IOH-NPs were rapidly cleared from the peritoneal cavity after intraperitoneal 
injection in mice and thereafter accumulated in abdominal organs. When we 
induced aGvHD in mice and treated them with IOH-NPs containing the GC 
betamethasone (BMP-NPs), the disease was ameliorated to a similar extent as 
by the free drug by limiting tissue destruction in the jejunum. The therapeutic 
effects were abrogated when GRlysM mice were treated with BMP-NPs, 
confirming that this nanoformulation mainly acted via macrophages in vivo. 
Nevertheless, BMP-NPs employed partially different mechanisms and reduced 
the local production of pro-inflammatory cytokines in the first place. Further in 
vivo analyses revealed that despite their cell type specificity, typical metabolic 
side-effects of GCs in muscle, liver and bone could not be circumvent by the 
use of IOH-NPs. Collectively, this work reveals an important role of myeloid 
cells as targets of GC therapy of aGvHD and suggest that specifically targeting 
these cells might improve certain aspects of this therapeutic regimen. 
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1.1 Hematopoietic stem cell transplantation  
Bone marrow transplantation (BMT), or more precisely, hematopoietic stem cell 
transplantation (HSCT) is most often the only promising therapeutic option for 
patients suffering from malignant or non-malignant hematological diseases 
(Blazar and Murphy, 2005). The first global survey on first HSCTs was 
conducted over a three-year period from 2006 to 2008 by the European Group 
for Blood and Marrow Transplantation (EBMT) Transplant Activity Survey 
Office. About 50.000 patients were transplanted annually and the main 
indications were 53 % lymphoproliferative disorders (lymphoma, plasma cell 
disorders), 36 % leukemia (acute, chronic and myelodysplastic syndrome/ 
myeloproliferative syndrome), 5 % solid tumors and 6 % non-malignant 
diseases such as sickle cell anemia (Gratwohl et al., 2013). HSCTs are 
subdivided by the origin of the stem cell transplant. Within the survey about     
55 % of the patients received their own stem cells (autologous conditions) 
whereas about 45 % of the patients received stem cells from a family member 
or an unrelated donor (allogeneic condition). Both forms have unique 
advantages. The allogeneic form is for example indicated when the patient 
suffers from a genetically based disease such as Fanconi anemia, affecting the 
red blood cells. The disadvantage is that patients need long-term 
immunosuppressive drugs, whereas in the autologous form such complications 
are avoided. In both HSCT forms, before receiving stem cells, patients are 
treated with chemotherapy and/ or radiation (conditioning regime). This is 
inevitable to destroy or at least minimize unwanted cancer cells, prevent bone 
marrow transplantation failure and, in allogeneic transplantation, induce 
immunosuppression that permits engraftment (Copelan, 2006, Nelson et al., 
2008). In 1968, the first successful allogeneic stem cell transplantation was 
carried out with BM cells as the source for hematopoietic stem cells. Over the 
next decades two further sources have been added. First, stem cells are 
stimulated by granulocyte colony stimulating factor (G-CSF) and are mobilized 
in the peripheral blood, referred to as peripheral blood stem cells (PBMCs). 




for allogeneic HSCT whereas it is no source for the autologous transplantation 
form. However, transplant physicians have three optional sources to choose 
from for allogeneic transplantations and have to consider the risks and benefits 
associated with each stem cell source. For example, PBMCs and CB contain 
fewer red blood cells compared to BM. It is therefore favored by a mismatch in 
blood groups between donor and recipient preventing hemolysis. Also a factor 
to consider is the number of mature T cells. Most mature T cells are found in 
PBMCs, with lower numbers in BM and CB. Higher numbers of T cells increase 
the risk of developing Graft-versus-Host Disease (GvHD), which is considered 
as the main source of transplant-related morbidity and mortality. Contrariwise, 
lower numbers of T cells increase the risk of a relapse in cases of malignant 
diseases (Cheuk, 2013). Further factors such as overall health status of the 
patient, its age and the planned conditioning regime also influence the success 
of transplantation. This shows that despite intensive research over decades, the 
medical decision-making process for the transplant procedure remains complex 
and problematic (Okamoto, 2017).  
 
1.2 Graft-versus-Host Disease 
Since the 1940s, experiments were performed that contribute to our current 
understanding of the complex pathophysiology of GvHD (Boieri et al., 2016). In 
1957, Simonson performed allogeneic transplantations in chickens by injecting 
adult splenocytes and blood cells into embryos. The recipients suffered from 
hemolytic anemia and splenomegaly. Simonson concluded that this result was 
ascribable to the adult immunologically competent cells of the donor as the 
recipient embryo has no sufficiently mature immune system as of yet to explain 
the results (Simonsen, 1957). In 1958, Billingham and Brent injected allogeneic 
adult lymphoid mouse tissue into newborn mice resulting in similar symptoms 
as ones observed in the chickens embryos before, namely an early death and 
growth retardation. They also concluded that it was a result of a GvH reaction 
(Billingham, 1958). Further BMT experiments of other researchers at the time 
confirmed the reaction of donor immune cells against the recipient and finally 
the cause of GvHD was revealed, even though not in its complexity (Egdahl et 




In 1966, Billingham outlined the key requirements of GvHD in his historic 
Harvey Lecture and this hypothesis is still valid. First, the graft must contain a 
sufficient amount of immunocompetent cells, by now known as donor T cells. 
Second, the host needs to express antigens, mostly unmatched major 
histocompatibility complex (MHC) class I and II molecules and polymorphic 
proteins, which are recognized as foreign by the donor cells, which hereby 
become stimulated. Third, the recipient is incapable to generate a sufficiently 
strong immune response to eliminate the transplanted cells (Billingham, 1966). 
Upon identification and typing of the human leucocyte antigen (HLA), which 
encodes the highly polymorphic MHC to which donor T cells mostly respond, 
allogeneic transplantation became feasible in the early 1960s (Copelan, 2006). 
The HLA is located on the short arm of chromosome 6 (p21) and inherited as 
haplotypes (Ball et al., 2008). HLA matching between donor and recipient is the 
most important factor in preventing GvHD (Kanda, 2013). The HLA loci A, B, C 
encode for MHC I proteins expressed on virtually all cell types, whereas the 
HLA loci, DR, DQ and DP encode for MHC II proteins expressed primarily on 
antigen presenting cells (APCs) (Teshima et al., 2002). Matches in HLA-A, B, C 
and HLA-DRB1 alleles are most preferable (Kanda, 2013), but besides focusing 
only on the HLA alleles themselves, disparities in their linked HLA region also 
correlates with the occurrence of GvHD (Morishima et al., 2016). Furthermore, 
genetic differences outside of the HLA loci, concerning the "minor" 
histocompatibility antigens (miHAs), increase the risk of GvHD as well. miHAs 
are polymorphic peptides, encoded by a wide range of genes. They derive from 
intracellular proteins, which are presented by MHC molecules to donor T cells, 
mostly MHC I (Ferrara et al., 2009). About 50 miHAs have been identified so 
far. HA-1 and HA-2 were the first ones to be described and mismatches 
between donor and recipient in these genes increases the risk of GvHD 
(Ghimire et al., 2017). Unlike MHC I and II, miHAs can differ in their tissue 
expression pattern among individuals (Shlomchik, 2007). Further risk factors for 
developing GvHD are gender disparities during transplantation, an increased 
age of both donor and recipient, an ineffective GvHD prophylaxis, the intensity 
of the conditioning regime (Nassereddine et al., 2017) and a low variety of the 




 Clinical features of GvHD 1.2.1
Clinically, GvHD occurs in two forms, the acute and the chronic form. 
Historically, both forms were defined by the time point of their onset. According 
to this definition, acute GvHD (aGvHD) occurs within the first 100 days post 
BMT and chronic GvHD (cGvHD) occurs only thereafter. Nowadays, it is 
acknowledged that this definition is inadequate, as both forms have their own 
pathophysiological entities, involved target organs and therapeutic management 
(Anderson et al., 2005, Blazar and Murphy, 2005). There are overlapping forms 
and the most important risk factor of cGvHD is aGvHD, as well as its treatment. 
In both forms, donor T cells play a central role in the immunologic attack of the 
host tissues. However, cGvHD has more diverse manifestations as aGvHD and 
shares characteristics with autoimmune diseases. It is dominated by Th2 cells 
and results, in most patients, in the generation of autoreactive T cells and a 
dysregulation of B cells followed by autoantibody production. It affects the skin, 
soft tissue, oral mucosa and sometimes the liver (Ratanatharathorn et al., 2001, 
Szyska and Na, 2016). In contrast, aGvHD is dominated by Th1 cells and 
affects the skin, the gastrointestinal (GI) tract and the liver, although other sites 
might be affected, too. Skin is the organ, which most often shows the first 
symptoms. Maculopapular rash usually starts at palms and soles but can 
spread throughout the whole body, in severe cases blisters can occur. Clinical 
manifestations in the GI tract are diarrhea, in severe cases it becomes bloody 
and is accompanied by cramping, vomiting, abdominal pain and failure to thrive. 
Jaundice, a consequence of hyperbilirubinemia, is characteristic for liver 
involvement (Jacobsohn and Vogelsang, 2007, Zeiser and Blazar, 2017, 
Salomao et al., 2016). aGvHD can be graded into four stages (I - IV, I mild,      
IV severe) based on the number, stage and degree of involvement of the three 
organs according to a staging system from 1994. This system subdivides 
patients into risk categories for complications and mortality (Przepiorka et al., 
1995). Patients with aGvHD of grade III - IV have a high mortality rate, with     
25 % of grade III and 5 % of grade IV long-term survival (Ferrara et al., 2009). 
In general, aGvHD affects about 10 - 80 % of the patients, depending on a 




the overall success of allogeneic HSCT after relapse (Garnett et al., 2013, 
Nassereddine et al., 2017).  
 
 Pathophysiology of aGvHD 1.2.2
The pathophysiology of aGvHD is much better understood in comparison to 





Figure 1: Pathophysiology of aGvHD. Modified from (Ferrara et al., 2009). The establishment 
of aGvHD occurs in three phases. 1) Activation of host tissues, including antigen presenting 
cells, by the conditioning regime. 2) Activation, proliferation, differentiation of donor T cells by 




The first phase, the so-called "priming phase" occurs even before donor cells 
are infused into the host. The underlying disease, treatment, infections and the 
conditioning regimen induce local inflammation due to their toxic effects causing 
damage to the host tissues (Jaksch and Mattsson, 2005). Subsequently, host 
tissue cells release danger-associated-molecular-patterns (DAMPs) (Blazar et 
al., 2012), which includes the secretion of pro-inflammatory cytokines such as 
2) Donor  
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      activation 
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tumor necrosis factor (TNF) α, Interleukin 6 (IL-6) and IL-1 and biological 
mediators such as nitric oxide (NO). Consequently, APCs are activated and 
excessively contribute to the "cytokine storm" (Ghimire et al., 2017). Of 
particular importance in this process is the injury to the intestinal mucosa and 
epithelium since bacterial endotoxins such as lipopolysaccharides (LPS) are 
consequently translocated from the lumen into the circulation. The release of 
pathogen-associated-molecular-patterns (PAMPs) greatly amplify the activation 
of APCs, which in turn upregulate the expression of MHC (Socie and Blazar, 
2009) and co-stimulatory molecules such as CD80 and CD86 forming an 
immunological synapse with the T cell receptor and CD28 on T cells leading to 
their activation. GvHD is entirely dependent on these crucial co-stimulatory 
molecules (Anderson et al., 2005). Since the conditioning regime boosts host 
APC activation, a reduced or even non-myeloablative regime as well as a 
delayed transfer of the graft contributes to the development of a less severe 
aGvHD (Johnson and Truitt, 1995, Perez-Simon et al., 2005).  
 
The second phase "donor T cell activation and expansion" is the core event of 
aGvHD. The danger signals, secreted in the first phase, lead to an increased 
expression of co-stimulatory molecules, such as CD28 by donor T cells making 
them susceptible for their activation (Ferrara, 1993). CD4+ T cells respond to 
disparities in MHC II molecules, whereas CD8+ T cells respond to differences in 
MHC I molecules between donor and recipient. Both T cell subsets can respond 
to miHAs differences (Sprent et al., 1988). Donor and recipient APCs trigger the 
activation, proliferation and differentiation of donor-derived T cells, which 
provoke the secretion of a Th1 dominated pro-inflammatory cytokine profile 
including IL-2, interferon (IFN)γ and TNFα (Ball et al., 2008). T cells are also 
crucial for the graft versus leukemia (GvL) effect. If malignant stem cells in the 
recipient survive the conditioning regime the patient might experience a relapse, 
unless such cells are eliminated by the activated donor T cells (Copelan, 2006). 
 
The third phase is the "T cell trafficking and effector phase". The alloreactive 
effector T cells migrate to target tissues in response to chemokines and their 




killer (NK) cells induce further tissue destruction by lysing cells via the Fas/FasL 
and perforin/granzyme pathways. LPS intensively leaks through the intestinal 
epithelium stimulating further cytokine secretion (Ghimire et al., 2017). The 
complex cascade of multiple cellular and inflammatory effectors leads to an 
escalation and the clinical end-organ-pathology manifestation (Nassereddine et 
al., 2017). Recent advances in research have further improved our 
understanding of the contributions of other innate and adaptive immune cells to 
the pathogenesis of aGvHD (Blazar et al., 2012).  
 
 The role of APCs in aGvHD 1.2.3
Hematopoietic cells, such as professional APCs, as well as non-hematopoietic 
cells, such as endothelial cells, are capable of participating or even initiating 
aGvHD by antigen presentation, although not with the same efficiency. 
Professional APCs predominantly comprise B cells, dendritic cells (DCs) and 
macrophages. They are highly efficient in loading peptides on MHC molecules 
and presenting them, together with crucial co-stimulatory molecules, to T cells. 
Naïve B cells circulate between the blood stream and secondary lymphoid 
organs, but their role in aGvHD is still unclear. In mouse models, they have 
been shown to reduce aGvHD due to the secretion of the anti-inflammatory    
IL-10 induced by the conditioning regime (Rowe et al., 2006). Circulating 
monocytes have a half-life of three days and can differentiate into DCs and 
macrophages. They are actively recruited to the side of inflammations, where 
they replenish the pool of tissue resident macrophages and DCs (Yang et al., 
2014). In contrast to macrophages, DCs present antigens in secondary 
lymphoid organs that have been taken up in peripheral tissues. Donor T cells 
can recognize and react to alloantigens either via direct antigen presentation on 
host APCs or via indirect presentation, so called cross-presentation, on donor 
APCs (Ghimire et al., 2017). In general, studies in BMT experimental mouse 
models have shown, that donor APCs intensify the disease at later stages 
(Matte et al., 2004). Host APCs though are essential to prime donor T cells and 
thus are involved in initiating aGvHD and the recruitment as well as priming of 
CTL during the effector phase in the target tissue including their GvL activity 




non-hematopoietic cells are insufficient in doing so (Shlomchik et al., 1999). In 
agreement with this notion, the local depletion of host DCs and macrophages, 
by the application of liposomal clodronate to mice, ameliorated aGvHD and 
prolonged the survival of the animals (Zhang et al., 2002b). The majority of host 
APCs and precursor populations are lost due to the conditioning regime within a 
few days. The loss is compensated by differentiated and progenitor stem cells 
derived from the graft. Nevertheless, resident macrophages of the recipient and 
skin DCs (dermal DCs and epithelial Langerhans cells) survive this regime, 
creating a chimeric APC repertoire. They persist in patients for many months 
after BMT and contribute to the long conserving risk of developing aGvHD 
(Haniffa et al., 2009). A small fraction of host CD11+ DCs survive too, but only 
for a few days. However, this is already enough to contribute to the priming of 
donor T cells (Zhang et al., 2002a). Resident macrophages stay, among many 
other locations, in secondary lymphoid tissues of the recipients. Here, they 
encounter the freshly transferred naïve T cells. Consequently, T cells intensively 
proliferate in lymph nodes, spleen and Peyer´s patches, and 3 to 4 days later 
they enter the blood stream and migrate to the target tissues (Chakraverty and 
Sykes, 2007). For many years, the dogma persisted that host macrophages and 
DCs harm the patient in terms of aGvHD due to their pro-inflammatory immune 
reaction in this setting (Hill et al., 1997). While this is true for host DCs, 
increased numbers of surviving host macrophages, induced by pre-transplant 
CSF-1 therapy, reduce the donor T cell pool and thereby positively influence the 
development of aGvHD (Duffner et al., 2004, Hashimoto et al., 2011). 
 
 The role of T cells in aGvHD 1.2.4
T cells are the major inducer of aGvHD and the beneficial GvL effect. Both 
processes are caused by similar mechanisms and are therefore hardly 
separated. Initially, the role of T cells became evident when mice received BM 
cells, in which donor T cells were specifically reduced or even removed, 
revealing that the amount of T cells correlated with aGvHD severity (Korngold 
and Sprent, 1978) and mortality, due to infections and relapse (Horowitz et al., 
1990, Wagner et al., 2005). However, the specific role of each T cell subset in 




exists in human and mice. Their activation and subsequent differentiation, as 
well as their fate, depends on various factors, such as the cytokine 
microenvironment and the priming by APCs, which is dependent on the type 
and degree of MHC or miHA compatibility. In MHC mismatch mouse models, 
CD4+ and CD8+ T cells can cause aGvHD (Korngold and Sprent, 1987). In                
miHA-mismatch models, CD4+ cells alone are sufficient for aGvHD and can 
boost alloreactive CD8+ cells (van Dijk et al., 1999).  
 
Different CD4+ subsets have been shown to be specifically involved in the 
pathogenesis of the affected organs. For example, Th1 cells dominate in the GI 
tract, whereas Th17 cells are found in the skin (Burman et al., 2007, Iclozan et 
al., 2010). Preventing the differentiation of naïve Th cells into these subsets 
thus ameliorated aGvHD in an MHC mismatch mouse model (Yu et al., 2011). 
In line with this study, transferring IL-17 deficient CD4+ T cells in an allogeneic 
mouse BMT model delayed, but did not improve aGvHD mortality and reduced 
the number of Th1 cells in the early phase of the disease. Additionally,          
pro-inflammatory cytokine production, such as IFNγ, was reduced (Kappel et 
al., 2009). Another study showed that adoptive transfer of in vitro differentiated 
Th17 cells leads to lethal aGvHD (Carlson et al., 2009). In contrast, the absence 
of Th17 cells in the graft was associated with an increased Th1 differentiation 
and infiltration (Yi et al., 2008). Although Th17 cells have been associated with 
aGvHD, they appear more important for cGvHD (Carlson et al., 2009). Th1 
cells, with their characteristic pro-inflammatory cytokine profile, are believed to 
be the main trigger of aGvHD and are associated with an earlier onset and a 
more severe disease course (Hill et al., 1997, Hill and Ferrara, 2000). 
Nevertheless, Th2 cells play also a role in the pathology, as well as in the 
prevention, of aGvHD (Nikolic et al., 2000, Fowler et al., 1994).  
 
Cytotoxic CD8+ T cells are also well-known to contribute to the tissue 
destruction in aGvHD by inducing apoptosis via the perforin/granzyme or 
Fas/FasL pathway. Braun et al. transferred T cells deficient for both lytic 
mediator pathways in an MHC mismatch mouse model and recipient mice 




when T cells, deficient for one lytic mediator, were transferred for disease 
induction, while protection from lethal aGvHD was mainly perforin dependent 
(Braun et al., 1996). Graubert et al. showed that the perforin/granzyme 
dependent mechanism was important in an MHC I restricted acute murine 
aGvHD model while the Fas/FasL dependent mechanism was rather crucial in 
an MHC II restricted acute murine aGvHD model (Graubert et al., 1997). In 
contrast, Maeda et al. found that CD8+ cells deficient for both pathways still 
induced aGvHD in a MHC I mismatch mouse model (Maeda et al., 2005). In line 
with the importance of T cells in aGvHD, blocking of co-stimulatory signals 
diminished their expansion and reduced aGvHD. Namely, application of       
anti-CD80 and anti-CD86 monoclonal antibodies prevented aGvHD lethality 
(Blazar et al., 1996). Regulatory T cells (Tregs) play a critical role in establishing 
tolerance against self-antigens, a feature which is beneficial in aGvHD, 
demonstrated in experimental mouse models. When Tregs, naturally present in 
the graft, were removed, the disease was accelerated. Conversely, the 
enrichment of the graft with freshly isolated Tregs, delayed aGvHD (Cohen et 
al., 2002). Moreover, infusion of clinical-grade-enriched Tregs from human 
PBMCs stem cells into mice (xenogeneic GvHD) resulted in delayed death. 
Mice which were given only Tregs experienced no clinical signs of GvHD 
(Hannon et al., 2014). In conclusion, the interaction between the various 
subsets of T cells and the individual microenvironment in patients determines 
the pathology of aGvHD. 
 
 Cytokines involved in aGvHD 1.2.5
An important factor determining the course and severity of aGvHD are cytokines 
secreted by immune cells and other cell types during the disease. They 
determine the phenotype of naïve T cells and macrophages, two crucial cell 
types in the context of aGvHD. The pro-inflammatory milieu, triggered by the 
conditioning-induced tissue damages, activates immune cells and thereby leads 
to cytokine secretion, which has a pivotal negative impact on aGvHD (Mapara 
et al., 2006). Key cytokines of Th1 cells are IL-2, IFNγ and TNFα, and their 
differentiation is initiated by IL-12, which is secreted by APCs (Hill and Ferrara, 




mouse models prevented acute as well as chronic GvHD. While the application 
of anti-IL-12 antibodies prevented Th1-mediated aGvHD by down regulation of 
IFNγ, it shifted the alloresponse towards a Th2 phenotype characterized by a 
cytokine profile, dominated by IL-4, IL-5 and IL-10 with mild cGvHD symptoms 
(Williamson et al., 1997).  
 
The role of the Th1 associated IFNγ cytokine is poorly understood and 
paradoxical, because it has multiple functions, either amplifying or reducing 
aGvHD (Jaksch and Mattsson, 2005). It activates macrophages, NK cells and 
cytotoxic CD8+ T cells, and promotes Th1 differentiation, thereby contributing to 
aGvHD (Wang et al., 2009, Hill and Ferrara, 2000). Furthermore, it causes a 
direct damage to the epithelium within the GI tract (Burman et al., 2007). 
Contrariwise, it protects against IL-12 and IL-18, both of which stimulate Th1 
differentiation (Yang et al., 1998, Lu and Waller, 2009). In addition, IFNγ inhibits 
proliferation and induces cell death of activated alloreactive donor T cells, 
thereby being beneficial in aGvHD (Asavaroengchai et al., 2007). A similar 
complex effect, as seen for IFNγ, has been noted for IL-2. It is currently a 
clinical target in aGvHD as it supports Th cell and CTL expansion, although it is 
also necessary to generate Tregs that are beneficial in aGvHD (Ball et al., 2008, 
Shin et al., 2011, Via and Finkelman, 1993). Höfer et al. suggested that IL-2 
acts in a dose-dependent manner, which can be explained by a competition for 
this cytokine by Tregs and T effector cells (Hofer et al., 2012). This is prevented 
when low-dose IL-2 is applied together with rapamycin, which selectively targets 
T effector cells by blocking the mTOR signaling pathway and thereby prevents 
their expansion. Since Tregs use other signaling pathways, they are able to 
consume IL-2 for their expansion (Shin et al., 2011).  
 
High levels of TNFα have been shown to correlate with the occurrence and a 
poor outcome of aGvHD (Holler et al., 1990). Specifically, TNFα have been 
shown to be toxic to the GI tract. Intensification of the conditioning regime 
increased gut damage, allowing for an increased translocation of LPS into the 
systemic circulation (Hill et al., 1997). LPS as well as IFNγ are potent 




et al., 1992). TNFα triggers the expression of adhesion molecules on the 
vascular epithelium. This enables T cells and other leucocytes to enter target 
organs and directly contributes to the tissue damage by inducing apoptosis as 
well as necrosis (Pober, 1987). Since TNFα is involved in all three steps of the 
pathogenesis of aGvHD, it is an important target for the prevention and 
treatment of this disease (Korngold et al., 2003).  
 
Elevated IL-6 serum levels in patients have been associated with aGvHD 
(Symington et al., 1992). Furthermore, IL-6 polymorphisms in recipients of   
HLA-matched sibling transplants has been linked to altered in vitro and in vivo 
IL-6 production and consequently to acute and cGvHD (Cavet et al., 2001). IL-6 
has pleiotropic biological functions and is produced by various cell types 
including monocytes, macrophages, T cells, B cells and endothelial cells 
(Nishimoto and Kishimoto, 2006). Infusion of IL-6 aggravated the disease, while 
antibody-mediated blockade of the IL-6 receptor improved experimental aGvHD 
and prevented the GvL effect (Givon et al., 1994, Tawara et al., 2011). This was 
partially due to the increased numbers of Treg cells and the concomitantly 
reduced numbers of Th1 and Th17 cells in aGvHD target organs (Chen et al., 
2009).  
 
Besides cytokines, multiple chemokines are produced as a consequence to the 
stimuli from the conditioning regime and host/ donor cell activation orchestrating 
the trafficking of crucial cells during aGvHD to secondary lymphoid organs as 
well as target organs (Castor et al., 2012). CCL-2, also known as monocyte 
chemoattractant protein-1 (MCP-1), is important for monocyte, T cell and NK 
cell attraction. It is produced by a variety of cells, including endothelial cells and 
epithelial cells but the main producers of the inflammatory chemokine CCL-2 
are monocytes and macrophages (Deshmane et al., 2009), which produce 
CCL-2 in response to inflammatory stimuli such as TNFα and IL-1 (Hildebrandt 
et al., 2004). The CC chemokine receptor 2 (CCR2), expressed on many 
hematopoietic cell types, binds to it ligand CCL-2. In murine bone BMT models, 




liver damage and improved the overall survival due to migratory defects into 
these target organs (Terwey et al., 2005).  
 
As a response, to cope with the strong inflammation during aGvHD, 
endogenous antagonistic molecules including cytokines, such as IL-10 are 
released. It is produced by monocytes, macrophages, activated T lymphocytes 
and B cells, and its action includes the inhibition of antigen-specific proliferative 
responses of T cells and the suppression of various pro-inflammatory cytokines, 
for instance IL-1β, IL-6 and TNFα (Holler et al., 2000, Min et al., 2001). In line, 
higher levels of IL-10 at the pre-transplant stage has a protective effect on 
patients undergoing allogeneic HSCT for transplant-related complications 
(Baker et al., 1999). IL-10, released by donor T cells, also accounted for a 
diminished aGvHD mortality in murine studies and administration of exogenous 
low doses of IL-10 protected mice from lethal aGvHD (Blazar et al., 1998).  
 
1.3 Current therapies of aGvHD 
The complex mechanisms leading to GvHD and GvL can hardly be separated. 
The challenge of GvHD prophylaxis and treatment is to successfully prevent the 
disease, while retaining the GvL effect and avoiding infectious complications 
and a relapse. Given that aGvHD is a multifaceted disease, standardized 
therapies are missing and protocols vary between clinical centers (Garnett et 
al., 2013). In the pre-transplant phase, the choice of the intensity of the 
conditioning regime dictates the therapy for the patient (Chao and Chen, 2006). 
Especially in cases with partial MHC-mismatch or non-myeloablative therapy, 
immunosuppressive drugs are already crucial in the pre-transplant phase to 
reduce the risk of GvHD (Boieri et al., 2016). Since T cells are contained in the 
stem-cell graft and assumed to be the main player in aGvHD, therapeutic 
strategies mainly focus on this cell type (Ho and Cutler, 2008). For example, 
calcineurin inhibitors, such as tacrolimus or cyclosporine target T cell activation 
and survival through the IL-2 pathway via NFAT (Chao and Chen, 2006, Zeiser 
et al., 2016). Usually calcineurin inhibitors are given in combination with 
methotrexate (MTx) as it is more effective than given alone (Storb et al., 1986). 




metabolism (Boieri et al., 2016). Calcineurin inhibitors and MTx are also given 
early after transplantation. They are gradually tapered after 100 days post 
transplantation and stopped 6 to 12 months post transplantation if the patient 
did not develop any GvHD symptoms in the meantime. Besides that, polyclonal 
antibodies, such as anti-thymocyte globulin (ATG) are commonly given in order 
to deplete T cells already in the pre-transplant phase (Chao and Chen, 2006). 
Further commonly used immunosuppressive prophylaxis are mycophenolate 
mofetil (MMF) combined with rapamycin (sirolimus). Both drugs are useful in the 
T cell-activation phase while they inhibit T cell proliferation via blocking the 
production of purines and the mTOR pathway (Svennilson, 2005, Zeiser and 
Blazar, 2017).  
 
Despite prophylaxis, aGvHD still develops in many patients and is then initially 
treated with glucocorticoids (GCs). Due to their potent anti-inflammatory effects, 
they are the golden first-line therapy form. Topical GCs are given when patients 
suffer from grade I aGvHD. Higher grades (II - IV) need administration of       
high-dose systemic application of GCs. Most centers start with a dose of                  
1 - 2 mg/kg/day prednisolone or methylprednisolone, depending on the severity, 
and increase the dose if necessary (Garnett et al., 2013, Svennilson, 2005). In a 
retrospective analysis, it turned out that only 55 % of the patients responded to 
the therapy of which 35 % showed complete remission and 20 % only a partial 
improvement of the symptoms (MacMillan et al., 2002). This analysis is 
representative as the percentage of steroid-refractory (SR-aGvHD) aGvHD 
patients varies between 50 and 70 % (Deeg, 2007, Garnett et al., 2013).       
SR-aGvHD is a serious problem and the likelihood to respond decreases with 
an increasing severity of GvHD in which mortality rates are high. For this 
reason, SR-aGvHD patients require a second-line therapy (Antin et al., 2004, 
Deeg, 2007). The most commonly applied agents are ATGs. Furthermore, 
monoclonal antibodies (mAbs) against TNFα, IL-2, or CD25 are applied. 
However, the outcome often remains unsatisfactory. Hence, GCs remain 
mandatory in the management of aGvHD even though responses rates are poor 
and unwanted side-effects occur (Antin et al., 2004, Klein, 2015, Zeiser and 





GCs, such as cortisol in humans and corticosterone in rodents, are steroid 
hormones (Reichardt and Schutz, 1998). Cortisone was discovered in the 
1930s by Edward Kendall. In 1948, adequate amounts had been synthesized by 
Louis Sarett and could be tested for the first time in the clinics. Philip Hench 
applied daily doses for three days intramuscularly (i.m.) to a patient, suffering 
from chronic polyarthritis, which led to a significant amelioration of her pain 
(Hillier, 2007). In the 1950s, a race started to improve the ´wonder drug´ 
cortisone with synthetic derivatives such as prednisolone, methylprednisolone, 
dexamethasone or betamethasone (Strehl and Buttgereit, 2013). They have 
now been used for more than 60 years as very efficient drugs to treat chronic 
inflammatory diseases, such as inflammatory bowel disease, autoimmune 
diseases including systemic lupus, allergic diseases including asthma or for 
immunosuppression of conditions, such as aGvHD (Klein, 2015).  
 
In contrast to these synthetic GCs, endogenous GCs are produced by the 
adrenal glands. Their release is tightly controlled via the hypothalamic-pituitary-
adrenal (HPA) axis, which coordinates physiological reactions to external stimuli 
(Figure 2). It functions as a neuroendocrine cascade with a negative feedback 
loop. In brief, higher brain areas stimulate the hypothalamus to secrete the 
corticotropin-releasing factor (CRF), which in turn stimulates the secretion of 
adreno-corticotropin-releasing hormone (ACTH) by the anterior pituitary. 
Consequently, the adrenal cortex is triggered to release cortisol. Cortisol 
prevents its own overproduction by blocking CRF and ACTH secretion 
(Reichardt and Schutz, 1998, Rhen and Cidlowski, 2005). Furthermore, local 
biosynthesis of active GCs has been reported to occur to a minor extent in 
selected organs such as the thymus, intestine, skin and the brain (Talaber et al., 
2013). About 90 % of the endogenously released cortisol in the blood is 
biologically inactive, because it is bound to the high affinity            
corticosteroid-binding globulin (CBG) (Rhen and Cidlowski, 2005). This protein 
plays a crucial role for the distribution of cortisol via the blood circulation to 
tissue-specific sites, for example neutrophils are capable of cleaving CBG 




1988). Within cells, free cortisol can be converted into the biologically inactive 
form cortisone by the enzyme 11β-hydroxysteriod dehydrogenase type II    
(11β-HSD II) whereas 11β-hydroxysteriod dehydrogenase type I (11β-HSD I) 
converts cortisone into cortisol (Rhen and Cidlowski, 2005, Cain and Cidlowski, 
2017). In comparison to natural GCs, most synthetic derivatives have, beside a 
longer plasma half-life, a lower affinity towards CBG. Additionally, they are not a 
substrate for 11β-HSD II. Together, these characteristics result in an improved 
potency and a reduced metabolic clearance (Schacke et al., 2002, Kadmiel and 
Cidlowski, 2013).  
 
The natural cortisol release is controlled by the circadian rhythm, for which 
reason the highest blood concentration in humans is usually found in the 
morning (Strehl and Buttgereit, 2013). Furthermore, GC secretion is triggered 
by acute and chronic stress, including elevated levels of pro-inflammatory 
cytokines, such as IL-1, TNFα or IL-6 (Watson et al., 2012, Kadmiel and 
Cidlowski, 2013, Dunn, 2000). GCs regulate up to 20 % of the genome, 
including several crucial physiological processes, such as energy metabolism 
(Strehl and Buttgereit, 2013, Cain and Cidlowski, 2017). Namely, it increases 
the blood glucose level via three mechanisms: it acts as an antagonist of 
insulin, triggers gluconeogenesis and the release of glucose from the liver 
(Strehl and Buttgereit, 2013). Finally, GCs also regulate development, 
reproduction, cardiovascular homeostasis and play a role in depression 







Figure 2: Glucocorticoid (GC) secretion is controlled via the hypothalamic-pituitary-
adrenal (HPA) axis. Upon stress the hypothalamus secretes the corticotrophin-releasing 
hormone (CRH). In turn the anterior pituitary gland releases the adreno-corticotropin-releasing 
hormone (ACTH) and subsequently the adrenal gland releases the biological active hormone 
cortisol into the blood stream. Here, 11β-HSD2 can convert cortisol into the biological inactive 
form cortisone and 11β-HSD1 can revert the process. GCs fulfill their function by binding to the 
ubiquitously expressed glucocorticoid receptor (GR) (Cruz-Topete and Cidlowski, 2015). 
 
 Mechanisms of GC action 1.4.1
GC effects are mediated mostly by genomic, but also non-genomic 
mechanisms. The former mechanisms are mediated by the binding of GCs to 
the cytosolic glucocorticoid receptor (GR), which regulates the expression of 
target genes (Strehl and Buttgereit, 2013). The GR is encoded by the NR3C1 
gene located on chromosome 5q31-32 in humans. GRα and GRβ isoforms are 
generated by alternative splicing, but GCs only bind to GRα while the GRβ 
isoform acts as dominant inhibitor of GRα. GRα is expressed in nearly all 
nucleated cells mediating the classical effects of GC signaling (Stahn and 
Buttgereit, 2008, Kadmiel and Cidlowski, 2013). The GR belongs to the nuclear 




(Baschant and Tuckermann, 2010, Stahn and Buttgereit, 2008, Rhen and 
Cidlowski, 2005). It is structured in three domains: an N-terminal transactivation 
domain (NTD), a central DNA binding domain (DBD) and a C-terminal ligand 
binding domain (LBD). A flexible hinge region is located between the DBD and 
LBD. The NTD contains an activation function domain (AF-1), which facilitates 
the recruitment and direct cooperation of other transcription factors or co-factors 
(Strehl and Buttgereit, 2013). The LBD, with its 12 α-helices and 4 β-strands, 
can form a hydrophobic-ligand binding pocket for GCs and additionally contains 
a second AF (AF-2). The LBD undergoes conformational changes upon     
ligand-binding, enabling the interaction of co-activator or co-repressor with the 
AF-2 domain. Two nuclear localization signals (NL) are located within the LBD. 
The DBD is a highly conserved region containing two zinc-finger domains 
allowing a homodimerization of the GR and the interaction with target DNA 
sequences, so called glucocorticoid responsive elements (GREs) (Oakley and 
Cidlowski, 2013, Stahn and Buttgereit, 2008, Strehl and Buttgereit, 2013). In the 
absence of a ligand, the GR stays in the cytoplasm forming a multiprotein 
complex with heatshock proteins (hsp), such as hsp 90, hsp 70, hsp 56 or hsp 
40, immunophilins, such as FKBP51 or FKBP52, co-chaperons such as p23 or 
Srk, or various kinases of the mitogen-activated protein kinase (MAPK) pathway 
preventing its degradation. GCs can bind with high affinity to the fully disposable 
ligand-binding site after having passed the cell membrane owing to their 
hydrophobic structure. Upon ligand-binding, the GR undergoes a 
conformational change and the multiprotein complex dissociates, leading to the 
exposure of the NL and consequently to the translocation into the nucleus 
(Stahn and Buttgereit, 2008, Strehl and Buttgereit, 2013).  
 
Transcription of target genes can either be activated or repressed via three 
mechanisms (Figure 3). First, direct DNA binding to GREs; second, indirect 
binding mediated via tethered transcription factors; third, direct DNA-binding, 
while interacting with nearby DNA-bound “composite” transcription factors 
(Cruz-Topete and Cidlowski, 2015). The first mechanism involves GR 
homodimers usually activating gene transcription by the recruitment and 




polymerase activity (Barnes, 2011). As a consequence, anti-inflammatory 
proteins, for instance IL-10, or proteins involved in metabolic processes, for 
example in gluconeogenesis, such as phosphoenolpyruvate carboxylase 
(PEPCK) and tyrosine aminotransferase (TAT), are expressed (Reichardt and 
Schutz, 1998, Strehl and Buttgereit, 2013). GR homodimers can also bind to 
negative GREs (nGRE) repressing transcription of target genes by the 
recruitment of cis-acting co-repressors (Vandevyver et al., 2013, Surjit et al., 
2011). The other two mechanisms involve GC monomers. Tethering of the GR 
with transcription factors, such as nuclear factor κB (NF-κB) or activator protein 
1 (AP-1), leads to transcriptional repression of pro-inflammatory genes (Barnes, 
2011, Cruz-Topete and Cidlowski, 2015). This is due to alterations in the    
DNA-binding capacity of the partnering transcription factors or an interference 
with the recruitment of co-regulators and/ or the transcriptional machinery. In 
general, GC monomers can control transcriptional activation and repression 
(Cruz-Topete and Cidlowski, 2015, Cain and Cidlowski, 2017). Beside genomic 
mechanisms, GC effects can also be achieved within seconds to minutes by 
non-genomic mechanisms (Kadmiel and Cidlowski, 2013). They can occur due 
to the binding to a postulated membrane-bound GR, the classical cytosolic GR 
or via GR-independent mechanisms, such as by binding to cellular membranes. 
The former two mechanisms are thought to be controlled by the interaction with 
kinases acting in signal transduction pathways, such as the ERK pathway 
(Cruz-Topete and Cidlowski, 2015). In contrast, interaction with cellular 
membranes is thought to influence the cellular metabolism by interfering with 
cation transport through plasma membranes (Buttgereit and Scheffold, 2002). 
The non-genomic mechanisms are less well studied, but may still participate in 
pharmacological and physiological GCs effects (Ayroldi et al., 2012). The 
expression of different GR isoforms, posttranscriptional GR modifications, 
including phosphorylation, sumoylation, ubiquitination, acetylation or 
methylation and differences in chromatin accessibility or expression of different 
GR cofactors impact the transcriptional activity of GCs as well. Consequently, 
these factors influence GC sensitivity and specificity, which differs between cell 
types and contributes to the complexity in GC signaling (Duma et al., 2006, 






Figure 3: Genetic mechanisms of glucocorticoids. In the extracellular space, corticosteroid-
binding globulin (CBG) binds to glucocorticoids, thereby keeping it in an inactive state. Free 
cortisol can diffuse through the cell membrane, here it can be converted by 11β-HSD1 into 
cortisone and vice versa by 11β-HSD2, and in addition cortisol can exert non-genomic 
functions. Moreover, cortisol can bind to the glucocorticoid receptor (GR)-chaperon assembly 
which leads to the disassembly of the multiproteins from the GR, allowing its translocation into 
the nucleus. Here it controls positive and negative gene regulation via three distinct 
mechanisms. First: via direct binding to glucocorticoid responsive elements ((+)GRE) or 
negative-GRE (nGRE). Second: via protein-protein interactions with transcription factors (TF) 
thereby controlling their transcriptional activity. Third: via composite binding to DNA and TF. All 
mechanisms regulate in the end the transcriptional machinery (TM); responsive elements (RE) 
(Cain and Cidlowski, 2017). 
 
 GC effects on immune cells  1.4.2
GC therapy is a common medication to treat inflammatory diseases, including 
aGvHD (Garnett et al., 2013). For a long time, the immunosuppressive effects 
of GCs have been predominantly attributed to the diminished T cell activation 
and T cell depletion (Almawi et al., 1996). However, nowadays it is well known 




too (Franchimont, 2004). In the following, GC actions will be summarized in 
selected cell types that play a major role in the initiation and establishment of 
aGvHD.  
 
GCs have an impact on DCs at various stages. DCs first need to process 
antigens upon uptake and then to receive co-stimulatory signals to mature. GCs 
promote antigen uptake by increasing the endocytic activity, but DCs are also 
kept in a more immature state, thus preventing their activation and 
consequently inhibiting their capacity to stimulate T cells (Piemonti et al., 1999b, 
Piemonti et al., 1999a). This can be explained by a reduced expression of MHC 
II, co-stimulatory molecules such as CD86 or CD80 and pro-inflammatory 
cytokines such as TNFα or IL-12, as well as an increased production of the  
anti-inflammatory cytokine IL-10 (Matyszak et al., 2000, Kitajima et al., 1996, 
Moser et al., 1995, Li et al., 2015, Rozkova et al., 2006). Phenotypical changes 
associated with this skewed development have also been described in DCs 
treated with GCs during the maturation process and in mature DCs after GC 
treatment (Rozkova et al., 2006, Butts et al., 2007, Rea et al., 2000). As IL-12 is 
critical in the development of Th1 cells and IL-10 for the development of Th2 
cells during the antigen presentation process, GCs promote humoral immunity 
(Elenkov, 2004). Furthermore, GCs arrest DCs in an undifferentiated state, 
which thereby acquire tolerogenic properties. Hence, they induce a state of 
anergy in naïve T cells and contribute to the maintenance of naturally occurring 
Tregs (Emmer et al., 2006, Unger et al., 2009). In addition, the number of 
mature DCs, but not immature DCs is reduced by high-dose GCs, as they are 
susceptible to GC-induced apoptosis (Cao et al., 2013). Finally, the tissue 
distribution of DCs is altered by GCs due to a reduced migration towards the 
lymph nodes via downregulation of the chemokine CCL7 (Vizzardelli et al., 
2006).  
 
Monocytes have the basic capacity to differentiate into highly specialized 
macrophage populations within the target tissue dependent on environmental 
stimuli (Murray et al., 2014, Laskin, 2009). Initially, they have been grouped into 




are activated by pro-inflammatory stimuli such as DAMPs, PAMPs, TNFα, IL-1β 
or IL-6 and display a cytotoxic inflammatory phenotype. M1 macrophages are 
crucial in the early phase of inflammation, as they are highly effective in 
destroying pathogens and recruiting immune cells to the site of infection. 
However, excessive activation of this phenotype can lead to pathological tissue 
destruction supported by their release of inflammatory mediators. The second 
category are anti-inflammatory, so called “alternative activated” M2 
macrophages. They suppress inflammatory responses and participate in the 
resolution of inflammation, wound healing and angiogenesis (Martinez et al., 
2008, Laskin, 2009, Roszer, 2015). GCs inhibit apoptosis in monocytes and 
polarize them towards an M2 state (Pemmari et al., 2019, Barczyk et al., 2010). 
GC-initiated gene programs increase the capacity of macrophages for 
phagocytosis, promote the clearance of apoptotic cells and debris, which in turn 
prevents the release of cytotoxic granule contents and pro-inflammatory 
cytokine production (Giles et al., 2001, Ehrchen et al., 2007, Liu et al., 1999). 
Examples, and at the same time hallmarks of M2 macrophages, are the 
enhanced expression of scavenger receptors and mannose receptors such as 
CD163 and CD206, respectively (Ehrchen et al., 2007, Hogger et al., 1998, 
Heideveld et al., 2018). Furthermore, GCs trigger the secretion of the           
anti-inflammatory cytokine IL-10 and TGFβ (Mozo et al., 2004, Ehrchen et al., 
2007). In turn, the release of pro-inflammatory cytokines, such as IL-1β, TNFα, 
IL-6 or IL-12, hallmarks for M1 macrophages, are repressed (Tuckermann et al., 
2005). Moreover, the synthesis of inducible nitric oxide synthase (iNOS) and its 
product nitric oxide (NO) are diminished. GCs suppress nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase, thus the synthesis of free oxygen 
radicals is reduced. The synthesis of eicosanoids, lipid mediators acting as 
vasodilator and permeably vessels, secreted by macrophages located in 
inflamed tissues, is inhibited, for example by preventing the expression of 
cyclooxygenase 2 or phospholipase 2 (Tuckermann et al., 2005, Franchimont, 
2004, Cain and Cidlowski, 2017). Also the migration of inflammatory monocytes 
is repressed due to a GC-mediated decrease in the expression of the 
chemokine receptor CXCR31 and decreased production of the chemokine  




that GCs lead to an increased migration of anti-inflammatory monocytes to 
inflammatory sites (Ehrchen et al., 2007).  
 
T cells are affected by GCs in many ways. Their phenotype is shifted from a 
Th1 towards a Th2 state, mainly by GC-induced effects on DCs and 
macrophages leading to a diminished IL-12 secretion, which is further promoted 
by their enhanced IL-10 secretion (Blotta et al., 1997, Matyszak et al., 2000, 
Franchimont, 2004). Consequently, less IFNγ and more IL-4 is production by 
Th1 and Th2 cells, respectively. These effects are further strengthened by the 
autocrine feedback loop of these cytokines (Elenkov, 2004, Arya et al., 1984). 
However, GCs can also directly act on T cells as IL-4 mRNA expression is 
induced upon GC stimulation in naïve T cells and they become unable to 
respond to IL-12, the former effect being restricted to physiological GC 
concentrations (Ramirez et al., 1996, Fahey et al., 2006). Furthermore, Th1 
development is inhibited at the transcriptional level by interfering with the Th1 
transcription factor T-bet. It is worth mentioning that pharmacological GC 
concentrations suppress Th2 cytokines by regulating the transcription factor 
GATA-3 (Liberman et al., 2009), although it is the common understanding that 
GCs ultimately favor a Th2 phenotype (Ashwell et al., 2000). Besides controlling 
mature T cells, thymocytes are particularly sensitive to GC-induced apoptosis, 
even at physiological concentrations (Gruber et al., 1994, Cohen and Duke, 
1984). This can be overcome by interactions of the co-stimulatory molecules 
CD28 and CTLA-4 with B7-1 or B7-2, independent of TCR ligation (Wagner et 
al., 1996) and also cytokines, such as IL-2 and IL-4 (Zubiaga et al., 1992). One 
mechanism which explains the different GC-sensitivities within T cell 
subpopulations is the protective effect of the anti-apoptotic protein Bcl-2 present 
in CD4+ and CD8+, but not in double-positive (DP) thymocytes (Hockenbery et 
al., 1991). In addition, through GC regulation of Bcl-2 at the post-transcriptional 
level, by for example micro RNAs, Th2 and Th17 cells are more resistant to  
GC-induced apoptosis than Th1 cells (Banuelos et al., 2016). Tregs express 
high levels of Bcl-2 and upon GC treatment, also higher levels of CTLA-4 and 
are therefore less susceptible to GC-induced cell death (Chen et al., 2004, 




with immune regulatory functions (Karagiannidis et al., 2004). The mechanisms 
of how GCs induce immunosuppressive functions, as mentioned here, are not 
yet completely understood, but they explain why GCs are such a powerful drug 
in regard to the treatment of aGvHD.  
 
 GC-induced side-effects 1.4.3
GCs have potent immunosuppressive activities, but they also have pleiotropic 
functions in regulating essential biochemical and physiological processes within 
the body (Oray et al., 2016). Hence, successful GC therapy is limited by 
inducing a wide range of side-effects. The reason for this is the ubiquitous 
expression of the GR acting in a context-specific pattern. Statistically, about   
0.5 - 1 % of the human population is treated with GCs and the limitations of GC 
therapy thus represent a major problem. Side-effects can range from cosmetic 
issues to more severe life-threatening forms. The development of side-effects 
and the therapeutic efficacy are often interdependent. Both criteria are 
dependent on multiple factors including drug type, dosage, duration, timing and 
route of application, individual susceptibility as well as the history of the patient 
(Petta et al., 2019). Nevertheless, the side-effects need to be considered 
individually in regard to the risk factors, but it is overall accepted that long-term 
administration represents the highest risk factor, followed by high dose 
application (Schacke et al., 2002).     
 
One important side-effect is myopathy. It is characterized by a reduction in 
muscle fibers due to a decreased rate of protein synthesis and an increased 
rate of protein breakdown. The underlying mechanisms are complex, ranging 
from reduced amino acid transport, negative intervention with the protein 
synthesis machinery to the augmented activity of the proteolytic system 
(Schakman et al., 2008, Schakman et al., 2013, Klein, 2015). Muscle fiber types 
show different sensitivities towards GCs. Hence, predominantly fast-twitch, 
particularly type IIx and IIb muscle fibers are affected, making glycolytic 
muscles e.g. the musculus gastrocnemius (M. gastrocnemius) more vulnerable 
than oxidative muscles e.g. the M. soleus (Fournier et al., 2003, Dekhuijzen et 




weakness, this side-effect strongly reduces the quality of life of the patients 
(Schakman et al., 2013).  
 
Another meaningful side-effect is GC-induced osteoporosis (GIO), which is the 
most common form of secondary osteoporosis. About 30 - 50 % of these 
patients will experience a fracture, occasionally asymptomatic fractures (Canalis 
et al., 2007). Pathogenic hallmarks of GIO are a reduced bone formation rate 
and an increase in bone resorption as a consequence of the altered gene 
expression. This can be explained by the observation that GCs impair 
osteoblast function, differentiation and proliferation, induce apoptosis in 
osteocytes, and that they lead to an intensified osteoclastogenesis combined 
with a prolonged osteoclasts life-span (Delany et al., 1995, Jia et al., 2006, 
O'Brien et al., 2004, Canalis, 2005). Noteworthy, experiments conducted by 
Rauch et al. demonstrated the importance of the GR in osteoblasts rather than 
in osteoclasts in regard to bone loss (Rauch et al., 2010). Besides that, all three 
cell types have distinct functions, which are tightly coordinated and orchestrated 
by cytokines, growth factors and hormones. GC application can alter these 
signals in the bone microenvironment, both by direct and indirect mechanisms, 
thereby contributing to the disruption of the physiological bone metabolism 
(Moutsatsou et al., 2012). 
 
One more frequent and severe GC-induced side-effect is type II diabetes, which 
is the consequence of an impaired glucose homeostasis. About 40 % of organ 
transplanted patients, receiving GCs, develop the so called post-transplant 
diabetes mellitus (Onwubalili and Obineche, 1992). The crucial role of GCs in 
this disease can be concluded from the fact that patients show an improvement 
upon GC withdrawal (Everson et al., 1999). GCs increase the synthesis of 
glucose, mainly mediated via the transactivation of enzymes involved in 
gluconeogenesis. Upon enhanced glucose synthesis, glycogen synthase is 
activated by GCs which is then stored in the liver. Insulin and GCs are 
opponents. Insulin prevents gluconeogenesis and triggers the uptake of glucose 
in insulin-sensitive tissue such as liver, skeletal muscle and adipose tissue, 




causes pancreatic β-cell dysfunction and alters the insulin-sensitivity in the 
respective tissue leading to glucose and insulin intolerance. Thus, 
hyperglycemia and hyperinsulinemia are the consequence of this destructed 
feedback loop (Pasieka and Rafacho, 2016). 
 
1.5 Targeted therapy of GCs    
GCs have been used in the clinics, to treat inflammatory diseases already 
before their mode of action was explored in more detail. About 7 decades of 
intensive research improved our knowledge and revealed the complexity of GC 
actions. As mentioned earlier, it operates in a cell type specific manner and is 
influenced by physiological processes within the body. Hence, it is not 
surprising that systemic long-term and high-dose applications of synthesized 
GCs, with its unspecific distribution within the organism has major drawbacks, 
namely the induction of life-threatening side-effects and GC resistances 
(Vandewalle et al., 2018). One possibility to overcome these hurdles is to 
increase the specificity of GCs by packaging them into carrier systems. Ideally, 
they fulfill the needs of being biocompatible, biodegradable, having prolonged 
biological life-times and are released at restricted sites and in cells of interests. 
These goals can be potentially achieved by using liposomes or nanoparticles 
(Luhder and Reichardt, 2017). Liposomes (LP) are phospholipid bilayer vesicles 
typically with a size of about 100 nm that can encapsulate hydrophobic and 
hydrophilic structures. Additionally they are often modified by a “shield” of 
polyethylene glycerol (PEG) preventing the opsonization of plasma proteins and 
consequently its phagocytic elimination (Alavi et al., 2017). Prednisolone 
phosphate loaded PEG-LPs were proven to be highly successful in an 
experimental rat model of arthritis when provided by a single i.v. injection and 
resulted in a complete remission of inflammatory symptoms due to the 
preferential delivery to the inflamed joints (Metselaar et al., 2003). Moreover, 
prednisolone loaded PEG-LPs improved the course of EAE (experimental 
autoimmune encephalitis), a well-established rodent model for multiple sclerosis 
(MS), and was superior to a 5-fold higher dose of free methylprednisolone most 
likely also due to specific drug targeting (Schmidt et al., 2003). Further support 




carried out in chronic demyelination models (Linker et al., 2008). This is in line 
with the study by Schweingruber et al., suggesting that GC-loaded LPs are not 
simply accumulating at the site of interests, but that they also show an altered 
mode of action compared to free GCs that mainly act on T cells during EAE 
therapy. In contrast, LPs are taken up by phagocytes, such as macrophages, 
thereby inducing an M2-like phenotype. Nevertheless, the GR in macrophages 
and T cells was required for a successful therapy with GC-loaded LPs, 
suggesting that this new delivery vehicle was not entirely cell type specific 
(Schweingruber et al., 2011). Taken together, these examples show the great 
potential of GC-loaded LPs in the treatment of inflammatory diseases. A 
number of LP-based drug formulations are available on the market, but none of 
them loaded with GCs (Bulbake et al., 2017). One complication of a therapy 
with LPs is that they are able to trigger the activation of the complement system 
leading to a “pseudoallergy” and upon reencounter to its rapid clearance 
(Sercombe et al., 2015, Luhder and Reichardt, 2017). 
 
Nanoparticles (NPs) as a carrier system are another possibility for targeted 
therapies. Most organic nanoparticle formulations have the advantage to be 
approved by the FDA due to the use of biodegradable reagents. One example 
is the widely used polymer poly(lactic-co-glycolic acid) PLGA, which is 
processed by the body, therefore avoiding the risk associated with 
bioaccumulation. To increase its target specificity even antibodies can be linked 
to it (Castillo et al., 2018). In terms of GC-targeted therapy, betamethasone 
sodium phosphate (BSP) encapsulated in PLGAs has been demonstrated to be 
highly effective in an animal model for arthritis also due its slow release and 
target delivery but still, also no GC-loaded PLGA formulations are on the market 
so far (Higaki et al., 2005). Inorganic nanoparticles are another option though 
only biocompatible agents, suitable for magnetic resonance images (MRI) are 
FDA approved. Furthermore, inorganic drug carriers are often associated with 
low drug loads (Luhder and Reichardt, 2017, Castillo et al., 2018). To overcome 
this issue, Heck et al. developed a novel material concept of inorganic-organic 
hybrid nanoparticles (IOH-NP). In brief, they are composed of an inorganic 




functional organic anions, functionalized with a phosphate group, for example 
betamethasone phosphate (BMP). Different organic anions can be fused, by 
this combining different properties, such as drug release, fluorescence e.g. 
flavinmononucleotide (FMN) or serving as a contrast agent, the former being 
suitable for flow cytometry and the later for MRI studies. The inorganic cation 
enables a synthesis in aqueous solutions while it converts the NPs into an 
insoluble compound. IOH-NPs have a hydrodynamic diameter of 30 - 40 nm, an 
optimal size for active uptake, and an enormous drug load of up to 90 wt % 
(Heck et al., 2015, Shang et al., 2014). Former studies did not provide any 
indications for cytotoxic effects of IOH-NPs and demonstrated a cell-type 
specificity towards macrophages, most likely due to their size. Furthermore, 
IOH-NPs loaded with BMP led to a reduction of pro-inflammatory cytokine 
secretion in vitro and an improvement of EAE symptoms while being as potent 
as free dexamethasone in vivo (Montes-Cobos et al., 2017, Heck et al., 2015). 
Findings reported by Nishiwaki et al. let assume that GC-targeted therapy 
towards macrophages is attractive in the setting of aGvHD, as they 
administered macrophage engulfing dexamethasone palmitate (DP), a 
liposteroid in an aGvHD mouse model thereby attenuating disease progression 
and mortality (Nishiwaki et al., 2014). In conclusion, IOH-NPs might represent a 
promising targeted therapeutic strategy in order to treat aGvHD while being 
more tolerable in comparison to systemic applied GCs.  
 
1.6 Objectives 
Acute GvHD is a severe life-threatening complication, which compromises the 
success of HSCT. Administration of GCs is the golden standard and first-line 
therapy owing to their anti-inflammatory and immunosuppressive actions. 
However, they often trigger severe unwanted side-effects and GC resistances, 
which might develop upon long-time and/ or at high-dose administration. This is 
explained by the fact that systemically applied GCs act in an unspecific manner 
as they can bind to the ubiquitously expressed GR. In order to overcome this 
hurdle the targeted delivery of GCs to specific organs and cells types of interest 
would be a possible solution. Analyses of pathophysiological mechanisms of 




not only T cells, but also other cells such as DCs or macrophages, with their 
broad spectrum of phenotypes, play a major role in the course of the disease. 
Previous results further indicate a high cell-type specificity of IOH-NPs towards 
macrophages. This thesis therefore aimed to define the role of the GR in 
recipient myeloid cells and to clarify whether IOH-NP therapy is beneficial in the 
context of aGvHD. To address these issues the thesis is subdivided into five 
parts.  
  
o The first part investigated effects of endogenous GCs and their relevance 
in radioresistant recipient myeloid cells in the context of aGvHD by using 
mice lacking the GR in this particular cell type. 
 
o The second part intended to gain a better understanding of the cell-type 
specificity, toxicity, cellular uptake mechanism and intracellular fate of 
IOH-NPs being a possible carrier system for the targeted delivery of GCs 
in aGvHD therapy. 
 
o The third part focused on the organ distribution of IOH-NPs after 
intraperitoneal (i.p.) injection into mice as a basis for their possible 
therapeutic application in aGvHD. 
 
o The fourth part addressed the therapeutic efficiency of IOH-NPs loaded 
with betamethasone in the treatment of aGvHD in wild type mice in 
comparison to free GC. Furthermore, the cell type specificity of this 
therapy was investigated using again mice, lacking the GR in myeloid 
cells.  
 
o The fifth part was dedicated to the question of whether GC-induced   








2 MATERIAL & METHODS  
2.1 Material 
 Instruments 2.1.1
If not otherwise declared, the supplier is located within Germany. 
Table 1: Instruments 
Equipment  Supplier 
Akku-jet® pro pipette controller Brand GmbH, Wertheim 
Animal Respirator Advanced TSE, Technical & Scientific Equipment 
GmbH, Bad Homburg 
Axio Scope A1 Zeiss, Jena  
Axio Scope Aplus Zeiss, Jena 
Balance MC1 RC 210P-OD1 Sartorius, Göttingen 
BD FACS Canto II BD Biosciences, Heidelberg 
BioTek® Power Wave 340 plate reader BioTek Instruments, Wetzlar 
Centrifuge 2-5 Sigma Laborzentrifugen, Osterode 
Centrifuge 5417R Eppendorf, Hamburg 
Centrifuge 5804-R Eppendorf, Hamburg 
Confocal Laser scanning microscope 
TCS SP2  
Leica, Wetzlar 
CONTOURTM Next, Ascencia Blood 
Glucose Monitoring System 
Bayer Healthcare AG, Leverkusen 
CONTOURTM, Ascencia Blood 
Glucose Meter  
Bayer Healthcare AG, Leverkusen 
EasyPet 3 Eppendorf, Hamburg 
EasySepTM Magnet STEMCELL Technologies, SARL, 
Cologne 
Electrophoresis power supply 301 Amersham Biosciences, Freiburg 
Freezer Hera freeze -80 °C Heraeus, Hanau 
Freezer Liebherr Comfort -20 °C Liebherr-International Deutschland 





Freezer VIP plus -150 °C SANYO Electric Co., Ltd., Moriguchi, 
Osaka, Japan 
ImageStream® X Mark II Imaging Flow 
Cytometry  
Merck KGaA, Darmstadt 
Incubator, HERACell 240 Heraeus, Hanau 
Infrared lamp Balance 100W   Philips, Amsterdam, Netherlands 
Laminar airflow cabinet, HERASafe Heraeus, Hanau  
Microscope Primo Star Zeiss, Jena 
Microscope Telaval 31 Zeiss, Jena 
Microtom SM2000R Leica Biosystems, Wetzlar 
Microwave R-212 Sharp, Osaka, Japan 
Multichannel pipette S-12, 20-200 µl Brandt, Wertheim 
Neubauer improved haemocytometer Henneberg-Sander GmbH, Giessen-
Lützellinden 
NuncTM Immuno Wash 12 Thermo Fisher Scientific, Wilmington, 
DE, USA 
pH-Meter 766 Calimatic Knick Elektronische Messgeräte 
GmbH & Co. KG, Berlin  
Photometer Nanodrop 2000 Peqlab Biotechnology, Erlangen 
Pipettes Eppendorf Research plus   
2.5 µl, 20 µl, 200 µl, 1000 µl 
Eppendorf, Hamburg 
Real-Time PCR System 7500 Applied Biosystems, Foster City, CA, 
USA 
Rectal Probe, BIO-BRET-3 Bioseb, Vitrolles, France 
Rodent thermometer BIO-TK8851 Bioseb, Vitrolles, France 
Rotilabo®-mini-centrifuge Carl Roth GmbH & Co.KG, Karlsruhe 
RS 225 X-Ray Research System Gulmay Medical Systems, Camberley, 
Surrey, UK 
Scale Acculab ALC-3100.2 Sartorius, Göttingen 
Scale TE313S Sartorius, Göttingen 







Thermocycler Mastercycler EP 
Gradient 
Eppendorf, Hamburg 
Thermomixer Comfort Eppendorf, Hamburg 
Tissue Homogenizer Ultra Turrax T18 
Basic  
IKA, Staufen 
Tissue Processor  Excelsior ES Thermo Fisher Scientific, Wilmingon, 
DE, USA 
Tissue Tek Prisma Slide Stainer Sakura Finetek. Staufen 
UV System with camera and gel 
imager (Chemostar) 
INTAS, Science Imaging Instruments 
GmbH, Göttingen 
VARIOMAG® Power direct magnetic 
stirrer 
Thermo Fisher Scientific, Waltham, 
USA 
Vortex Genie-2 Scientific Industries, Bohemia, New 
York, USA 
Water bath W12  Labortechnik Medingen, Dresden 
Water Purification System Arium Pro  Sartorius, Göttingen 
 
 Consumables  2.1.2
Table 2: Consumables 
Consumable Supplier 
6-well, 12-well, 24-well Suspension 
Culture Plates Cellstar 
Greiner bio-one GmbH, Frickenhausen 
BD FalconTM 5 ml Polystrene Round-
Bottom Tube with Cell-Strainer Cap 
BD Biosciences, Heidelberg 
BD Micro-FineTM + Demi U-100 Insulin 
Syringes (0.3 ml, 30G) 
BD Biosciences, Heidelberg 
BD MicrolanceTM 3 (20G 1.5“)  BD Biosciences, Heidelberg 
BD Microtainer® SSTTM tubes BD Biosciences, Heidelberg 
CELLSTAR Culture Flasks 75 cm2, 
175 cm2 
Greiner bio-one GmbH, Frickenhausen 
CELLSTAR PS 100 x 20 mm Cell 
Culture Dishes 







CELLSTAR® serological pipettes         
5 ml, 10 ml, 25 ml  
Greiner bio-one GmbH, Frickenhausen 
CONTOUR NEXT® Test stripes Bayer Vital GmbH, Leverkusen 
CONTOUR® Test stripes Bayer Vital GmbH, Leverkusen 
Cover glas bottom 1.0 Imaging dishes Zell-Kontakt, Nörten-Hardenberg 
CryoTubeTM Vials Nunc, Roskilde, Denmark 
EASYstrainerTM (40 µm) Greiner bio-one GmbH, Frickenhausen 
Falcon 5 ml Polystrene Round-Bottom 
Tube, non-sterile  
Th. Geyer GmbH & Co. KG, 
Renningen 
Falcon tubes 15 ml, 50 ml Greiner bio-one GmbH, Frickenhausen 
Filter paper 66 x 24 mm DiaTec, Bamberg 
Glas pipettes 10 ml, 25 ml Brand GmbH, Wertheim 
Hypodermic needle Sterican®         
26G x 0.5“, 24G x 1“ 
B Braun, Melsungen 
Labsolute® Pasteur pipettes 3 ml Th. Geyer GmbH & Co. KG, 
Renningen  
Microscope Cover Slips, 24 x 60 mm Menzel-Gläser, Braunschweig 
Microscope Slides SuperFrost Plus Menzel-Gläser, Braunschweig 
Nitril® Next Gen® single-use gloves Meditrade®, Kiefersfelden 
Nunc-ImmunoTM MicroWellTM 96 well 
solid plates, flat bottom  
eBioScience, San Diego, USA 
Optical Adhesive Covers Applied Biosystems, Foster City, USA 
Parafilm Bemis, Neeth, WI, USA 
PCR reaction tube Multiply® -µStrip 
Pro 8-Strip 
Sarstedt, Nümbrecht 
Pipette tips, 2.5 µl, 200 µl, 1000 µl Greiner bio-one GmbH, Frickenhausen 
PP Tube sterile 14 ml Greiner bio-one GmbH, Frickenhausen 
Reaction tubes, 1.5 ml, 2 ml Greiner bio-one GmbH, Frickenhausen 
Saphire Microplate, 96 well, natural for 
PCR 
Greiner bio-one GmbH, Frickenhausen 
Syringe BD DiscarditTM II, 2 ml, 5 ml BD Biosciences, Heidelberg 






 Chemicals and Reagents 2.1.3
Table 3: Chemicals and Reagents 
Chemical/ Reagent Supplier 
3, 3´, 5, 5´-Tetramethylbenzidin  Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
Acetic acid Rotipuran 100 % p.a.  Carl Roth GmbH & Co.KG, Karlsruhe 
Ammonium chloride Merck KGaA, Darmstadt 
BD FACS Clean Solution BD Biosciences, Heidelberg 
BD FACS Flow Sheath Fluid BD Biosciences, Heidelberg 
BD FACS Shutdown Solution BD Biosciences, Heidelberg 
Betamethasone phosphate 
nanoparticles  
Prof. Dr. Klaus Feldmann, Institute for 
anorganic chemistry KIT, Karlsruhe 
Bovine serum albumin  Carl Roth GmbH & Co.KG, Karlsruhe 
Celestan soluble 4 mg/ml MSD Sharp & Dohme GmbH, Haar 
Chloroform  Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
Citric acid Carl Roth GmbH & Co.KG, Karlsruhe 
Dimethylsulfoxid 99.8 % Rotipuran p.a. Carl Roth GmbH & Co.KG, Karlsruhe 
Disodium hydrogen phosphate Carl Roth GmbH & Co.KG, Karlsruhe 
Dithiothreitol  Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
Empty nanoparticles Prof. Dr. Klaus Feldmann, Institute for 
anorganic chemistry KIT, Karlsruhe 
Ethanol Rotipuran 99.8 % p.a. Carl Roth GmbH & Co.KG, Karlsruhe, 
Chemsolute® Th. Geyer GmbH & Co. 
KG, Renningen 
Ethidiumbromide solution 1 % in H2O  Carl Roth GmbH & Co.KG, Karlsruhe 
Ethylendiaminetetraacedic acid Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
F-518 Phusion® HF buffer with 7.5 mM 
magnesiumchlorid  
Thermo Fischer Scientific, Waltham, 
USA 







Prof. Dr. Klaus Feldmann, Institute for 
anorganic chemistry KIT, Karlsruhe 
Gene Ruler 1kb, DNA ladder Thermo Fischer Scientific, Waltham, 
USA 
Gibco® 0.25 % Trypsin - EDTA (1x) Thermo Fischer Scientific, Waltham, 
USA 
Gibco® 2-Mercaptoethanol  Thermo Fischer Scientific, Waltham, 
USA 
Glycerol Carl Roth GmbH & Co.KG, Karlsruhe 
Hydrogen Peroxide 30 % Rotipuran Carl Roth GmbH & Co.KG, Karlsruhe 
Neomycin trisulfate salt hydrate Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
Nucleoside triphosphate Genaxxon bioscience, Ulm 
Orange G sodium salt Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
Paraffin wax Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
pegGOLD Universal Agarose  Peqlab Biotechnology GmbH, 
Erlangen 
Penicillin/ Streptomycin (10.000 U/ml) Invitrogen, Carlsbad, CA, USA 
Potassium chloride Merck KGaA, Darmstadt 
Potassium dihydrogen phosphate Merck KGaA, Darmstadt 
Power SYBR® Green Master Mix Applied Biosystems, Foster City, USA 
QIAzolTM Lysis Buffer Qiagen, Hilden 
Roti Histofix 4 % pH 7 (4 % 
Paraformaldehyde) 
Carl Roth GmbH & Co.KG, Karlsruhe 
Sodium carbonate Merck KGaA, Darmstadt 
Sodium chloride, 99.5 % p.a. Carl Roth GmbH & Co.KG, Karlsruhe 
Sodium hydrogen carbonate Merck KGaA, Darmstadt 
Sulfuric acid, 95 - 98 % Merck KGaA, Darmstadt 







 Commercial kits 2.1.4
Table 4: Commercial kits 
Commercial kit Supplier 
CellTiter 96® AQeous One Solution Cell 
Proliferation Assay Kit 
Promega, Madison, WI, USA 
DynabeadsTM mRNA Purification Kit ThermoFischer Scientific, Waltham, 
USA 
EasySepTM negative selection mouse 
T cell isolation Kit  
STEMCELL Technologies SARL, 
Cologne 
EasySepTM positive selection mouse 
CD90.2 Kit II 
STEMCELL Technologies SARL, 
Cologne  
ELISA MAXTM Standard Set Mouse    
IL 2 
BioLegend, San Diego, USA 
ELISA MAXTM Standard Set Mouse    
IL 6 
BioLegend, San Diego, USA 
ELISA MAXTM Standard Set Mouse 
IFNγ 
BioLegend, San Diego, USA 
ELISA MAXTM Standard Set Mouse 
TNFα 
BioLegend, San Diego, USA 
ELISA READY-SET-Go! Mouse CCL-2 
(MCP-1)  
Affymetrix eBioscience, Frankfurt on 
the Main 
iScriptTM cDNA Synthesis Kit Bio-Rad Laboratories GmbH, Munich  





Table 5: Enzymes 
Enzyme Supplier 
Collagenase type 1-A (25 mg/ml) Sigma-Aldrich Chemie GmbH, 
Taufkirchen 






DNase I recombinant, RNase-free 
(10.000 U/ml)  
Merck KGaA, Darmstadt 
PfuS polymerase kindly provided by Steffen Frey, Max-














1:400 BD Biosciences, 





1:500 BD Biosciences 





1:400 BD Biosciences 
α-mouse CD3 - 
 
M-20 1:2.000 Santa Cruz, 
Biotechnology 
α-mouse CD68 - FA-11 1:200 Abcam, Cambridge, UK/ 
Biolegend, San Diego, 
USA 
α-mouse Ly6C APC Cy7 HK1.4 1:2.000 BioLegend 
α-mouse Ly6G APC 1A8 1:500 BioLegend 
α-mouse CD3 APC 17A2 1:1.000 BioLegend 
α-mouse CD8 PE Cy7 53-6.7 1:1.000 BioLegend 
α-mouse CD4 APC Cy7 RM4-5 1:1.000 BioLegend 
α-mouse  CD11b PE Cy7 M1/70 1:1.000 BD Biosciences 
α-mouse  CD86 PE GL-1 1:1.000 BioLegend 
 










α-mouse  CD16/ 
32 





(HRP) - - mmPRESS HRP 
Polymer Detection Kit; 
Vector Laboratories, 
Burlingame, USA  
 
 Fluorescent dyes 2.1.7











Exc.: 647 nm, 
Em.: 668 nm 




Deep Red FM 
Mito-
chondrien 
Exc.: 644 nm, 
Em.: 665 nm  


































Table 9: Oligonucleotides 
Gene Sequence 5´- 3´ 
Chemokine (C-C 
motif) ligand 2    
(Ccl2) 
Fwd.: AGC TGT AGT TTT TGT CAC CAA GC 
Rev.: GAC CTT AGG GCA GAT GCA GT 
Collagen, type I, 
alpha 1 (Col1a1) 
Fwd.: GTG TTC CCT ACT CAG CCG TC 
Rev.: ACT CGA ACG GGA ATC CAT CG 
FK506-binding 
protein 51 (Fkbp51) 
Fwd.: GAA CCT GGC CAT GTG CTA CCT 
Rev.: GTC CAG TCC AAG GGC CTT GT 
Forkhead box O1 
(Foxo1) 
Fwd.: GTT GCC CAA CCA AAG CTT CC 
Rev.: ATG TAG CCT GCT CAC TAA CTC TT 
Heterochromatin 
protein 1 (Hp1) 
Fwd.: GCC CAA GAT GGA CGC AAT C 





Fwd.: GTC CTG TGG CCA TCT GCC TA 
Rev.: GGG ACG CAG CAA CTG ACA TT 
Interferon gamma 
(Ifng) 
Fwd.: ACT GGC AAA AGG ATG GTG AC 
Rev.: TGA GCT CAT TGA ATG CTT GG 
Interleukin 1 beta     
(Il1b) 
Fwd.: CTC ATC TGG GAT CCT CTC CA 
Rev.: AAG CAG CCC TTC ATC TTT TG 
Interleukin 10 (Il10) Fwd.: AGG CAG AGA AGC ATG GCC CAG 
Rev.: CGG GAG AAA TCG ATG ACA GCG CC 
Interleukin 2 (Il2) Fwd.: ACT TGC CCA AGC AGG CCA CA 
Rev.: CCA GAA CAT GCC GCA GAG GTC C 
Interleukin 6 (Il6) Fwd.: AGT TGC CTT CTT GGG ACT GA 
Rev.: CAG AAT TGC CAT TGC ACA AC 
Metallothionein 2 
(Mt2) 
Fwd.: ATA GAC CAT GTA GAA GCC TAG CCT TT  




Fwd.: AAA GCA TTC AAC GCC AGG TT 






factor alpha (Tnfa) 
Fwd.: ATG GCC TCC CTC TCA TCA GT 




Fwd.: CCT CTG GAA GCT AAG GAT GTC ATT 
Rev.: AAC ACG GCT AGA CAC AGC TCA A 
 
 Cell lines 2.1.10
All cell lines originate from the species Mus musculus. 
Table 10: Cell lines 
Cell 
line 
Origin Strain Culture 
medium 
Supplier 





C3H/An DMEM++ Kindly provided by Prof. Dr. 
Jan Tuckermann, Institute 




cells type II 




BALB/c RPMI+++ Kindly provided by Prof. Dr. 
Frauke Alves, Max-Planck 








DMEM++ Kindly provided by Assoc. 
Prof. Marco Herold, Institute 














 Media  2.1.11
Table 11: Media 
Medium Supplier 
1 x LCCM  Kindly provided by Dr. Katharina Jörß 
(AG Reichardt) 
Gibco® DMEM + GlutaMAXTM 1 x/ 
phenol-free 
ThermoFischer Scientific, Waltham, 
USA 
Gibco® F-12 NutMix ThermoFischer Scientific, Waltham, 
USA 
Gibco® RPMI1640 + GlutaMAXTM 1 x ThermoFischer Scientific, Waltham, 
USA 
 
Table 12: Supplemented media  
Supplemented medium  Component 
DMEM++ and RPMI++   DMEM/ RPMI1640,  
10 % FCS,  
1 % Penicillin/ Streptomycin 
RPMI+++  RPMI1640, 
10% FCS, 
1 % Penicillin/ Streptomycin, 
0.05 mM 2-Mercaptoethanol 
F-12 NutMix++  F-12 NutMix,  
15 % FCS,  
1 % Penicillin/ Streptomycin 
     
  Buffers 2.1.12
Table 13: Buffers 
Buffer Component 
EasySepTM Recommended medium  2 % BSA 
1 mM EDTA 
in PBS  





ELISA Coating buffer  
(0.1 M Sodium carbonate) 
1000 ml ddH2O 
8.4 g NaHCO3 
3.56 g Na2CO3 
pH 9.5 
ELISA Substrate buffer  0.1 M Citric acid 
0.2 M Na2HPO4  
in ddH2O 
ELISA Developing solution ELISA Substrate buffer  
1 % TMB in DMSO 
0.2 % H2O2 
Phosphate saline buffer pH 7.2 137 mM NaCl 
2.7 mM KCl 
10 µM Na2HPO4 
2 mM KH2PO4  
in ddH2O 
ELISA Washing buffer 0.05 % Tween ® 20 % in PBS 
TAE buffer 40 mM Tris 
20 mM Acetic acid  
1 mM EDTA 
in ddH2O 
FACS buffer  0.1 % BSA 
0.01 % Sodium azide  
in PBS pH 7.2 
Orange G Loading Dye  100 ml ddH2O 
100 mg Orange G sodium salt 
30 % Glycerol 
PBS/ BSA  0.1 % BSA in PBS 
ELISA Stop solution 1 M H2SO4 in ddH2O 
TAC buffer  20 mM Tris 







Table 14: Software 
Software Supplier 
7500 System SDS Software version 
1.4.0.25 
Applied Biosystems, Foster City, CA, 
USA 
Adobe Photoshop version 9.0 Adobe Systems, San Jose, CA, USA 
BD FACS DivaTM Software version 
6.1.2 
BD Biosciences, Heidelberg 
BioTek® Gen 5 version 1.09.8 BioTek Instruments, Bad Friedrichshall 
EndNoteX9 Clarivate analytics, Philadelphia, USA 
FlowJo version 7.6.5 Tree Star, Inc., Ashland, OR, USA 
GraphPad Prism 5 GraphPad Software, La Jolla, CA, 
USA 
IDEAS Application version 6.2 187.2 Amnis part of MilliporeSigma, Seattle, 
WA, USA 
ImageJ 1.51j8 National Institute of Health, USA, open 
source, http://imagej.nih.gov/ij 
Leica Confocal software  Leica, Wetzlar 
Microsoft Office 2010 Microsoft, Redmond, WA, USA 
Nanodrop 2000 Software Thermo Scientific, Wilmington, WA, 
USA 







 Animal experimentation  2.2.1
C57BL/6 wild type (wt) mice were purchased from the commercial breeder 
Charles River in Sulzfeld or Janvier Labs in St. Berthevin in France. All other 
mice were bred and kept at our own animal facility at the University Medical 
Center in Göttingen. They were housed under specific-pathogen-free conditions 
(SPF) in individually ventilated cages (IVC) in a 12 hour light/ dark cycle. Food 
and water was supplied ad libitum. Mice were used at an age of 8 to 12 weeks.  
 
Our aGvHD experiments are based on a total MHC haplotype mismatch bone 
marrow transplantation (BMT) model employing two different inbred mouse 
strains. C57BL/6 wt mice have the haplotype H2b and served as donor, 
whereas BALB/c wt mice with the haplotype H2d served as recipients. Beside 
recipient BALB/c wt mice, Nr3c1tm2Gsc Lyz2tm1(cre)lfo mice (GRlysM), which carry a 
knockout of the GR that is restricted to the myeloid linage have been used as 
recipients. In these GRlysM mice the cre recombinase is expressed under the 
control of the lysosome M promotor, which leads to a tissue specific deletion of 
the GR in about 83 - 98 % of all mature macrophages, nearly 100 % of all 
granulocytes and 16 % of all dendritic cells. Nr3c1tm2Gsc BALB/c mice (GRflox) do 
not express the cre recombinase and have been used as control mice 
(Tuckermann et al., 2007). All experiments were conducted according to 
national and international guidelines and were approved by the responsible 
authority of Lower Saxony (Niedersächsisches Landesamt für Verbraucher-
schutz und Lebensmittelsicherheit). 
 
 Acute GvHD mouse model: disease induction   2.2.2
 Experimental setup 2.2.2.1
Female wt, GRflox or GRlysM mice on a BALB/c background were used as 
recipients. Two days before BMT (day -2), the drinking water of recipient mice 
was supplemented with 25 µg/ml neomycin as an antibiosis and renewed every 
second day for up to three weeks. One day before BMT (day -1), recipient mice 




with a dose of 8.5 Gy (1 Gy/min) using an X-Ray source, which operated at   
200 kV, 15 mA and 0.5 mm Cu filtration. At day 0, the day of BMT, 1 x 107               
T cell depleted bone marrow (BM) cells and 2 x 106 purified splenic T cells were 
resuspended in 200 µl PBS and injected intravenously (i.v.) with a 30G syringe 
into the tail vein of recipient mice to induce aGvHD. BM mice served as controls 
and received only 1 x 107 BM cells resuspended in 200 µl PBS (Figure 4).  
 
 
Figure 4: Scheme of aGvHD mouse model induction. 
 
 Preparation of T cell depleted bone marrow cells 2.2.2.2
C57BL/6 wt mice were used as donor mice and sacrificed by CO2 inhalation at 
day 0, the day of BMT. From these mice tibiae, femora and humeri were 
collected and placed in ice cold PBS. Under sterile conditions, the bones were 
opened at both sides and the BM was flushed out with ice cold PBS/ 0.1 % BSA 
by using a 24G needle, which was attached to a 5 ml syringe. The BM was 
passed through a 40 µm EASY cell strainer into a 50 ml falcon tube and 
centrifuged at 300 x g for 7 minutes at 4 °C. The cells were counted with the 
help of a Neubauer haemocytometer and adjusted to a concentration of 1 x 108 
cell/ml by adding the respective amount of EasySepTM recommended medium. 
In the following, T cells were depleted by using the EasySepTM positive selection 
mouse CD90.2 Kit II according to the manufacturer´s instructions. In brief, a 
selection cocktail was mixed with the ratio of 1:1 and left for 5 minutes at room 
temperature (RT). 50 µl/ml was added to the sample and incubated for              
3 minutes at RT. 40 µl/ml of streptavidin RapidSpheres was added and left for  
3 minutes at RT. Cell suspension was adjusted to a total volume of 2.5 ml by 
adding the respective amount of EasySepTM recommended medium. 
Afterwards, the tube was placed into the EasySepTM magnet for 3 minutes at RT 
and subsequently CD90.2- cells were poured into another tube. The cells were 
centrifuged, counted and adjusted to a concentration of 1 x 108 cells/ml with 
day -2           day-1              day 0                 
Neomycin 





PBS. 100 µl, which corresponds to 1 x 107 BM cells, was added to a tube for 
each mouse. 
 
 Preparation of splenic T cells 2.2.2.3
Spleens were isolated from donor mice after sacrificing them with CO2. The 
freshly isolated organs were placed in ice cold PBS and passed through a       
40 µm EASY cell strainer under sterile conditions. Subsequently, the cells were 
centrifuged at 300 x g for 7 minutes at 4 °C and T cells were purified by using 
the EasySepTM negative selection mouse T cell isolation Kit according to 
manufacturer´s instructions. In brief, the cells were counted and adjusted to a 
concentration of 1 x 108 cells/ml by adding the respective volume of PBS/ 0.1 % 
BSA. 50 µl/ml of normal rat serum and 50 µl/ml of mouse T cell isolation cocktail 
was added to the sample and incubated for 10 minutes at RT. 75 µl/ml of 
streptavidin RapidSpheres were added and incubated for 2.5 minutes at RT. 
The cell suspension was brought up to a total volume of 2.5 ml by adding the 
respective volume of PBS/ 0.1 % BSA. The tube was placed in the EasySepTM 
magnet for 3 minutes at RT and the T cells were poured into another tube. The 
cells were centrifuged, counted and adjusted to a final concentration of 2 x 107 
cells/ml with PBS. 100 µl, corresponding to 2 x 106 T cells, were added to a 
tube for each mouse. For BM mice, which did not receive T cells, 100 µl PBS 
was added instead. 
 
 Purity control of cell preparation 2.2.2.4
The purity of T cells and T cell depleted bone marrow cells was analyzed by 










 Acute GvHD mouse model: disease progression  2.2.3
 Monitoring of clinical symptoms 2.2.3.1
The vital state and aGvHD progression of recipient mice was monitored from 
day 2 after BMT onwards based on an established aGvHD clinical scoring 
system (Cooke et al., 1996, Theiss-Suennemann et al., 2015). This system 
includes five parameters: posture, activity, fur texture, diarrhea and weight loss. 
According to the severity of the symptoms the mice received a clinical score 
between 0 (no symptoms) and 2 (severe symptoms) for each parameter, which 
resulted in a total score of 0 to 10. Mice with a clinical score of 7 or higher and 
mice with a reduction in body weight of more than 20 % at two consecutive days 
were sacrificed for ethical reasons. Mice, which died or had to be sacrificed 














Figure 5: Gating 
strategy of flow 
cytometric 




purified T cells. 
T cell depleted 
bone marrow 
cells (A) and 
purified T cells 
(B) were first 
gated for living 
cells (C) based 
on forward 
scatter (FSC) 
and side scatter 
(SSC), then on 
singlets (not 
depicted) and 
lastly on TCR-β 
chain
+










Table 15: aGvHD clinical grading system 
 
Parameter 0 1 2 
Posture Normal Hunching Impaired movement 
Activity Normal Resting Stationary unless stimulated 
Fur texture Normal Ruffling Absent grooming, greasy fur 
Diarrhea None Mild Severe (bloody) 
Body weight loss 0 % - 10 % 10 % - 20 % More than 20 % 
 
 Long-term and short-term acute GvHD experiments 2.2.3.2
Acute GvHD studies were either performed as long-term or short-term 
experiments. In the long-term experiments, the survival of mice was monitored 
for 50 days. In short-term experiments, aGvHD mice were sacrificed at the first 
peak of the disease at day 6 after BMT, but partially also in addition at day 4 









 Treatment regimens 2.2.3.3
Three days after BMT, aGvHD mice developed mild symptoms of the disease. 
Therefore, the mice in the short-term experiments were treated at day 3, 4 and 
5 after BMT intraperitoneally (i.p.) either with 10 mg/kg free betamethasone 
(BMX) (Celestan) or BMP-NPs (IOH-NPs, that contain betamethasone 
phosphate). As a control for potential side-effects of the nanoparticles 
themselves, the mice were treated with the same volume of EP-NPs (empty 
IOH-NPs, which served as vehicle control) or PBS. Mice within the long-term 
experiments were additionally treated at day 7, 9 and 12 after BMT (Figure 6). 







day 2             3          4          5        7            9           12                              50 




 In vivo and ex vivo analyses of mice  2.2.4
 Body temperature 2.2.4.1
The body temperature of recipient mice from aGvHD short-term experiments 
was measured by using a rodent thermometer BIO-TK8851, which was 
equipped with a BIO-BRET-3 rectal probe.  
 
 Blood glucose level 2.2.4.2
Blood glucose level was measured with Ascencia CONTOUR and CONTOUR 
NEXT test stripes and the corresponding Ascencia CONTOUR blood glucose 
monitoring system. The tail vein of mice was punctured with a needle and a 
blood drop was analyzed with the automated device. 
 
 Serum collection 2.2.4.3
Mice were sacrificed by placing them in a cage, which was filled with CO2. 
Afterwards, blood was harvested by cardiac heart puncture using a 24G needle 
and transferred to a BD Microtainer SST tube. It was left for coagulation for     
30 minutes at RT and centrifuged at 14.000 x g for 2 minutes to separate the 
blood and obtain the serum. The serum was collected and stored at -20 °C for 
further analysis. 
 
 Tissue culture of jejunum biopsies for the analysis of cytokine  2.2.4.4
                   secretion by infiltrated immune cells 
In short-term aGvHD experiments recipient mice were sacrificed at the first 
peak of the disease at day 6. The jejunum of the animals was removed, four 
pieces from different sites of 5 mm length were harvested and flushed with ice 
cold PBS. The pieces were placed in individual wells in a 24-well plate and 
incubated with 500 µl of RPMI++ at 37 °C in 5 % CO2 atmosphere for 24 hours. 
The jejunum pieces were weighted to correct for differences in size and the 





 Flow cytometric characterization of the cellular composition of   2.2.4.5
                   immune cells in the lamina propria   
Recipient mice from short-term aGvHD experiments were sacrificed at day 6, 
the jejunum was removed and the size used was standardized. The tissue was 
removed 4 cm after the stomach and before the caecum, was flushed with ice 
cold PBS, the payer patches were removed and the jejunum was opened 
longitudinally before placing it in individual wells of a 6-well plate filled with  
PBS/ 60 mM EDTA/ 3 mM DTT for 45 minutes on ice. The samples were 
transferred into 50 ml falcon tubes containing 20 ml PBS, were shaken 
manually for 1 minute and the supernatant was discarded. This step was 
repeated twice with 20 ml PBS and once with 5 ml RPMI++ to remove epithelial 
cells and traces of EDTA. Meanwhile, the digestion solution was prepared in   
50 ml falcons, for each mouse using 5 ml RPMI++ supplemented with 4 mg 
collagenase type II, 4 mg collagenase type 1-A and recombinant 500 U DNase 
I, which resulted in the release of cells from the tissue. Jejunum samples were 
cut into 3 cm pieces, transferred to the digestion solution and incubated for     
30 minutes at 37 °C. Every 10 minutes, the samples were vortexed and finally 
passed through a 40 µm EASY cell strainer. 30 ml of RPMI++ was added to the 
cells, centrifuged at 300 x g for 10 minutes and the supernatant was discarded. 
The cells were resuspended with 400 µl PBS and counted. 1x106 cells/ sample 
were transferred into individual FACS tubes and incubated with anti-mouse 
CD16/32 for 20 minutes in the dark at 4 °C to prevent unspecific binding to    
Fc-receptors. Characterization of the cellular composition of the lamina propria 
in the jejunum was analyzed via FACS (see 2.2.9.1). The gating strategy is 




























Figure 7: Gating 
strategy of flow 
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 Inductively Coupled Plasma-Mass Spectrometry 2.2.4.6
Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) was performed to 
determine the tissue distribution of zirconium (Zr) after BMP-NP administration. 
500 µl BMP-NPs, which contained 0.2 mg Zr, were injected i.p. and 5 and       
24 hours later the mice were sacrificed by CO2 inhalation. The lung, left kidney, 
a central piece of 20 cm length of the jejunum, left and caudate liver lobe and 
stomach were dissected, washed with PBS, weighted and stored at -80 °C. The 
samples were sent for analysis to the commercial microanalytical laboratory 
Pascher (Remagen, Germany).  
 
 Experimental setup for the analysis of glucocorticoid associated  2.2.5
           side-effects in mice 
 Hyperglycemia 2.2.5.1
C57BL/6 wt mice were treated with either 10 mg/kg BMX or BMP-NPs or with 
equal amounts of either PBS or EP-NPs i.p. for 14 consecutive days in the 
morning. Food was removed at 6 p.m. at day 13, the day before analysis. Two 
hours after the last treatment, at day 14, blood glucose levels were measured 
(see 2.2.4.2), subsequently the mice were sacrificed and liver biopsies were 
shock frozen at -80 °C. The expression of gluconeogenetic enzymes was 
analyzed via qRT-PCR (see 2.2.7.6).  
 
 Myopathy 2.2.5.2
C57BL/6 wt mice were treated as in 2.2.5.1 and the bodyweight was determined 
at day 14. Two hours after the last treatment, at day 14, mice were sacrificed 
and the M. gastrocnemius of the right leg was removed, weighted and shock 
frozen at -80 °C. The expression of myopathy related genes was analyzed via 
qRT-PCR (see 2.2.7.6). 
 
 Osteoporosis  2.2.5.3
10 weeks old female BALB/c wt mice were treated as in 2.2.5.1. Mice were 
sacrificed at the end of the experiment and serum was collected for the analysis 




ELISA at the Institute of Comparative Molecular Endocrinology at the University 
of Ulm by Yasmine Hachemi. 
 
 In vitro analysis of IOH-NPs in cell culture 2.2.6
 Cellular uptake of IOH-NPs into primary immune cells 2.2.6.1
Splenocytes were isolated from wt mice as described earlier (see 2.2.2.3). 
Erythrocytes were lysed by incubation with 4 ml TAC buffer/ml of cell 
suspension for 12 minutes at RT. The volume was adjusted to 20 ml with PBS 
and the cells were centrifuged at 300 x g at 4 °C for 5 minutes. The supernatant 
was discarded, the pellet was resuspendend in a total volume of 1 ml with 
RPMI++ medium and the cells were counted with the help of a Neubauer 
haemocytometer. To this end, 1 x 106 cells/ml were cultured in RPMI++ medium 
in 24-well plates without or with ascending concentrations of EP-NPs (2.5, 12.5, 
25, 50 µg/ml) for 24 hours at 37 °C and 5 % CO2. Cells were harvested and  
EP-NP uptake into CD3+, B220+ and CD11b+ cells was analyzed by flow 
cytometry (see 2.2.9.1). 
 
 Cellular uptake of IOH-NPs into different cell lines 2.2.6.2
IOH-NP uptake was analyzed in 6 different cell lines (see Table 10). In one 
setup, 1 x 105 cells/ml cells were seeded in 3 ml of the respective culture 
medium (see Table 10) and cultured in 6-well plates at 37 °C and 5 % CO2 
atmosphere for 48 hours. Subsequently, 2.5 µg/ml EP-NPs were added to the 
samples for 0.5 to 6 hours. Alternatively, the cells were first cultured for           
24 hours and then 2.5 µg/ml BMP-NPs or 2.5 µg/ml EP-NPs were added for 
another 24 hours. In another setup, MH-S cells were cultured for 48 hours and 
50 µg/ml BMP-NPs were added for 6 hours or alternatively, MH-S cells were 
cultured for 24 hours and thereafter 50 µg/ml BMP-NPs were added for another 
24 hours. As a control, cells were cultured in the absence of IOH-NPs. In the 
end, IOH-NP uptake was analyzed via flow cytometry (see 2.2.9.1). MH-S, 
L929, C2C12 and LA-4 cells were detached from the bottom of the wells by 
sucking of the medium and adding 0.25 % trypsin-EDTA (1 x) for 5 minutes. 




 Viability test of cell lines 2.2.6.3
The viability of the cell lines was analyzed after incubation with IOH-NPs and/ or 
and pharmacological inhibitors. Therefore, 1 x 106 cells/ml were seeded and 
100 µl were cultured in 96-well plates in the presence or absence of 2.5 µg/ml 
EP-NPs or BMP-NPs for 6 hours. For comparison, 10 % DMSO was added to 
the culture medium for 3 hours as negative control. Alternatively, MH-S cells 
were incubated in the presence of 6 µg/ml BMP-NPs, with or without 1 µg/ml 
CytoD (cytochalasin D), 0.5 mM/ 1 mM/ 2 mM Amiloride (amiloride 
hydrochloride hydrate) or 100 µM/ 150 µM MDC (monodansyl-cadaverine) for 
24 hours. For comparison, 10 % DMSO was added to the culture medium as 
negative control. In addition, MH-S cells were incubated with 6 µg/ml BMP-NPs 
together with the inhibitors for 3 to 6 hours as well as 24 hours. For comparison, 
10 % DMSO was added to the culture medium as negative control. In all 
conditions, the cell viability was assessed by using a MTS cell proliferation 
assay (CellTiter 96® AQeous One Solution Cell Proliferation Assay Kit) according 
to manufacturer´s instructions. In brief, 20 µl of MTS tetrazolium compound was 
added to the cells, which gets bioreduced by metabolically active cells into a 
colored formazan product that is soluble in the culture medium. The absorbance 
of the colored formazan was recorded at 490 nm by spectrophotometry. 
 
 Characterization of BMP-NP uptake into MH-S cells 2.2.6.4
To study the endocytic pathway via which IOH-NPs are taken up, MH-S cells 
were seeded at a concentration of 5 x 105 cells/ml in a volume of 1 ml in 24-well 
plates and cultured for 48 hours. Subsequently, 50 µg/ml BMP-NPs were added 
for up or 6 hours in addition to 1 µg/ml CytoD or 1 mM Amiloride or 100 µM 
MDC. For comparison, MH-S cells were cultured in the presence of BMP-NPs, 
but in the absence of pharmacological inhibitors. Alternatively, MH-S cells were 
first cultured for 24 hours and subsequently, increasing concentrations of   
BMP-NPs (2.5, 12.5, 25 or 50 µg/ml) in addition to 1 µg/ml CytoD or 1 mM 
Amiloride or 100 µM MDC were added for 24 hours. For comparison, MH-S 
cells were cultured in the presence of BMP-NPs, but in the absence of 





 Bone marrow derived macrophages  2.2.6.5
In order to obtain bone marrow derived macrophages (BMDMs), bone marrow 
from mouse tibia and femora was cultured in the presence of macrophage 
colony-stimulating factor (M-CSF) present in LCCM (L929 cell conditioned 
medium) medium. In brief, bone marrow was harvested as described earlier 
(see 2.2.2.2). Cells were resuspended in pre-warmed DMEM++, adjusted to a 
concentration of 1 x 106 cells/ml and cultured for 24 hours. Whereas fibroblasts 
and stromal cells adhered to the surface of the culture dish, non-adherent cells 
representing myeloid progenitor cells could be harvested from the supernatant 
on the next day. Cells were washed and 2 x 106 cells were plated in 10 cm2 
petri dishes with LCCM medium. At day 4, LCCM medium was added to boost 
the maturation process of these cells. At day 7 to 9, the myeloid progenitor cells 
fully matured to BMDMs and were harvested by adding PBS/ 2 mM EDTA for 
30 minutes at 37 °C in 5 % CO2 atmosphere. Cells were washed and              
resuspended in DMEM++ medium and used for further flow cytometric analysis 
(see 2.2.9.1). 
 
 Flow cytometric analysis of BMDMs 2.2.6.6
The expression of extracellular surface antigens after treatment with IOH-NPs 
was analyzed in BMDMs. Therefore, 1 x 106 cells/ml of differentiated BMDMs 
from BALB/c wt mice were seeded and cultured in a volume of 1 ml in 24-well 
plates. Either EP-NPs or BMP-NPs in increasing concentrations (25, 250 ng/ml, 
2.5, 25, 50 µg/ml) or, as a control, no IOH-NPs were added to the cells and 
incubated for 24 hours. Subsequently, the cells were harvested and analyzed 
via flow cytometry (see 2.2.9.1).  
   
 Molecular analyses 2.2.7
 Enzyme Linked Immunosorbant Assay  2.2.7.1
Cytokine and chemokine concentrations were analyzed in serum samples and 
the supernatant of tissue cultures of jejunum biopsies by using different Enzyme 
Linked Immunosorbant Assay (ELISA) Kits (Table 4) according to 




plates were coated with 100 µl of the respective capture antibody, which was 
diluted in coating buffer and incubated at 4 °C overnight (O/N) in the dark. Next 
day, the plates were washed four times. Afterwards 200 µl ELISA assay diluent 
were added to each well and incubated for 1 hour on the shaker at RT to 
prevent non-specific binding. Washing was repeated and samples were diluted 
in ELISA assay diluent and incubated in duplicates for 2 hours at RT as well as 
the standard, which was incubated in triplicates. After another washing step, the 
respective detection antibody was diluted in ELISA assay diluent and 100 µl 
were added for 1 hour at RT. The plates were washed and 100 µl of ELISA 
Horse Radish Peroxidase (HRP) were added to the wells for 30 minutes at RT. 
Afterwards the plates were intensively washed five times by leaving the washing 
solution within the wells for 30 seconds before sucking it off after each washing 
step. Finally, 100 µl of ELISA Developing solution were added and left for 15 to 
20 minutes in the dark to allow peroxidase activity to proceed. The reaction was 
stopped by adding 50 µl of ELISA Stop solution to each well and the color 
change was measured by spectrophotometry at 450 nm and 570 nm. 
 
 RNA isolation 2.2.7.2
RNA was isolated using the Qiagen RNeasy Plus Universal Mini Kit according 
to manufacturer´s instructions. In brief, frozen tissue biopsies were transferred 
into sterile 14 ml tubes. 900 µl of QIAzolTM Lysis Buffer was added. The tissue 
was homogenized using the Tissue Homogenizer Ultra Turrax T18 Basic, 
transferred into a tube and placed on ice. 100 µl of gDNA eliminator solution 
were added and vortexed for 15 seconds. 180 µl of chloroform were added and 
vortexed for 15 seconds. The samples were placed on ice for 3 minutes 
afterwards they were centrifuged for 15 minutes at 20.817 x g at 4 °C. 600 µl of 
the upper phase were harvested and transferred into another tube subsequently 
mixed with 600 µl of 70 % ethanol. 600 µl of the sample were transferred into an 
RNeasy-Mini column and centrifuged at 20.817 x g for 20 seconds at RT. The 
flow-through was discarded and this step was repeated. 700 µl of RWT buffer 
were added and vortexed for 20 seconds at 10.621 x g. The flow-through was 
discarded and 500 µl of RPE buffer were added. The samples were vortexed for 




columns, which contained the samples bound to the membrane, were dried by 
centrifugation at 10.621 x g for 1 minute. Finally, the RNA was eluted by adding, 
in two steps, 70 µl (35 µl each) RNase free H2O followed by centrifugation at 
10.621 x g for 1 minute. The samples were frozen at -20 °C/ -80 °C. By using a 
Nanodrop device, the RNA concentration was determined based on the 260 nm 
absorption. Protein contamination was measured at 280 nm and organic 
compound contamination at 230 nm. RNA quality control was based on the 
characteristic bands of 18S and 28S rRNA in a ratio of 1:2 after visualizing it on 
a 1 % TAE agarose gel. Therefore 1 µg RNA, 5 µl Orange G and ddH20 
,adjusted to a volume of 20 µl, was loaded on the gel. 
 
 mRNA isolation 2.2.7.3
mRNA was harvested from total RNA preparations by using the DynabeadsTM 
mRNA Purification Kit accordingly to manufacturer´s instructions. In brief, 50 µl 
of RNA was heated to 65 °C for 2 minutes and then immediately placed on ice. 
Meanwhile 100 µl of Dynabeads per sample were transferred to a tube and 
placed in a magnet for 30 seconds. The beads attached to the wall and the 
supernatant was discarded. 50 µl of binding buffer was added to the tubes 
outside of the magnet and thereafter placed in the magnet again. The 
supernatant was discarded and 50 µl of binding buffer were added outside of 
the magnet. RNA and Dynabeads were mixed in a ratio of 1:1 and incubated on 
a shaker at RT for 5 minutes. The samples were placed in the magnet again 
and the supernatant was removed. Outside of the magnet 100 µl of buffer A 
was added and the tubes were placed in the magnet. The supernatant was 
discarded and this washing step was repeated twice with 100 µl of buffer B. 
Finally, mRNA was eluted by adding 15 µl of 10 mM Tris-HCl, pH 7.5 and 
heated at 80 °C for 2 minutes. The samples were immediately placed in the 
magnet and mRNA was transferred to another tube.  
 
 cDNA synthesis 2.2.7.4
cDNA was synthesized from total RNA or mRNA samples by using the iScriptTM 
cDNA Synthesis Kit according to manufacturer´s instructions. In brief, 1 µg total 




Mix, 0.25 µl iScript Reverse Transcriptase and nuclease-free H2O adjusted to a 
volume of 20 µl were mixed in a tube and placed on ice. cDNA synthesis was 
then conducted by using the following reaction protocol in a thermocycler: 
Priming (5 minutes at 25 °C); Reverse Transcriptase (30 minutes at 42 °C); 
Inactivation (5 min at 85°C).  
 
 Polymerase Chain Reaction  2.2.7.5
To verify whether cDNA synthesis has been successful, a Polymerase Chain 
Reaction (PCR) was performed. Therefore, the expression of the housekeeping 
gene hypoxanthine guanine phosphoribosyl transferase (Hprt) or 
heterochromatin protein 1 (Hp1) was analyzed. The PCR reaction mix for each 
sample contained the following components:  
 
Table 16: PCR reaction mix 
Volume [µl] Reagent 
12.7 dd H2O 
4 Phusion Reaction Buffer HF 
0.5 Hprt or Hp1 Primer forward [10 pmol/µl] 
0.5 Hprt or Hp1 Primer reverse [10 pmol/µl] 
1 dNTPs [5 mM] 
1  cDNA template 
0.3 PhuS (DNA polymerase) 
 
The PCR reaction was conducted in a Thermocycler Mastercycler EP Gradient 
by applying the following program:  
 
Table 17: PCR reaction program 
Step Time Temperature [°C] Cycle 
Denaturation I 2 minutes 98.5 1 
Denaturation II 20 seconds 98.5  
Annealing  15 seconds 64 30 
Elongation I 20 seconds 72  




5 µl of Orange G was added to the final PCR products and loaded on a 1 % 
TAE agarose gel.  
 
 Quantitative Reverse Transcription-PCR 2.2.7.6
Quantitative Reverse Transcription-PCR (qRT-PCR) was used to analyze the 
gene expression of target genes. The qRT-PCR reaction mix for each sample 
contained 12.5 µl SYBR green reaction mix, 11 µl ddH2O, 1 µl template (cDNA), 
0.25 µl Hprt or Hp1 forward primer and 0.25 µl Hprt or Hp1 reverse primer     
(10 pmol/µl). The components were mixed on ice in 96-well Saphire Microplates 
and then sealed with Optical Adhesive Covers. The plates were centrifuged and 
subsequently placed in the Real-Time PCR System 7500 for cDNA 
amplification. Afterwards, the expression level of target genes was calculated in 
relation to the housekeeping genes Hprt or Hp1 by using the ΔΔCT method. 
 
 Histology 2.2.8
 Preparation of tissue sections 2.2.8.1
At the peak of the disease, at day 6, and partially before and after the peak, 
namely at day 4 and 8, a 3 cm central piece of the jejunum was removed and 
flushed with 4 % paraformaldehyde (PFA) using a 24 G needle. Subsequently 
the pieces were placed in individual wells of a 24-well plate filled with 4 % PFA 
and left for 48 hours at RT. The pieces were cut in three 1 cm pieces, 
enwrapped in filter papers in which they have been transferred into histology 
cassettes. Dehydration and paraffin embedding was performed with the Tissue 
Processor Excelsior ES, an automatic system installed at the Institute of 
Pathology of the University Medical Center (UMG) in Göttingen (Dr. med. 
Hanibal Bohnenberger). 
 
In the following, the samples were placed upside down in metal forms, which 
were filled with hot paraffin and left for cooling. 2 µm sections of the paraffin 





All stainings of the tissue sections were performed at the Institute of Pathology 
of the UMG by Jennifer Appelhans from the group of Dr. med. Hanibal 
Bohnenberger using the automatic system Tissue Tek Prisma Slide Stainer.  
 
 Evaluation of histological stainings 2.2.8.2
All histological evaluations of stained tissue sections were done in a blinded 
manner. Histopathological scores were determined based on H&E stainings. 
Four criteria were assessed in ten fields per section. (1) Villous blunting/ 
flattening (0 = none, 1 = yes; 20 x magnification), (2) number of apoptotic cells 
(40 x magnification), (3) grade of inflammation (0 = none, 1 = mild, 2 = 
moderate without abscess, 3 = presence of abscess, erosions or ulcer; 20 x 
magnification, (4) edema (0 = none, 1 = yes; 20 x magnification). The sum of all 
four criteria of each individual was calculated to obtain the total histological 
score.  
 
The number of goblet cells was determined based on PAS stainings. PAS+ cells 
were counted per villus in a total of 10 villi in a 40 x magnification and the 
average was calculated.  
 
The number of T cells (CD3+ cells) and macrophages (CD68+ cells) was 
determined based on immunohistochemical stainings. CD3
+
 cells were 
individually counted by photomicrographs, which were acquired with a Zeiss 
Axio Scope A1 microscope in a 20 x magnification. The average of cells within 
ten pictures was calculated. For macrophages, the photomicrographs at 20 x 
magnification were additionally processed with ImageJ and the stained area 
was measured. The average of the stained area of ten pictures was calculated. 
 
 Optical methods 2.2.9
 Flow Cytometry 2.2.9.1
Flow Cytometry was used to determine the cellular composition, IOH-NP uptake 
or extracellular antigen expression within samples. To this end, 1 x 106 cells 




incubated for 20 minutes at 4 °C in the dark. Cells were washed with 3 ml FACS 
Buffer and centrifuged for 5 minutes at 300 x g. The supernatant was discarded 
and the pellet was resuspended in the reflux. Of note, IOH-NP uptake was 
determined based on the emission of green fluorescence originating from the 
dye FMN. Analyses were performed with the device FACS Canto II by using the 
software BD FACS DivaTM. 30.000 to 50.000 cells/ sample were recorded and 
data were processed with the software FlowJo.  
 
 Imaging Flow Cytometry 2.2.9.2
Imaging Flow Cytometry was used to visualize IOH-NPs within different cellular 
compartments in MH-S cells. In brief, 5 x 106 MH-S cells were cultured in 30 ml 
in 175 cm2 flasks in the presence of 6 µg/ml BMP-NPs for 24 hours. Medium 
was removed, cells were washed with pre-warmed PBS and fresh pre-warmed 
medium was added together with either 100 nM Lysotracker® Deep Red (DR) or 
100 nM Mitotracker® DR FM for 30 minutes. Alternatively, MH-S cells were 
cultured for 24 hours and subsequently 6 µg/ml BMP-NPs were added for         
6 hours. The medium was removed, cells were washed with pre-warmed PBS 
and fresh medium was added together with either 100 nM Lysotracker® DR or 
100 nM Mitotracker® DR FM for 30 minutes. The samples were harvested, 
centrifuged at 300 x g for 5 minutes at 4 °C and the supernatant was discarded. 
The pellet was resuspended in 500 µl FACS Buffer and passed through the 
nylon mesh within the cap of a 5 ml falcon tube. 100 µl of this cell suspension 
was used for Imaging Flow Cytometry analysis and 1.000 to 2.000 focused cells 
were recorded by using the device ImageStream®X Mark II Imaging Flow 
Cytometry. Data were processed with the software IDEAS and the                  
co-localization wizard was applied. To this end, focused cells were gated on R2, 
double positive events (FMN+ and DR+) and the Bright Detail Similarity were 
assessed, which identifies the small punctate stainings in imaged pairs and 
measures the correlation of these dots.    
 
 Confocal laser scanning microscopy 2.2.9.3
Confocal laser scanning microscopy was used to visualize IOH-NPs in MH-S 




cover glas bottom 1.0 Imaging dishes for 24 hours in the presence of 6 µg/ml 
BMP-NPs. Afterwards the cells were washed with PBS, 100 µl of phenol-free 
RPMI++ were added to the cells and the uptake of BMP-NPs was visualized 
with the help of a Leica TCS SP2 confocal laser scanning microscope installed 
at the Institute of Medical Microbiology (Prof. Dr. Carsten Lüder) in Göttingen. 
 
 Magnetic Resonance Imaging 2.2.9.4
Magnetic Resonance Imaging (MRI) was used to visualize the distribution of 
IOH-NPs in living BALB/c mice in vivo. The experiments were conducted in 
collaboration with Prof. Dr. Susann Boretius at the German Primate Center 
(DPZ) in Göttingen. In brief, mice were anaesthetized subcutaneously (s.c.) with 
0.6 ml/kg ketamine and 0.4 ml/kg medetomidine. Subsequently, they were 
intubated and ventilated with a mixture of O2, ambient air and, if anesthesia was 
necessary, with 0.5 to 1 % isoflurane anesthesia with a constant respiratory 
frequency of 85 breaths/min (Animal Respirator Advanced) during the entire 
analysis. Thereafter, mice received 500 µl GAP-NP (Gd3+2[AMP]2-3 IOH-NPs) 
containing 0.1 mg gadolinium (Gd) i.p. and MRI scans of the abdominal region 
were performed with the Bruker BioSpec 94/30 MRI scanner prior the i.p. 
injection and continuously thereafter up to 6 hours at regular intervals. The data 






3.1 Role of the GR in myeloid cells in aGvHD 
Acute GvHD is a life-threatening complication that often occurs after allogeneic 
HSCT. It is a strong inflammatory disease with a complex pathophysiology that 
involves various innate and adaptive immune cells. GCs are the only proven 
first-line aGvHD therapy due to their strong immunosuppressive effects. Of 
note, studies conducted by our group demonstrated the importance of the GR in 
transplanted T cells using a fully MHC-mismatch aGvHD mouse model. In 
particular, when CD8+ T cells were GR-deficient, clinical symptoms and 
histological features were aggravated and survival times were reduced (Theiss-
Suennemann et al., 2015). Although, it is believed that GC therapy mainly 
targets T cells, radioresistant recipient myeloid cells are also important player in 
aGvHD pathophysiology, where they participate in the initiation phase of the 
disease and induce tissue damage by the release of mediators, including 
reactive oxygen species (ROS) or reactive nitrogen species (RNS). GCs can 
further polarize macrophages towards an anti-inflammatory phenotype and 
hereby participate in wound healing and the resolution of inflammation. The 
importance of the GR in myeloid cells in keeping inflammatory processes at 
bay, has been shown, for example, in sepsis and acute lung injury (Vettorazzi et 
al., 2015, Kleiman et al., 2012). Previous data from our group taking advantage 
of the GRlysM mouse model further showed that the resistance of radioresistant 
myeloid cells to endogenous GCs induces early mortality in aGvHD (Baake et 
al., 2018). The first part of this thesis will therefore focus on the role of myeloid 
cells and their regulation by endogenous GCs in aGvHD and shed light on the 
pathogenic mechanisms leading to the reduced survival in GRlysM mice 
compared to GRflox mice in this disease model.  
 
 Deletion of the GR in recipient myeloid cells exacerbated aGvHD 3.1.1
In order to compare the early phase of aGvHD in a fully MHC-mismatch mouse 
model, GRflox and GRlysM mice were analyzed at different time points after 




day, they were transplanted with BM cells and purified T cells from wild type 
C57BL/6. Mice receiving only T cell depleted BM served as control. According 
to an established scoring system, their health status was monitored for 4, 6 or 8 
days. In addition the body weight and the body temperature was determined 
(Figure 8A-C). At the first time point analyzed, namely day 4, there were no 
differences in the clinical symptoms detectable between both genotypes and the 
scores were similar to the ones of control BM mice (Figure 8A). BM mice 
showed the lowest clinical score, as expected, since they were only exposed to 
irradiation, but did not suffer from aGvHD. At day 6 and 8, GRlysM mice 
developed significantly higher clinical scores in comparison to GRflox control 
mice (Figure 8A). Furthermore, the mice increasingly lost body weight while the 
disease proceeded, although there was no significant difference between both 
genotypes (Figure 8B). The body temperature of GRlysM mice was already 
reduced on day 4 in comparison to GRflox mice. At day 6, it further dropped and 
was significantly lower in GRlysM mice at day 8 (Figure 8C). Taken together, GR 
deletion in radioresistant myeloid cells leads to an aggravated disease course, 
which is in line with the increasing mortality of these mice after aGvHD induction 



















































































Figure 8: Clinical features of aGvHD in the GR
lysM





 recipient mice were transplanted with BM and purified T cells from donor 
C57BL/6 wt mice. BM controls received T cell depleted BM only. (A) Clinical scores were 
monitored for 4, 6 or 8 days after aGvHD induction (dead mice were documented with a score 













; day 8); data pooled from 
multiple experiments, including data from Katarina Jörß and Laura Roßmann. (B) Body weights 
were monitored for 4, 6 or 8 days after aGvHD induction; analysis of BM controls was 








; day 6), 




; day 8); data pooled from multiple experiments. (C) Body temperatures 
were monitored for 4, 6 or 8 days after aGvHD induction; analysis of BM controls was 








; day 6), 




; day 8); data pooled from multiple experiments, including data from 
Katarina Jörß and Laura Roßmann. All values are depicted as mean ± SEM. Statistical analyses 
were performed by Mann-Whitney U test (*p < 0.05; **p < 0.01; ***p < 0.001; n.s.: non-







 The disease course of aGvHD in GRlysM mice cannot be explained  3.1.2
           by target tissue damage in the jejunum 
Searching for an explanation for the exacerbated disease progression in GRlysM 
mice we performed a histological analysis in one of the aGvHD target tissues, 
the jejunum. Histological alterations were identified by H&E staining and 
examined based on an established scoring system (Theiss-Suennemann et al., 
2015). The analysis revealed a strong and significant increase in tissue 
damage, intensifying from day 4 to 8 in both genotypes, which was 
characterized by more extensive villus blunting, inflammatory infiltration, edema 
formation and higher numbers of apoptotic cells (Figure 9A, B). Furthermore, 
the number of goblet cells per villus declined from day 4 to 8 in both genotypes 
(Figure 9A, C). Importantly, there were no differences in the histological score 
or the number of goblet cells between GRflox and GRlysM mice at any time point. 
Consequently, the tissue damage caused by aGvHD is not responsible for the 













































































Figure 9: Histological analysis of the aGvHD target tissue jejunum in the GR
lysM
 mouse 




 recipient mice were transplanted with BM 
and purified T cells from donor C57BL/6 wt mice. BM controls received T cell depleted BM only. 
Mice were sacrificed and analyzed on day 4, 6 and 8 after BMT; analysis of BM controls was 





 mice stained by H&E and PAS reaction. Scale bar: 100 µm. (B) 
Histological scores imply villus blunting, inflammatory infiltrates, edema and apoptotic cells. It 

















; day 8); data 
pooled from multiple experiments, including data from Katarina Jörß and Laura Roßmann. (C) 


















; day 8); data pooled from multiple experiments, including data from Katarina Jörß 
and Laura Roßmann. All values are depicted as mean ± SEM. Statistical analyses were 
performed by Mann-Whitney U test (*p < 0.05; **p < 0.01; ***p < 0.001; n.s.: non-significant) 
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 The disease course of aGvHD in GRlysM mice cannot be explained  3.1.3
            by different infiltration of immune cells into the jejunum 
Since differences in tissue damage and goblet cell numbers per villus were not 
responsible for the exacerbated disease course in GRlysM mice, we examined 
the number of CD3
+
 T cells and CD68
+
 myeloid cells in sections of the jejunum 
by immunohistochemical stainings. These analyses revealed an increase of 
CD3+ T cells numbers from day 4 to 6, which remained at the same level at day 
8 in both genotypes (Figure 10A, B). The number of CD68+ myeloid cells 
increased from day 4 to 6, too, but then decreased at day 8 in both genotypes 
(Figure 10A, C). The decrease of myeloid cells at day 8 might mirror the 
extensive destruction of the villi at this advantaged stage of aGvHD. It is 
noteworthy, that there were no differences in the number of infiltrating immune 
cells at any of the analyzed time point in the early phase of aGvHD between 
both genotypes, which indicates that this pathophysiological feature cannot 
















































































Figure 10: Immunohistochemical analysis of the jejunum in aGvHD in the GR
lysM
 mouse 




 recipient mice were transplanted with BM 
and purified T cells from donor C57BL/6 wt mice. BM controls received T cell depleted BM only. 
Mice were sacrificed and analyzed on day 4, 6 and 8 after BMT; analysis of BM controls was 





 mice stained with antibodies recognizing CD3 (upper panel) or 
CD68 (lower panel). Scale bar: 100 µm. (B) Number of CD3
+
 T cells per mm
2
 were examined by 


















; day 8); data pooled from multiple experiments, 
including data from Katarina Jörß and Laura Roßmann. (C) CD68
+
 myeloid cells were examined 




 mice by measuring the percentage of stained 













; day 8); data pooled from multiple experiments, including data 
from Katarina Jörß and Laura Roßmann. All values are depicted as mean ± SEM. Statistical 
analyses were performed by Mann-Whitney U test (*p < 0.05; **p < 0.01; ***p < 0.001; n.s.: non-
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 GRlysM mice show almost no differences in the cytokine expression  3.1.4
           in the target organ jejunum in comparison to GRflox mice 
Since our analyses so far did not unveil the reason for the exacerbated disease 
course in GRlysM mice, we analyzed another important pathophysiological 
feature of aGvHD, namely cytokine gene expression in the jejunum. Therefore, 
mice were sacrificed at day 4, 6 and 8 and RNA from the jejunum was isolated 
and analyzed by quantitative RT-PCR. The cytokine expression pattern of Il6, 
Tnfa and Ifng was similar in both genotypes, it increased strongly from day 4 to 
6 and decreased again at day 8 (Figure 11A). There were no significant 
differences between both experimental groups except for day 4, at which Ifng 
was slightly reduced in GRlysM mice in comparison to the control GRflox mice. 
Additional cytokines, including the anti-inflammatory cytokine Il10, were 
analyzed only at day 6, which is the peak of the disease during the early phase 
of aGvHD. With the exception of Il1b, the mRNA levels of Ccl2, Il2 and Il10 
significantly increased at day 6 in comparison to control BM mice (Figure 11B). 
However, we detected no differences between both genotypes at that time 
point. In conclusion, there are basically no differences in the expression profiles 
of the predominantly pro-inflammatory cytokines in the aGvHD target organ 
jejunum, for which reason an explanation for the exacerbated disease course in 











































































































































Figure 11: Cytokine expression in the jejunum of aGvHD in the GR
lysM
 mouse model. 




 recipient mice were transplanted with BM and 
purified T cells from donor C57BL/6 wt mice. BM controls received T cell depleted BM only. (A) 
Relative mRNA levels of Il6, Tnfa, Ifng in jejunum biopsies were analyzed on day 4, 6 and 8 
after BMT by quantitative RT-PCR using hypoxanthin-phosphoribosyl-transferase (Hprt) for 
normalization; gene expression analysis of BM controls was conducted on day 6 and arbitrarily 













; day 8); data pooled from multiple experiments. (B) Relative mRNA levels of Il1b, 
Ccl2, Il2 and Il10 in jejunum biopsies were analyzed on day 6 after BMT by quantitative         
RT-PCR using Hprt for normalization; gene expression analysis of BM controls was arbitrarily 




; day 6); data pooled from multiple experiments. All 
values are depicted as mean ± SEM. Statistical analyses were performed by Mann-Whitney U 






 GRlysM mice show only minor differences in the cytokine expression  3.1.5
           in the target organ liver in comparison to GRflox mice 
Since differences in the gene expression profile in the jejunum are unlikely to be 
responsible for the exacerbated disease course of GRlysM mice, we investigated 
the gene expression profile in the liver, another major aGvHD target organ. 
Therefore, mice were sacrificed at day 4, 6 and 8 and RNA from the liver was 
isolated and analyzed by quantitative RT-PCR. The cytokine expression pattern 
of Ifng in the liver matched with the cytokine pattern in the jejunum (Figure 12A). 
In fact, the increase from day 4 to 6 and the decrease from day 6 to 8 were 
even more pronounced. However, the expression levels in both genotypes were 
similar at all examined time points. The expression pattern of Tnfa and Il6 
differed between the jejunum and the liver. Tnfa expression was almost 
unchanged in the liver of GRflox mice, but significantly elevated in GRlysM mice at 
day 6. Il6 increased from day 4 to 8 in GRflox mice, whereas in GRlysM mice Il6 
increased only from day 6 to 8. At day 6, Il6 was significantly reduced in GRlysM 
mice compared to GRflox mice. In addition, the pro-inflammatory cytokines Il1b, 
Ccl2, Il2 and the anti-inflammatory cytokine Il10 were analyzed only at day 6. 
The expression of these cytokines was unaltered when comparing GRflox mice 
with control BM mice, with the exception of an increased expression level of Il10 
in GRflox mice (Figure 12B). This was in contrast to the expression pattern of 
Il10 in the jejunum. The expression levels in the liver of Ccl2 and Il2 were 
similar in both genotypes in contrast to Il1b, which was significantly increased in 
GRlysM mice, and Il10, which was significantly decreased in GRlysM mice. This 
was also in contrast to the expression pattern in the jejunum where no 
differences between both genotypes were detectable at day 6. Collectively, 
minor differences in the expression pattern between the jejunum and the liver, 
as well as minor differences in the expression pattern in the liver between both 
















































































































































Figure 12: Cytokine expression in the liver of aGvHD in the GR
lysM





 recipient mice were transplanted with BM and purified T 
cells from donor C57BL/6 wt mice. BM controls received T cell depleted BM only. (A) Relative 
mRNA levels of Il6, Tnfa, Ifng in liver biopsies were analyzed on day 4, 6 and 8 after BMT by 
quantitative RT-PCR using Hprt for normalization; gene expression analysis of BM controls was 













; day 8); data pooled from multiple experiments. (B) 
Relative mRNA levels of Il1b, Ccl2, Il2 and Il10 in liver biopsies were analyzed on day 6 after 
BMT by quantitative RT-PCR using Hprt for normalization; gene expression analysis of BM 




; day 6); data pooled from 
multiple experiments. All values are depicted as mean ± SEM. Statistical analyses were 






 Local cytokine secretion in the target organ jejunum in GRlysM mice  3.1.6
           shows only minor differences compared to GRflox mice 
Next, we analyzed the local release of pro-inflammatory cytokines in the aGvHD 
target organ jejunum. To this end, jejunum biopsies were cultured for 24 hours 
in RPMI++ medium and subsequently the cytokine levels in the supernatant 
were measured by using ELISA. Generally, the secretion of IL-6, TNFα and 
IFNγ showed mild to no fluctuations and matched only partially with the pattern 
of the RNA expression in the jejunum and liver (Figure 13). There were no 
differences in the secretion of IL-6 and TNFα between both genotypes at any 
time point analyzed (Figure 13). In contrast, the release of IFNγ was slightly 
diminished in GRlysM mice at day 4, increased at day 6 and was similar between 
both groups at day 8. In conclusion, also the very minor differences in the local 
cytokine production in the aGvHD target organ jejunum between both 
genotypes in the early phase of aGvHD cannot explain the exacerbated disease 






































































Figure 13: Local cytokine secretion in the jejunum of aGvHD in the GR
lysM
 mouse model. 




 recipient mice were transplanted with BM and 
purified T cells from donor C57BL/6 wt mice. BM controls received T cell depleted BM only. 
Mice were sacrificed and analyzed on day 4, 6 and 8 after BMT; analysis of BM controls was 
conducted on day 6. Jejunum biopsies were cultured for 24 hours in RPMI++ medium and the 
local cytokine production of IL-6, TNFα and IFNγ was measured in the supernatant by using 













; day 8); data pooled from multiple experiments. All values are depicted as mean ± 
SEM. Statistical analyses were performed by Mann-Whitney U test (*p < 0.05; **p < 0.01; ***p < 
0.001; n.s.: non-significant) (Baake et al., 2018). 
 
 Systemic cytokine secretion in GRlysM mice is strongly elevated  3.1.7
           compared to GRflox mice 
Ultimately, the systemic cytokine secretion was analyzed in an effort to find the 
reason for the fulminant disease course in GRlysM mutant mice. Already at day 4 
the serum levels of IL-6, TNFα and IFNγ were strongly increased in both 
genotypes and remained high throughout the experiment in comparison to 
control BM mice (Figure 14). IL-6 and TNFα levels were similar in both 
genotypes at day 4 and modestly increased at day 6 in GRlysM mice. However, 
the IL-6 serum levels at day 8 were eightfold higher in GRlysM mice compared to 
GRflox mice and the TNFα serum levels were also sixfold higher. In contrast, the 




and 8. They did not show significant differences between both genotypes at any 
time point analyzed. Taken together, the deletion of the GR in radioresistant 
recipient myeloid cells causes a fulminant disease course in GR lysM mice, which 
is presumably due to the uncontrolled systemic cytokine release, in particular of 
IL-6 and TNFα, leading to an early mortality of the mutant mice (Baake et al., 
2018). These results highlight the beneficial role of GCs acting in a               
GR-dependent manner on myeloid cells in aGvHD. It is against this background 
that a targeted delivery of GCs to macrophages appears particularly attractive 



































































Figure 14: Systemic cytokine levels in aGvHD in the GR
lysM





 recipient mice were transplanted with BM and purified T 
cells from donor C57BL/6 wt mice. BM controls received T cell depleted BM only. Mice were 
sacrificed and analyzed on day 4, 6 and 8 after BMT; analysis of BM controls was conducted on 













; day 8); data 
pooled from multiple experiments, including data from Katarina Jörß and Laura Roßmann. All 
values are depicted as mean ± SEM. Statistical analyses were performed by Mann-Whitney U 





3.2 Cell type specificity of IOH-NPs 
GCs are a powerful therapeutic drug and doubtlessly profitable in the treatment 
of aGvHD. Notwithstanding, especially when given at high-dose and/ or for 
longer durations, side-effects might occur ranging from sorely cosmetic issues 
to even life-threatening complications, which are the consequence of their broad 
activity profile. To make things even worse, GC resistance develops in many 
patients limiting the therapeutic success. A chance to overcome these 
drawbacks is the targeted delivery of GCs to specific cell types. In this therapy 
form, a reduced dose of GCs could be applied while the drug load would still be 
increased in areas of interest, causing less side-effects, and in the end a better 
benefit-to-risk profile for the patient. In fact, within the last years, targeted 
therapy has attracted the attention of many researchers dealing with the 
development of carrier systems, for example nanoparticles, being biocompatible 
and improving the kinetics of the pharmacological agent. Initial work from our 
group characterized the features of another type of delivery vehicle, namely 
IOH-NP loaded with betamethasone in vitro as well as in vivo in the context of 
EAE, a mouse model for the neuroinflammatory disease multiple sclerosis 
(Montes-Cobos et al., 2017). These data indicated that IOH-NPs act indeed in a 
cell-type specific manner. Namely, they are preferentially taken up by 
macrophages and only to a minor extent by T and B cells. Furthermore, GCs 
delivered by IOH-NPs exerted anti-inflammatory effects in myeloid cells in a 
GR-dependent manner. Since my previous data, shown in the first part of this 
thesis, demonstrated beneficial immuno-modulatory properties of GCs in 
radioresistant myeloid cells in the context of aGvHD, IOH-NPs might be useful 
to selectively deliver GCs to macrophages in this disease. Using this strategy 
might allow to diminish disease symptoms and tissue destruction, while keeping 
inflammatory responses at bay. Most importantly, such a therapy may also 
provoke less side-effects in comparison to systemically applied GCs. The 
second part of this work focuses on characterizing the features of IOH-NPs, 
such as their cell-type specificity, toxicity, their cellular uptake mechanism and 





 Characterization of the cellular uptake of IOH-NPs in primary  3.2.1
           immune cells and the macrophage cell line MH-S 
Initial work by our group indicated the preferential uptake of IOH-NPs by 
macrophages. To confirm these results, IOH-NPs were used that contained the 
fluorescence dye FMN, but no pharmacologically active drug (designated      
EP-NPs). Splenocytes were cultured and incubated with these EP-NPs at 
ascending concentrations for 24 hours and the percentage of FMN+ cells 
amongst T and B lymphocytes as well as in macrophages was analyzed via 
FACS. The uptake of EP-NPs was most efficient in CD11b+ macrophages, 
B220+ B cells showed only a moderate uptake while hardly any internalization 
was visible in CD3+ T cells. All subpopulations incorporated EP-NPs in a     
dose-dependent manner, although with highly different efficiencies (Figure 
15A). Furthermore, IOH-NP uptake was exemplarily demonstrated and 
visualized in the alveolar macrophage cell line MH-S. In this experiment,      
IOH-NPs, which contain the GC betamethasone in addition to FMN, were used 
(designated BMP-NPs). The MH-S cells were incubated with BMP-NPs for 24 
hours and analyzed by confocal microscopy for fluorescence emitted by FMN. 
The signals were predominantly located in spots within the cytosol but sparing 
the nucleus (Figure 15B). In addition, MH-S cells were incubated with BMP-NPs 
for 6 and 24 hours and analyzed by FACS. This study revealed an increased 
incorporation of BMP-NPs into the cells over time (Figure 15C). Taken together, 
the incorporation of a fluorescent dye in IOH-NPs allows to study their uptake 
by using imaging techniques such as confocal microscopy and FACS in cell 

































   
 
Figure 15: Characterization of IOH-NPs in cultures and MH-S cells. (A) Splenocytes were 
incubated with ascending concentrations of EP-NPs (w/o NP, 2.5, 12.5, 25 and 50 µg/ml) for 24 






 cells was analyzed 
via FACS. All values are depicted as mean ± SEM (N = 3) (B) MH-S cells were incubated with 6 
µg/ ml BMP-NPs for 24 hours on cover glas bottom imaging dishes and NP incorporation was 
visualized by confocal microscopy. Scale bar: 15 µm. (C) MH-S cells were incubated without 
(w/o NP) or with 50 µg/ml BMP-NP for 6 or 24 hours in 24-well plates and the FMN signal within 
the cells was analyzed via FACS. Exemplary histograms are depicted for both time points 
blotting the FMN signal on the x-axis (N = 3) (Kaiser et al., submitted).           
 
 Cell type specific uptake of IOH-NPs 3.2.2
Cell types vary in their capacity to engulf substances via endocytic pathways 
and thus this feature can be used to specifically target individual cell types with 
nanoformulations. To further analyze the potential cell type specificity of      
IOH-NPs, the kinetics and incorporation of IOH-NPs in six representative cell 
lines was studied. Three of them are derived from immune cells as MH-S 
resemble macrophages, and WEHI7.1 (Wang et al., 2006) and WEHI231 are T 






tissues. Specifically L929, LA-4 and C2C12 are derived from fibroblasts, 
epithelial cells and myoblasts, respectively. In the first step, we incubated the 
cell lines with 2.5 µg/ml EP-NPs for up to 6 hours and measured the FMN signal 
within the cells over time via FACS (Figure 16A). MH-S cells were most efficient 
in taking up EP-NPs whereas hardly any incorporation was detectable in 
WEHI7.1 and WEHI231 cells. L929 cells were almost as efficiently incorporating 
EP-NPs as MH-S cells, whereas LA-4 and C2C12 showed only a moderate 
uptake. Next, we incubated the cell lines with 2.5 µg/ml EP-NPs or BMP-NPs for 
24 hours and measured the percentages of FMN+ cells via FACS (Figure 16B). 
Longer incubation times with the IOH-NPs increased the percentages of FMN+ 
cells in all cell types. However, the pattern of uptake efficiency in all cell types 
was similar to the patterns observed for the shorter EP-NP incubation times, 
even though MH-S cells were here clearly most efficient in incorporating      
IOH-NPs. Taken together, these studies show clear differences in the ability to 
engulf IOH-NPs between representative cell types. MH-S cells are most efficient 




















































































Figure 16: Cell type specific IOH-NP uptake in vitro. (A) Six different cell lines were 
incubated without (w/o NP) or with 2.5 µg/ml EP-NPs in 6-well plates for up to 6 hours and the 
FMN signal was analyzed within the cells via FACS (N = 3). (B) Six different cell lines were 
incubated without (w/o NP) or with 2.5 µg/ml EP-NPs or BMP-NPs for 24 hours and the FMN 
signal was analyzed within the cells via FACS. All values are depicted as mean ± SEM (N = 3) 
(Kaiser et al., submitted). 
 
 Cell viability in different cell lines upon IOH-NP treatment 3.2.3
In order to exclude toxic effects of IOH-NPs in the previously described cell 
lines, we studied their metabolic activity upon treatment with the IOH-NPs, 
which is an indicator for cell viability. The cell lines were incubated with          
2.5 µg/ml EP-NPs or BMP-NPs for 6 hours and the metabolic activity was 
analyzed based on an MTS test (Figure 17). The metabolic activity was neither 
affected upon the treatment with EP-NPs nor with BMP-NPs in any of the six 
cell lines, but it was clearly reduced in the control group that was treated with a 
toxic dose of 10 % DMSO for 3 hours. These results support the use of        
IOH-NPs as a potential harmless carrier system for targeting selective cell 



































Figure 17: Cell viability upon IOH-NP treatment in different cell lines in vitro. Six different 
cell lines were incubated without (w/o NP) or with 2.5 µg/ml EP-NP or BMP-NP in 96-well plates 
for 6 hours or for 3 hours with 10 % DMSO. Subsequently, a MTS assay was performed 
analyzing the metabolic activity as an indicator for cell viability. For each cell line, the metabolic 
activity was set to 100 % when cultured in the absence of IOH-NPs. All values are depicted as 
mean ± SEM (N = 4) (Kaiser et al., submitted). 
 
 Characterization of the endocytic IOH-NP uptake pathway in MH-S  3.2.4
           cells 
Eukaryotic cells constantly form and internalize membrane vesicles allowing 
bidirectional fluxes of extracellular fluids, membrane lipids or integral proteins 
from the in- and outside of the cell surface by a process called endo- and 
exocytosis, respectively. Depending on the characteristics of the cargo and the 
cell type, different endocytic pathways are used for internalization (Doherty and 
McMahon, 2009, Kou et al., 2013, Conner and Schmid, 2003). Since our 
pervious results highlighted that MH-S cells were most efficient in taking up 
IOH-NPs, we investigated in the following experiments the endocytic pathway of 
IOH-NPs in these cells by applying three pharmacological inhibitors in vitro. In 
brief, CytoD (cytochalasin D) blocks actin polymerization thereby preventing the 
formation of macropinosomes and phagosomes, which consist of F-actin-coated 
vesicles. Amiloride (amiloride hydrochloride hydrate) acts as a sodium-proton 
exchange inhibitor and hereby predominantly prevents the formation of 
macropinosomes. Finally, MDC (monodansyl-cadaverine) is an inhibitor of 
clathrin-mediated endocytosis, because it interferes with transglutaminase, 
which is necessary for the protein-crosslinking that enables the clustering and 




2012). In order to employ the optimal concentration of the inhibitors that results 
in minimal toxicity, we treated the cells with different concentrations of the 
before mentioned inhibitors for 24 hours and analyzed the metabolic activity 
with the help of an MTS test (Figure 18A). The metabolic activity was clearly 
reduced in the control group, when treated with a toxic concentration of           
10 % DMSO. In contrast, the viability of the cells was not affected when they 
were incubated with 1 µg/ml CytoD whereas the cells showed a reduced 
metabolic activity with increasing concentrations of Amiloride (0.5, 1 and 2 mM) 
and MDC (100 µM and 150 µM). Consequently, we decided to use 1 µg/ml 
CytoD, 0.5 mM Amiloride and 100 µM MDC in the following experiments. Next, 
we incubated MH-S cells with 50 µg/ml BMP-NPs together with either CytoD, 
Amiloride or MDC for up to 6 hours and analyzed the FMN signal in the cells via 
FACS (Figure 18B). IOH-NP uptake increased with longer incubation times, but     
IOH-NP internalization was partially inhibited by CytoD and Amiloride, but not 
with MDC, suggesting that IOH-NP uptake was mediated via the endocytic 
pathway macropinocytosis. Furthermore, we analyzed the IOH-NP uptake in 
MH-S cells when treated for 24 hours with increasing concentrations of      
BMP-NPs and either CytoD, Amiloride or MDC. FMN+ cells were again 
identified via FACS (Figure 18C). BMP-NP uptake increased in a                
dose-dependent manner in all four conditions and was partially inhibited by 
CytoD and Amiloride, but not MDC, providing additional evidence for 
macropinocytosis being the preferential IOH-NP uptake pathway. Finally, we 
analyzed potentially toxic effects of all three inhibitors for MH-S cells when 
treated for 3 to 6 hours and 24 hours by applying the MTS test (Figure 18D). In 
general, all inhibitors were well tolerated with the exception of Amiloride, which 

































































































































Figure 18: Endocytotic 
IOH-NP internalization 
pathway in MH-S cells in 
vitro. (A) Cells were 
cultured with 6 µg/ml BMP-
NPs and without (w/o 
inhibitor) or with either 1 µg/ 
ml Cytochalasin D (CytoD), 
0.5, 1 or 2 mM Amiloride 
hydrochloride hydrate 
(Amiloride), 100 µM or 150 
µM Monodansyl-cadaverine 
(MDC) or 10 % DMSO in 
96-well plates for 24 hours. 
Subsequently, a MTS assay 
was performed analyzing 
the metabolic activity as an 
indicator for cell viability. For 
each cell line, the metabolic 
activity was set to 100 % 
when cultured in the 
absence of inhibitors (N = 
4). (B) Cells were cultured 
with 50 µg/ml BMP-NPs and 
without or with 1 µg/ml 
CytoD, 1 mM Amiloride or 
100 µM MDC for up to 6 
hours in 24-well plates. The 
FMN signal within the cells 
was measured via FACS (N 
= 3). (C) Cells were cultured 
with BMP-NPs in increasing 
concentrations (w/o, 2.5, 
12.5, 25 or 50 µg/ml) and 
with or without either 1 
µg/ml CytoD, 1 mM 
Amiloride or 100 µM MDC in 
24-well plates for 24 hours. 
The FMN signal within the 
cells was measured via 
FACS (N = 4). (D) Cells 
were cultured with 6 µg/ml 
BMP-NPs and with or 
without either 1 µg/ml 
CytoD, 1 mM Amiloride or 
100 µM MDC or 10 % 
DMSO in 24-well plates for 
3 to 6 hours or 24 hours. 
Subsequently, a MTS assay 
was performed analyzing 
the metabolic activity as an 
indicator for cell viability. For 
each cell line, the metabolic 
activity was set to 100 % 
when cultured in the 
absence of inhibitors. All 
values are depicted as 
mean ± SEM (N = 5) (Kaiser 





 Intracellular fate of IOH-NPs upon engulfment  3.2.5
The pathway by which nanoparticles enter the cell influences their intracellular 
fate. Vesicles, that carry the cargo can either fuse with lysosomes for 
degradation, can be carried to the Golgi complex, are released outside from the 
cell or are delivered to the endoplasmatic reticulum (ER) and afterwards 
eventually to the cytosol, mitochondria or nucleus. Only cargo, which enters the 
cell via calveolae-mediated endocytosis does not end up in lysosomes, whereas 
all other pathways are associated with lysosomes (Kou et al., 2013). While we 
could show that IOH-NPs enter MH-S cells via macropinocytosis, we 
additionally investigated whether their intracellular fate was indeed associated 
with lysosomes. Therefore, we took advantage of imaging flow cytometry that 
combines two techniques, namely FACS and confocal microscopy, which 
enabled us to detect IOH-NP within selected cellular organelles. To this end, we 
incubated MH-S cells with 6 µg/ml BMP-NPs for 6 or 24 hours and stained 
either the mitochondria or the lysosomes with Mitotracker or Lysotracker, 
respectively. Both dyes were conjugated to a deep red (DR) fluorescence dye 
or fluorescence detection (Figure 19). The overlay of both signals, namely FMN 
and DR, resulted in a strong yellow signal when lysosomes were stained, 
indicating a corresponding localization of both dyes (Figure 19A). In contrast, 
isolated green and red dots were visible when mitochondria were labeled. 
Furthermore, by applying the co-localization wizard tool in the IDEAS software 
we were able to quantify the co-localization of BMP-NPs with lysosomes or 
mitochondria within the cells based on the Bright Detail Similarity (BDS, Figure 
19B). The BDS identifies the small punctate stainings in imaged pairs and 
measures the similarity of these dots. Up to 78 % of the cells showed a          
co-localization of BMP-NPs and lysosomes, when incubated for 6 and 24 hours, 
whereas the co-localization scores were only around 4 % when the 
mitochondria were stained (Figure 19C). Collectively, these data indicate that 
IOH-NPs are incorporated in MH-S cells by macropinocytosis and subsequently 








Figure 19: Intracellular fate of IOH-NPs in MH-S cells in vitro. (A) Cells were cultured in the 
presence of 6 µg/ ml BMP-NPs in 175 cm
2
 flasks for 6 hours and lysosomes or mitochondria 
were stained for 30 minutes with 100 nM Lysotracker or Mitotracker, respectively. Both tracker 
were conjugated with a deep red fluorescence dye. The cells were analyzed by imaging flow 
cytometry. Exemplary figures of brightfield and fluorescence images, including fluorescence 
overlays are depicted. (B) Cells were cultured in the presence of 6 µg/ ml BMP-NPs in 175 cm
2
 
flasks for 6 and 24 hours and lysosomes or mitochondria were stained, as described above. 
Double-positive cells were analyzed for the co-localization of BMP-NPs and lysosomes or 
mitochondria based on the bright detail similarity value. Figures depict exemplary both time 
points of one representative experiment. (C) Quantitative analysis of the co-localization of  
BMP-NPs and either lysosomes or mitochondria based on the bright detail similarity. Depicted 
are both time points. All values are depicted as mean ± SEM. Data derive from three 
independent experiments (Kaiser et al., submitted). 
 
 Biological effects of IOH-NPs in macrophages 3.2.6
In order to release the pharmacological drug betamethasone from the 
phosphate-based IOH-NPs, phosphatases or other enzymes need to hydrolyze 
the phosphate-ester-bond in the functional anions (Heck et al., 2015). Since 
lysosomes contain suitable enzymes for this purpose, we investigated the 
biological effect of BMP-NPs in primary macrophages. To this end, bone 
marrow derived macrophages (BMDMs) were cultured in the presence of 
ascending concentrations of BMP-NPs, but also with EP-NPs, as a control 
group. Subsequently, the expression of surface markers was analyzed via 
FACS (Figure 20A, B). MHCII and CD86 were chosen because they are known 






step of aGvHD. We found that the expression of both surface markers was 
reduced with ascending concentrations of BMP-NPs. In contrast, the expression 
of CD86 was unaltered when treated with EP-NPs and MHCII was only reduced 
to a minor extent by EP-NPs. These data indicate that betamethasone must be 
released from the BMP-NPs within the lysosomes of the BMDMs, thereby 
leading to an anti-inflammatory effect, amongst others, by downregulating the 
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Figure 20: Biological effect of IOH-NPs in BMDMs in vitro. Fully matured bone marrow 
derived macrophages (BMDMs) were cultured in 24-well plates without (w/o NP) or with 
increasing concentrations of BMP-NPs or EP-NPs for 24 hours. Subsequently, the expression 
of surface markers, such as MHCII (A) and CD86 (B), was analyzed via FACS. All values are 
depicted as mean ± SEM (N = 4/5) (Kaiser et al., submitted). 
 
3.3 Organ distribution of IOH-NPs in vivo after intraperitoneal injection  
           into mice 
Conventional pharmacological reagents consist most often of small molecules 
and thus have the disadvantage of equal systemic distribution. Consequently, 
higher doses are necessary to increase the concentration of the reagent at 
target sites, which causes intended and unintended activities, the latter 
contributing to unwanted side-effects. Theoretically, nanomedicines can 
circumvent these difficulties by targeting cells, tissues or organs. The 
pharmacokinetics and organ distribution of NPs relies on various parameters, 
such as size or surface properties. NPs with a size of 30 - 100 nm, in which 
category IOH-NPs belong, are known to accumulate in the liver, the spleen, 
lymph nodes, the bone marrow and vessels. These organs are       





distribution of IOH-NPs strongly impacts the activity profile of the delivered GCs 
in vivo, the third part of this thesis focuses on the resorption and organ 
distribution of IOH-NPs after i.p. injection into mice in vivo and ex vivo.  
 
 Resorption and organ distribution of GAP-NPs in vivo 3.3.1
To address the question of resorption and organ distribution of IOH-NPs in vivo, 
we took advantage of the magnetic resonance imaging (MRI) technique. Wild 
type mice were anaesthetized and kept actively ventilated throughout the whole 
experiment. Cross-sections of the abdominal region were taken every 30 
minutes, starting before the i.p. injection of 500 µl GAP-NPs containing 0.1 mg 
Gd until 6.5 hours later when the experiment was terminated (Figure 21A). 
Regions of interests (ROI) were drawn within the peritoneum and selected 
organs in order to quantify the accumulation and later the disappearance of 
GAP-NPs (Figure 21B). Within 30 minutes after the injection, GAP-NPs induced 
a strong signal in the peritoneal cavity, between the liver lobes, within the 
intestinal loops, and enwrapped the stomach, the kidneys and the spleen. The 
signal faded over time and eventually cleared out in some areas, but was still 
detectable for example within the stomach. The ROI analysis in the peritoneal 
cavity confirmed the disappearance of GAP-NPs within two hours upon 
injection. The signal within the liver and small intestine increased slightly over 
time, whereas the signal in the stomach peaked at 3 hours after injection and 
stayed at this level until the end of the experiment. In contrast, no signal was 
visible within the kidney. Taken together, these data demonstrate a slow 
release of GAP-NPs from the peritoneal cavity and a subsequent accumulation 





Figure 21: Resorption and organ distribution of GAP-NPs via MRI in vivo. Mice were 
anaesthetized and actively ventilated throughout the whole experiment. 500 µl GAP-NPs were 
injected i.p. and abdominal cross-sections were obtained 30 minutes before the injection and 
6.5 hours onwards with the help of an MRI scanner. (A) Exemplarily are depicted two cross-
section levels at the time points -30 min, +30 min, 3 and 5 hours upon injection. Region of 
interests (ROI) are marked for the intraperitoneal cavity 1 + 2 (IP1+2), liver (li), kidney (ki), small 
intestine (si) and stomach (st). (B) Quantitative analysis of GAP-NPs distribution within the 






 Organ distribution of IOH-NPs analyzed ex vivo 3.3.2
In order to obtain supporting evidence for our previous results with regard to the 
organ distribution of GAP-NPs in vivo, we determined the zirconium (Zr) 
concentration within selected organs upon i.p. application of BMP-NPs to mice 
by Inductive Coupled Plasma-Mass Spectrometry (ICP-MS). Selected organs 
were dissected and analyzed ex vivo either 5 or 24 hours after the application of 
500 µl BMP-NPs containing 0.2 mg Zr. At the early analytical time point, namely 
5 hours after the injection, we observed the highest absolute amount of Zr in the 
liver, followed by the stomach and jejunum. In contrast, Zr was hardly 
detectable in the kidney and lung (Figure 22A). Over time, namely 24 hours 
after injection, the Zr content slightly decreased in the liver and was reduced by 
half in the jejunum (Figure 22B). In summary, these ICP-MS data are indeed in 
line with our in vivo data acquired from MRI scans and let us assume that     
IOH-NPs are slowly resorbed by the intraperitoneal cavity via lymphatic 
drainage. Subsequently, IOH-NPs accumulate in the liver, jejunum and 
















































24 hrs upon injection
Figure 22: Organic distribution of IOH-NPs analyzed via ICP-MS ex vivo. 500 µl BMP-NPs 
containing 0.2 mg zirkonium (Zr) was injected ip. into mice. Selected organs were dissected 
either 5 hours or 24 hours upon the injection and the Zr content within these organs was 
analyzed. (A) absolute Zr content in liver, jejunum, kidney, lung and stomach 5 hours upon the 
injection. (B) absolute Zr content in liver and jejunum 24 hours upon the injection. All values are 









3.4 Application of BMP-NPs as a targeted therapy for aGvHD in mice 
Considering the findings presented in this thesis up to now, BMP-NPs could be 
a potential powerful carrier system for a targeted GC therapy of aGvHD mice, 
and eventually also in humans. In brief, we have shown the importance of the 
GR in recipient myeloid cells in an aGvHD mouse model and found that       
IOH-NPs show a considerable cell-type specificity mainly towards macrophages 
in the absence of any notable toxic effects in six different cell lines. Moreover, 
MRI and ICP-MS analyses revealed a favorable organ distribution in healthy 
mice, including an accumulation in the small intestine and liver being major 
target organs of aGvHD. Hence, the fourth part of this thesis focuses on the 
suitability and pathomechanism of BMP-NPs in the treatment of aGvHD in a 
mouse model in vivo in comparison to free betamethasone (BMX).  
 
 BMP-NP and BMX treatment prolongs the survival in a mouse  3.4.1
           model of aGvHD mice with similar efficiency 
To explore and compare the treatment efficiencies of BMP-NPs and BMX in the 
fully MHC-mismatched aGvHD mouse model, which was also used in the first 
part of this thesis, we monitored the survival of mice from the different treatment 
groups for 50 days (Figure 23). BALB/c wild type mice served as recipients and 
C57BL/6 wild type mice were used as donor mice for the BM and T cell graft. 
The recipients were treatment at day 3, 4, 5, 7, 9 and 12 to mimic a pulse 
therapy followed by the tapering of the drug. The mice received either 10 mg/kg 
BMX or BMP-NPs containing an equal amount of the drug at each time point. 
Similar volumes of either EP-NPs or PBS were injected as controls. The 
majority of EP-NP and PBS treated mice succumbed to death before day 10                 
post-transplantation. No significant differences were noted between both control 
groups. In comparison to the PBS control group, BMX treated mice died 
significantly later or had to be sacrificed for ethical reasons, between day 18 
and 24 (Figure 23). The majority of BMP-NP treated mice died over a longer 
time period, namely between day 14 and 31, which was significantly later than 
the respective EP-NP control group (Figure 23). In this experiment, BMP-NP 
was slightly more efficient than BMX in prolonging the survival of the mice 




the end of the experiment. From this long-term experiment we concluded, that 
BMX and BMP-NP treatment prolonged the survival in aGvHD mice with largely 
similar efficiency, although BMP-NP was slightly better.  




























Figure 23: Survival of aGvHD wt mice upon treatment with GCs. Lethally irradiated BALB/c 
wt recipient mice were transplanted with BM and purified T cells from donor C57BL/6 wt mice. 
BM controls received T cell depleted BM only. Mice received either 10 mg/kg BMP-NPs or BMX 
or equal amounts of EP-NPs or PBS at day 3, 4, 5, 7, 9 and 12 i.p.. Survival of mice was 
recorded for 50 days. N = 4 (BM), N = 8 (PBS), N = 10 (BMX), N = 7 (EP-NP), N = 9 (BMP-NP); 
data pooled from multiple experiments, including data from Laura Roßmann. Survival curves 
were compared using the Mantel-Cox test (*p < 0.05; **p < 0.01; ***p < 0.001; n.s.: non-
significant). 
 
 BMP-NP and BMX treatment ameliorates clinical features in the  3.4.2
           early phase of aGvHD to a similar extent 
In the following, we wanted to explore the mechanisms that may underlay the 
ameliorating effects of BMP-NPs in the early phase of aGvHD. Thereto, aGvHD 
was induced in wild type mice followed by treatment with either 10 mg/kg   
BMP-NPs or BMX, or equal amounts of EP-NPs or PBS at day 3, 4 and 5. 
Clinical parameters, such as the clinical score and the body weight were 
monitored for 6 days, which corresponds to the first peak of the disease. 
Additionally, the body temperature was recorded at day 6 after BMT. Control 
mice treated with PBS or EP-NPs developed the expected disease course 
characterized by the progressively increasing clinical scores that were highest 
at day 6 (Figure 24A, B). In contrast, aGvHD symptoms were attenuated in 
BMX and BMP-NP treated mice, indicated by significantly lower clinical scores 




Furthermore, body weight and body temperature at day 6 were significantly 
lower in PBS and EP-NP treated mice in comparison to BMX and BMP-NP 
treated mice, respectively (Figure 24C, D). When we compared all three 
parameters at day 6 after BMT between PBS and EP-NP treated mice as well 
as between BMX and BMP-NP treated mice, we did not detect any significant 
differences. Finally, BM mice did not suffer from aGvHD, which was indicated 
by the low clinical score, normal body weight and body temperature. 
Collectively, PBS and EP-NP treated mice suffered strongly from aGvHD 
characterized by high clinical scores, a low body weight and a low body 
temperature. In contrast, BMX and BMP-NP treatment ameliorated aGvHD 
symptoms to a similar extent in the early phase of the disease in these       
short-term experiments.    


















































































































Figure 24: Clinical features 
of aGvHD in GC-treated wt 
mice in the early phase. 
Lethally irradiated BALB/c wt 
recipient mice were 
transplanted with BM and 
purified T cells from donor 
C57BL/6 wt mice. BM 
controls received T cell 
depleted BM only. Mice 
received either 10 mg/kg 
BMP-NPs or BMX or equal 
amounts of EP-NPs or PBS 
at day 3, 4, 5 i.p.. (A) Clinical 
scores were monitored for 
six days after aGvHD 
induction (dead mice were 
listed with a score of 10). (B) 
Clinical scores at day 6 after 
BMT. (C) Body weights at 
day 6 day after BMT; N = 12 
(BM), N = 21 (PBS), N = 22 
(BMX), N = 23 (EP-NP), N = 
23 (BMP-NP); (D) Body 
temperature at day 6 after 
BMT; N = 6 (BM), N = 10 
(PBS), N = 12 (BMX), N = 9 
(EP-NP), N = 12 (BMP-NP).  
Data pooled from multiple 
experiments, including data 
from Laura Roßmann. All 
values are depicted as the 
mean ± SEM. Statistical 
analyses were performed 
using the unpaired one-tailed 
students t-test (*p < 0.05; **p 
< 0.01; ***p < 0.001; n.s.: 
non-significant). 




 BMP-NP and BMX treatment ameliorates target tissue destruction in  3.4.3
           the jejunum in the early phase of aGvHD with similar efficiency 
Having demonstrated that BMP-NPs ameliorate aGvHD symptoms in the early 
phase as efficiently as BMX treatment in mice in vivo, we next wanted to get 
insights into the beneficial mode of action of BMP-NPs versus BMX in the early 
phase of aGvHD. Thereto, mice from the short-term experiments (see 3.4.2), 
including all treatment groups, as well as BM mice were sacrificed at day 6 after 
BMT and histological analyses of the aGvHD target organ jejunum were 
performed. The histological score we calculated includes villus blunting, 
inflammation and the number of apoptotic cells and edemas. Collectively, it is 
an indicator for the degree of tissue destruction, caused by the disease. 
Moreover, it is assisted by the number of goblet cells per villus, which is 
reduced in case of a strong tissue destruction. Both parameters are common 
aGvHD hallmarks. As expected, PBS and EP-NP treated mice showed 
significantly higher histopathological scores in comparison to BMX and BMP-NP 
treated mice (Figure 25A, B). Also the number of goblet cells per villus was 
significantly reduced in the control groups PBS and EP-NP in contrast to BMX 
and BMP-NP treated mice, respectively (Figure 25A, C). Based on the before 
mentioned parameters, BM mice exhibited an intact jejunum, which was not 
affected by the disease. Taken together, these results suggest, that both ways 
of GC applications ameliorate the disease by reducing the tissue destruction in 

















































































Figure 25: Histological analysis of the jejunum in the early phase of aGvHD in GC-treated 
wt mice. Lethally irradiated BALB/c wt recipient mice were transplanted with BM and purified T 
cells from donor C57BL/6 wt mice. BM controls received T cell depleted BM only. Mice received 
either 10 mg/kg BMP-NPs or BMX or equal amounts of EP-NPs or PBS at day 3, 4, 5 i.p.. Mice 
were sacrificed at day 6 after BMT and histological analysis of the jejunum was performed. (A) 
Representative microphotographs of sections of the jejunum stained by H&E or PAS reaction. 
Scale bar: 100 µm. (B) Histological scores imply villus blunting, inflammatory infiltrates, edema 
and apoptotic cells analyzed by H&E stained jejunum sections; N = 3 (BM), N = 10 (PBS),        
N = 11 (BMX), N = 9 (EP-NP), N = 12 (BMP-NP); (C) Goblet cell numbers per villus were 
analyzed by PAS reaction of jejunum sections; N = 3 (BM), N = 11 (PBS), N = 11 (BMX), N = 9 
(EP-NP), N = 11 (BMP-NP); Data pooled from multiple experiments. All values are depicted as 
the mean ± SEM. Statistical analyses were performed using the unpaired one-tailed students t-













 BMX, but not BMP-NP treatment reduces infiltration of CD68+ and  3.4.4
           CD3+ into the jejunum in the early phase of aGvHD 
GC treatment similarly reduced the tissue destruction in the jejunum regardless 
of the application form. Therefore we were next interested whether this is 
because they both prevent the infiltration of immune cells into the jejunum or 
whether they rather locally influence the phenotype of aGvHD relevant immune 
cells. First, we examined the infiltration of CD3+ and CD68+ cells by 
immunohistochemical stainings of jejunum sections. The numbers of CD3+       
T cells and CD68+ myeloid cells were elevated in PBS treated mice in 
comparison to BM control mice (Figure 26). Furthermore, the number of both 
immune cell types was significantly decreased in the BMX treated group in 
comparison to the PBS group. Surprisingly, the number of both immune cell 
types was similarly elevated in EP-NP and BMP-NP treated mice in comparison 
to the BM control group, from which we conclude that BMP-NPs neither reduces 























































































Figure 26: Immunohistochemical analysis of the jejunum in the early phase of aGvHD in 
GC-treated wt mice. Lethally irradiated BALB/c wt recipient mice were transplanted with BM 
and purified T cells from donor C57BL/6 wt mice. BM controls received T cell depleted BM only. 
Mice received either 10 mg/kg BMP-NPs or BMX or equal amounts of EP-NPs or PBS at day 3, 
4, 5 i.p.. Mice were sacrificed at day 6 after BMT and immunohistochemical analysis of the 
jejunum was performed. (A) Representative microphotographs of sections of the jejunum 





 were examined by computer-aided counting of stained cells in jejunum sections 
using the Zeiss Zen lite software; N = 4 (BM), N = 11 (PBS), N = 11 (BMX), N = 9 (EP-NP),       
N = 12 (BMP-NP); (C) CD68
+
 myeloid cells were examined in jejunum sections by measuring 
the percentage of stained area using the ImageJ software; N = 4 (BM), N = 11 (PBS), N = 8 
(BMX), N = 9 (EP-NP), N = 12 (BMP-NP). Data pooled from multiple experiments. All values are 
depicted as the mean ± SEM. Statistical analyses were performed using the unpaired one-tailed 













To allow a more refined analysis of immune cell subtypes in the infiltrated 
jejunum of the aGvHD mice, they were isolated from the lamina propria and 
analyzed via FACS. The percentage of CD4+ CD3+ T cells was significantly 
higher, and of the CD8+ CD3+ T cells significantly lower in BM mice in 
comparison to PBS treated mice (Figure 27A). Moreover, in BMX treated mice 
the percentage of CD4+ CD3+ T cells was significantly elevated, and CD8+ CD3+ 
T cells reduced (p=0.05) in comparison to the PBS group. In agreement with the 
previous immunohistochemical analysis, such differences were not observed 
between BMP-NP treated mice in comparison to EP-NP treated mice. Next, we 
examined the abundance of different subpopulations of CD11b+ Ly6Glow 
myeloid cells, which correspond to different types of macrophages and 
monocytes. Ly6Chigh cells, which represent the inflammatory phenotype, were 
significantly lower in BM mice in comparison to the PBS treated group, whereas 
Ly6Clow cells, representing the resting non-inflammatory phenotype, were 
significantly higher (Figure 27B). BMX treatment significantly reduced the 
percentage of Ly6Chigh myeloid cells and significantly increased the percentage 
of Ly6Clow myeloid cells in comparison to the PBS treatment. Surprisingly,   
BMP-NP treatment solely caused a weak shift in the same direction in 
comparison to EP-NP treatment. To summarize these results, BMP-NP 
treatment, in contrast to the BMX treatment, neither prevents the infiltration of 
CD3+ nor CD68+ cells in the jejunum. Furthermore, BMP-NPs neither impact the 
percentage of CD4+ and CD8+ T cells nor of Ly6Chigh myeloid cells. This let us 
to conclude, that both GC application forms apply different mechanisms in order 

















































































































day 6 after BMT
Figure 27: Characterization of the cellular composition of the inflammatory infiltrate in 
the lamina propria in the jejunum in GC-treated wt mice in the early phase of aGvHD. 
Lethally irradiated BALB/c wt recipient mice were transplanted with BM and purified T cells from 
donor C57BL/6 wt mice. BM controls received T cell depleted BM only. Mice received either    
10 mg/kg BMP-NPs or BMX or equal amounts of EP-NPs or PBS at day 3, 4, 5 i.p.. Mice were 
sacrificed at day 6 after BMT, cells present in the lamina propria were isolated from the jejunum 









 T cells (right panel) based on the expression of the respective surface 













 myeloid cells 
(right panel) based on the expression of the respective surface markers. N = 3 (BM), N = 7 
(PBS), N = 4 (BMX), N = 4 (EP-NP), N = 5 (BMP-NP). Data pooled from multiple experiments. 
All values are depicted as the mean ± SEM. Statistical analyses were performed using the 
unpaired one-tailed students t-test (*p < 0.05; **p < 0.01; ***p < 0.001; n.s.: non-significant). 
 
 GR expression in myeloid cells is required for therapeutic efficacy  3.4.5
           of BMP-NP treatment in the early phase of aGvHD   
Our findings indicated that BMP-NPs and BMX use different mechanisms in 
order to ameliorate aGvHD. Therefore, we wanted to explore whether GC 
effects in myeloid cells were indeed essential to ameliorate aGvHD by using 
GRlysM mice that we had already studied in the first part of this thesis (see 3.1). 
GRlysM mice carry a deletion of the GR in myeloid cells, which makes them 
unsusceptible to GCs. GRlysM and GRflox control mice were treated either with  
10 mg/kg BMP-NPs or equal amounts of EP-NPs at day 3, 4 and 5. The mice 






Clinical parameters were monitored and histological analyses were performed 
to obtain insights into the health status of the animals. GRflox and GRlysM mice 
treated with EP-NPs, not containing any GCs, progressively developed disease 
symptoms over time. This was indicated by the constantly increasing clinical 
scores (Figure 28A, B). In contrast, when we treated both mice strains with 
BMP-NPs, the disease only improved in GRflox, but not in GRlysM mice (Figure 
28A). GRflox mice treated with BMP-NPs had significantly lower clinical scores 
and a higher body temperature in comparison to GRflox mice treated with        
EP-NPs (Figure 28B, C), which is in line with the previous results obtained in 
wild type BALB/c mice (see Figure 24). However, we detected no differences in 
both parameters between GRlysM mice treated with either BMP-NPs or EP-NPs 
(Figure 28B, C). As expected, control BM mice did not suffer from aGvHD 































































































Figure 28: Clinical features in the early phase of aGvHD in the GR
lysM
 model treated with 




 recipient mice were transplanted with 
BM and purified T cells from donor C57BL/6 wt mice. BM controls received T cell depleted BM 
only. Mice received either 10 mg/kg BMP-NPs or equal amounts of EP-NPs at day 3, 4, 5 i.p.. 
(A) Clinical scores were monitored for six days after aGvHD induction (dead mice were listed 
with a score of 10). (B) Clinical scores at day 6 after BMT (C) Body temperatures at day 6 after 
BMT; N = 4 (BM), N = 7/10 (GR
flox
; EP-NP/BMP-NP), N = 10/9 (GR
lysM
; EP-NP/BMP-NP).  Data 
pooled from multiple experiments. All values are depicted as the mean ± SEM. Statistical 
analyses were performed using the unpaired one-tailed students t-test (*p < 0.05; **p < 0.01; 
***p < 0.001; n.s.: non-significant). 
 
To support our conclusions derived from monitoring the disease course in 
GRlysM mice treated with BMP-NPs, we also performed histological analyses 
similar to our previous study of wild type mice (see Figure 25). The histological 
score was significantly lower and the number of goblet cells was significantly 
higher in GRflox mice treated with BMP-NPs in comparison to GRflox mice treated 
with EP-NPs (Figure 29A). These results are in agreement with our earlier 
findings (see Figure 25). In contrast, we detected no differences in both 
parameters in GRlysM mice treated either with BMP-NPs or EP-NPs. BM mice 
had an intact jejunum based on the histological score and the number of goblet 
cells per villus. Additionally, immunohistochemical analysis of the jejunum was 
done to study the infiltration of CD3+ T cells and CD68+ myeloid cells into this 






mice (Figure 29B) as seen before (see Figure 26). The same observation was 
made for GRlysM mice, as expected. In contrast, BM mice showed low numbers 
of CD3+ T cells and CD68+ myeloid cells compared to GRflox mice treated with 
EP-NPs. In conclusion, BMP-NP treatment improves aGvHD symptoms only in 
GRflox mice in the early phase of aGvHD, whereas GRlysM mice do not respond 
to BMP-NP treatment. This finding proves that BMP-NPs indeed mainly act on 

















































































































Figure 29: Histological and immunochemical analyses of the jejunum in the early phase 
of aGvHD in the GR
lysM





 recipient mice were transplanted with BM and purified T cells from donor C57BL/6 wt 
mice. BM controls received T cell depleted BM only. Mice received either 10 mg/kg BMP-NPs or 
equal amounts of EP-NPs at day 3, 4, 5 i.p.. Mice were sacrificed at day 6 after BMT and 
histological and immunohistological analyses of the jejunum were performed. (A) Histological 
scores (left figure) and goblet cells/ villus (right figure) were determined in sections of the 
jejunum stained by H&E or PAS reaction, respectively. Histological scores imply villus blunting, 
inflammatory infiltrates, edema and apoptotic cells; N = 4 (BM), N = 7/7 (GR
flox
; EP-NP/        
BMP-NP), N = 8/9 (GR
lysM
; EP-NP/BMP-NP). Goblet cells/ villus; N = 3 (BM), N = 7/7 (GR
flox
;          
EP-NP/BMP-NP), N = 8/8 (GR
lysM
; EP-NP/BMP-NP). (B) Number of CD3
+





 myeloid cells (right figure) were determined in the jejunum stained with 
antibodies recognizing CD3 or CD68, respectively. Numbers of CD3
+
 T cells per mm
2
 were 
examined by computer-aided counting of stained cells in jejunum sections using the Zeiss ZEN 
lite software; N = 4 (BM), N = 6/10 (GR
flox
; EP-NP/BMP-NP), N = 10/9 (GR
lysM
; EP-NP/        
BMP-NP). CD68
+
 myeloid cells were examined in jejunum sections by measuring the 
percentage of stained area using the ImageJ software; N = 4 (BM), N = 7/8 (GR
flox
;                
EP-NP/BMP-NP), N = 10/8 (GR
lysM
; EP-NP/BMP-NP). Data pooled from multiple experiments. 
All values are depicted as the mean ± SEM. Statistical analyses were performed using the 













 BMP-NP and BMX treatment does not reduce systemic cytokine  3.4.6
           secretion in the early phase of aGvHD 
Deletion of the GR in myeloid cells of the GRlysM mouse model resulted in a 
systemic pro-inflammatory cytokine secretion in the early phase of aGvHD, 
which was responsible for the development of a fulminant disease course with 
early lethality (Baake et al., 2018). These finding suggest that preventing a 
cytokine storm is the primary mechanism by which GCs interfere with aGvHD. 
Hence it is conceivable that treatment with BMX or BMP-NPs uses the same 
mechanism. In the following, we were therefore interested whether the 
therapeutic efficacy of BMP-NPs could be explained by a reduction of the 
systemic secretion of pro-inflammatory cytokines associated with macrophages 
and indirectly also with T cells. To address this question, aGvHD was induced in 
wild type mice as previously described, which subsequently received either     
10 mg/kg BMP-NPs or BMX, or equal amounts of EP-NPs or PBS at day 3, 4 
and 5. The mice were sacrificed at day 6 after BMT and cytokine levels in the 
sera were analyzed by ELISA. All inspected cytokines, namely TNFα, IL-6, 
CCL-2 and IFNγ were elevated in PBS treated aGvHD mice in contrast to BM 
mice (Figure 30). However, the levels of all cytokines were unaltered when 
comparing PBS and BMX treated mice as well as EP-NP and BMP-NP treated 
mice. This finding indicates that suppression of systemic cytokine secretion is 


























































































Figure 30: Systemic cytokine levels in the early phase of aGvHD in wt mice treated with 
GCs. Lethally irradiated BALB/c recipient wt mice were transplanted with BM and purified T 
cells from donor C57BL/6 wt mice. BM controls received T cell depleted BM only. Mice received 
either 10 mg/kg BMP-NPs or BMX or equal amounts of PBS or EP-NPs at day 3, 4, 5 i.p.. Mice 
were sacrificed at day 6 after BMT. Serum levels of IL-6, TNFα, IFNγ and CCL-2 were 
determined by ELISA. IL6: N = 4 (BM), N = 11 (PBS), N = 12 (BMX), N = 11 (EP-NP), N = 13 
(BMP-NP). TNFα: N = 4 (BM), N = 9 (PBS), N = 5 (BMX), N = 8 (EP-NP), N = 8 (BMP-NP).  
CCL-2: N = 7 (BM), CCL-2: N = 11 (PBS), N = 13 (BMX), N = 11 (EP-NP), N = 14 (BMP-NP). 
IFNγ: N = 6 (BM), N = 10 (PBS), N = 13 (BMX), N = 11 (EP-NP), N = 14 (BMP-NP). Data pooled 
from multiple experiments. All values are depicted as mean ± SEM. Statistical analyses were 
performed using the unpaired one-tailed students t-test (*p < 0.05; **p < 0.01; ***p < 0.001; n.s.: 
non-significant). 
 
 BMP-NP and BMX treatment reduces the cytokine gene expression  3.4.7
           in the early phase of aGvHD in the jejunum to a similar extent  
Since we had failed to detect any differences in the systemic cytokine secretion 
between the four treatment groups, we investigated the local cytokine 
expression in the aGvHD target organ jejunum. Therefore, RNA was isolated 
from jejunum biopsies at day 6 after BMT and analyzed by quantitative          
RT-PCR. Gene expression of all cytokines that we analyzed, namely Tnfa, Il6, 
Ccl2, Il10, Il2 and Ifng were significantly increased in PBS treated aGvHD mice 
compared to BM controls (Figure 31). Conversely, BMX treatment reduced the 
mRNA levels of all cytokines in comparison to the PBS group, an effect that was 




effects compared to EP-NP treatment, which was again significant, except for 
Ccl2 and Il6. Taken together, both forms of GCs similarly provoke a local 
reduction of mainly macrophage and T cell associated pro-inflammatory 
cytokines, as well as of the anti-inflammatory cytokine Il10. We conclude that 
this effect is the common and main mechanism by which BMX and BMP-NPs 































































































































Figure 31: Cytokine expression in the jejunum in the early phase of aGvHD in wt mice 
treated with GCs. Lethally irradiated BALB/c recipient wt mice were transplanted with BM and 
purified T cells from donor C57BL/6 wt mice. BM controls received T cell depleted BM only.  
Mice received either 10 mg/kg BMP-NPs or BMX or equal amounts of PBS or EP-NPs at day 3, 
4, 5 i.p.. Mice were sacrificed at day 6 after BMT. Relative mRNA levels of Tnfa, Il6, Ccl2, Il10, 
Il2 and Ifng in jejunum biopsies were analyzed by quantitative RT-PCR using Hprt for 
normalization; gene expression analysis of BM controls was arbitrarily set to 1. Tnfa: N = 6 
(BM), N = 7 (PBS), N = 10 (BMX), N = 9 (EP-NP), N = 12 (BMP-NP), Il6, Ccl2, Il2, Ifng : N = 6 
(BM), N = 8 (PBS), N = 11 (BMX), N = 10 (EP-NP), N = 12 (BMP-NP), Il10: N = 6 (BM), N = 8 
(PBS), N = 11 (BMX), N = 9 (EP-NP), N = 12 (BMP-NP). Data pooled from multiple 
experiments. All values are depicted as mean ± SEM. Statistical analyses were performed using 








3.5 Assessing the side-effect profile of a targeted GC therapy using  
           IOH-NPs  
Synthetic GCs are widely used for the treatment of inflammatory diseases and 
represent the golden standard for aGvHD first-line therapy due to their  
immuno-modulatory effects. Nevertheless, the frequent occurrence of severe 
side-effects considerably complicates their use in clinical practice. Our previous 
results confirmed that BMP-NPs are highly suitable for the treatment of aGvHD, 
at least in mouse models, and suggest that they possess a clearly increased 
cell type specificity, in particular for macrophages. In the last part of this thesis, 
we therefore investigated whether BMP-NPs were able to circumvent 
undesirable common GC side-effects as a result of their target mode of action 
and thus might be a superior drug formulation for the treatment of aGvHD. 
 
 BMP-NP treatment upregulates metabolic liver enzymes similar to  3.5.1
           BMX 
One common side-effect of GCs concerns the liver as one of the major 
metabolic organ of our body. Synthetic GCs increase the blood glucose level 
and the expression of liver enzymes involved in gluconeogenesis. In order to 
analyze these parameters, C57BL/6 wild type mice were treated with 10 mg/kg 
BMP-NPs or BMX or equal amounts of PBS or EP-NPs for 14 consecutive 
days. Subsequently, the animals were fasted overnight and the blood glucose 
as well as the mRNA levels of gluconeogenetic enzymes were analyzed two 
hours after the last injection. The former feature was investigated via tail vein 
puncture using a standard electronic device and the latter was analyzed via 
quantitative RT-PCR. The blood glucose level was slightly increased in BMX 
treated mice compared to PBS treated mice, and also a minor increase was 
detectable in BMP-NP treated mice compared to the EP-NP group (Figure 32A). 
However, both effects failed significance. In contrast, all analyzed liver 
enzymes, namely FK506-binding protein (Fkbp51), tyrosine aminotransferase 
(Tat) and phosphoenolpyruvate-carboxykinase (Pepck) were significantly 
upregulated in BMX treated mice compared to PBS treated mice as well as in 
BMP-NP treated mice compared to EP-NP treated mice (Figure 32B). This let 




enzymes as efficiently as BMX treatment. Hence, it is unlikely that IOH-NPs 





































































































































Figure 32: Blood glucose level and metabolic enzyme expression in the liver after GC 
treatment in wt mice. C57BL/6 wt mice were treated with10 mg/kg BMP-NPs or BMX or equal 
amounts of PBS or EP-NPs i.p. for 14 consecutive days in the morning at 9 a.m.. Food was 
removed at 6 p.m. at the day before analysis. (A) Blood glucose levels were measured two 
hours after the last injection via tail vein puncture at day 14 upon fasting ON. N = 13 (PBS),      
N = 14 (BMX), N = 14 (EP-NP) N = 14 (BMP-NP); data pooled from multiple experiments, 
includes data from Elena Montes-Cobos (B) Relative mRNA expression levels of FK506-binding 
protein (Fkbp51), tyrosine aminotransferase (Tat) and phosphoenolpyruvate-carboxykinase 
(Pepck) in liver biopsies analyzed by quantitative RT-PCR using heterochromatin protein 1 
(Hp1) for normalization. Samples were collected at day 14, two hours after the last i.p. injection. 
Gene expression in PBS treated mice was arbitrarily set to 1. N = 10 (PBS), N = 10 (BMX),       
N = 10 (EP-NP), N = 10 (BMP-NP); data pooled from multiple experiments. All values are 
depicted as mean ± SEM. Statistical analyses were performed by using the unpaired one-tailed 






 BMP-NP treatment induces myopathy to a similar extent as free  3.5.2
           BMX treatment   
GCs reduce protein synthesis and increase protein degradation, which leads to 
a reduction in muscle mass, known as myopathy (Schakman et al., 2008). By 
setting up the following experiment, we investigated whether BMP-NP treatment 
was able to circumvent this side-effect. C57BL/6 wild type mice were treated 
with 10 mg/kg BMP-NPs or BMX or equal amounts of PBS or EP-NPs for 14 
consecutive days. The body weight of mice was measured two hours after the 
last injection. In addition, the M. gastrocnemius was dissected and weighted. 
Finally, mRNA levels of myopathy-related genes were analyzed in the muscle 
by quantitative RT-PCR, in detail collagen type I α 1 (Col1a1), metallothionein 2 
(Mt2) and Forkhead box O1 (Foxo1). The expression of Col1a1 is crucial for the 
preservation of the extracellular matrix of the muscle. MT2 inhibits the Akt 
pathway, thereby reducing the amino acid synthesis and FoxO1 is a 
transcription factor that activates E3 ligases, involved in the proteolytic 
machinery (Summermatter et al., 2017, Watson et al., 2012). We found that the 
total body weight and the weight of the M. gastrocnemius were both significantly 
reduced in BMX treated mice in comparison to PBS treated mice (Figure 33A). 
The same was also observed for the comparison between EP-NP and BMP-NP 
treated mice. BMP-NPs lost slightly more body weight in comparison to BMX 
treated mice, even though the muscle mass was similarly reduced by GCs 
regardless of whether they were applied as free drug or by using IOH-NPs 
(Figure 33A). Furthermore, BMX and BMP-NP treatment both significantly 
reduced the expression of Col1a1 compared to the respective control groups 
receiving PBS or EP-NPs. In contrast, Mt2 and Foxo1 were significantly 
increased in both GC-treatment groups compared to their respective control 
groups (Figure 33B). Taken together, the altered expression of myopathy 
related genes in BMX and BMP-NP treated mice parallels the loss of muscle 
mass by both treatments, let us to conclude that BMP-NPs provoke this 










































































































































































Figure 33: Body weight, muscle weight and gene expression in the M. gastrocnemius 
after GC treatment in wt mice. C57BL/6 wt mice were treated with10 mg/kg BMP-NPs or BMX 
or equal amounts of PBS or EP-NPs i.p. for 14 consecutive days in the morning at 9 a.m.. Body 
weight was monitored and the M. gastrocnemius was dissected and weighted two hours after 
the last i.p. injection. (A) Body weight [g] and M. gastrocnemius weight [mg] measured in mice. 
N = 12 (PBS), N = 14 (BMX), N = 10 (EP-NP) N = 12 (BMP-NP); data pooled from multiple 
experiments, includes data from Elena Montes-Cobos (B) Relative mRNA expression levels of 
collagen type I α 1 (Col1a1), metallothionein 2 (Mt2) and forkhead box O1 (Foxo1) in M. 
gastrocnemius biopsies analyzed by quantitative RT-PCR using Hprt for normalization. Gene 
expression in PBS treated mice was arbitrarily set to 1. N = 6 (PBS), N = 7 (BMX), N = 7      
(EP-NP) N = 7 (BMP-NP); data pooled from multiple experiments. All values are depicted as 
mean ± SEM. Statistical analyses were performed by unpaired one-tailed student´s t-test (*p < 







 BMP-NP treatment reduces the bone turnover similar to BMX  3.5.3
           application  
Osteoporosis is one more common and very severe side-effect of therapeutic 
GC administration (Moutsatsou et al., 2012). Markers of bone turnover 
measured in serum samples are a reliable method to investigate ongoing 
creeping processes within the bone. Bone formation markers are separated into 
two categories. On the one hand, there are bone resorption markers, measuring 
byproducts of osteoclast activity such as the formation of C-terminal telopeptide 
of type I collagen (CTX-1), a collagen degradation product. On the other hand, 
there are bone formation markers, measuring products of active osteoblasts, 
such as pro-collagen type 1 N-terminal peptide (P1NP), a byproduct of collagen 
synthesis (Shetty et al., 2016). Based on these parameters, we investigated 
whether BMP-NP treatment was able to circumvent the induction of 
osteoporosis. BALB/c wild type mice were treated with 10 mg/kg BMP-NPs or 
BMX, or equal amounts of PBS or EP-NPs for 14 consecutive days. 
Subsequently, serum samples were collected via heart puncture two hours after 
the last injection and bone turnover markers were analyzed via ELISA. The 
CTX-1 level was slightly elevated by about 15 %, although without reaching 
significance in BMX treated mice compared to PBS treated mice and the same 
held true for BMP-NP treated mice compared to EP-NP treated mice (Figure 
34). In contrast, BMX treatment significantly reduced the P1NP level compared 
to PBS treatment and the same pattern was observed for BMP-NP treatment 
compared to EP-NP treatment. These results let us to conclude that BMP-NP 
treatment negatively affects the bone turnover, mainly via acting on osteoblasts 
rather than osteoclasts. Hence it is likely that BMP-NPs similarly induce 
































































Figure 34: Systemic levels of bone resorption and formation marker in GC-treated wt 
mice. BALB/c wt mice were treated with10 mg/kg BMP-NPs or BMX or equal amounts of PBS 
or EP-NPs i.p. for 14 consecutive days in the morning at 9 a.m.. Blood was collected by heart 
puncture two hours after the last injection. CTX-1 and P1NP levels were analyzed by ELISA.    
N = 4 (PBS), N = 5 (BMX), N = 6 (EP-NP) N = 6 (BMP-NP); data pooled from multiple 
experiments. All values are depicted as mean ± SEM. Statistical analyses were performed by 







4.1 Role of the GR in myeloid cells in the context of aGvHD mice 
HSCT is often the only curative therapy for a variety of diseases of malignant or 
non-malignant origin. However, its success is limited by the frequently occurring 
life-threatening complication aGvHD (Ferrara et al., 2009, Shlomchik, 2007). 
Systemic administration of GCs is the standard procedure for initial treatment of 
aGvHD in the clinics due to their well-described immunosuppressive and      
anti-inflammatory effects. To ameliorate the disease course, GCs are most 
often applied at high dosage and over a long period of time leading to unwanted           
side-effects and GC resistances (Garnett et al., 2013). Gaining a better 
understanding of GC actions in the context of aGvHD might enable us to 
develop efficient and more tolerable therapies in the future. GCs exert their 
functions by binding to the ubiquitously expressed GR and regulating gene 
expression (Strehl and Buttgereit, 2013). Hence, it is also expressed in 
macrophages, which play a fundamental role in the pathophysiology of aGvHD 
(Hashimoto et al., 2011). The role of macrophages in this disease has been 
neglected for a long time compared to T cells for a long time, which are known 
as the major inducers of aGvHD. This is also the reason why therapeutic 
strategies mainly focus on T cells (Ho and Cutler, 2008). In this thesis we now 
defined an important role of the GR in radioresistant recipient myeloid cells in 
the context of aGvHD by taking advantage of the GRlysM mouse model. 
 
GR deletion in radioresistant recipient myeloid cells of GRlysM mice in the early 
phase of aGvHD leads to an aggravated disease course, which is characterized 
by higher clinical scores, lower body temperatures and a more pronounced 
body weight loss compared to GRflox control mice. This is in line with previous 
data from our group revealing an early mortality in the same knock-out mice 
(Baake et al., 2018). Surprisingly, tissue destruction in one of the major aGvHD 
target organs, the jejunum, was not altered in comparison to GRflox control mice, 
which contrasts experiments performed in GRlck mice lacking the GR in T cells 
(Theiss-Suennemann et al., 2015).The disease in the latter model was strongly 




damage. Already from this finding one can conclude that the mechanisms by 
which the deletion of the GR in the two cell types impacts disease severity must 
be different. Furthermore, at least in GRlysM mice, the destruction of the jejunum 
can be excluded as a possible reason for the fulminant disease course. 
Interestingly, also other hallmarks of aGvHD did not differ between GR lysM and 
GRflox mice, such as the number of infiltrating CD3+ T cells and CD68+ myeloid 
cells in the jejunum, local cytokine expression and secretion in the jejunum, and 
cytokine expression in the liver, another important aGvHD target. In contrast, 
the serum levels of IL-6 and TNFα in GRlysM mice were strongly increased at 
day 6 and 8, which correlates with the time point of death of these animals 
(Baake et al., 2018). This finding indicates that the GR in radioresistant myeloid 
cells in the early phase of aGvHD is mainly responsible to keep pro-
inflammatory cytokine secretions at bay rather than to suppress myeloid cells in 
target organs such as jejunum and liver.  
 
Former animal studies have also noted an important function of the GR in 
preventing cytokine hypersecretion. These studies have been performed in the 
GRdim mouse model, which is not restricted to myeloid cells in contrast to our 
studies (Baake et al., 2018). A point mutation within the dimerization region of 
the GR prevents the receptor from homodimerization in GRdim mice (Reichardt 
et al., 1998). This manipulation affects the DNA-binding capacity of the GR and 
largely abolishes its gene regulation function (Frijters et al., 2010). Mortality was 
increased in GRdim mice compared to GRwt mice after aGvHD induction, and at 
the peak of the disease, GRdim mice had a strongly reduced body temperature. 
Similar to GRlysM mice, the systemic level of the pro-inflammatory cytokine IL-6 
was also increased. Treatment of GRdim mice with a neutralizing anti-IL-6 
antibody reduced the severity of the disease and consequently mortality, 
indicating that a cytokine storm could indeed also explain the phenotype of 
GRlysM mice (Baake et al., 2018). The situation encountered in aGvHD is 
comparable to sepsis, another severe inflammatory disease. Sepsis studies 
conducted in GRdim mice as well as GRlysM mice revealed that these animals 
were unable to diminish systemic pro-inflammatory cytokine secretion in this 




2012). In aGvHD, as well as in sepsis, myeloid cells seem to be responsible for 
systemic cytokine secretion of IL-6 and TNFα when their GR is abolished. Of 
note, the deletion in GRlysM mice affects about 83 - 98 % of mature 
macrophages, nearly 100 % of granulocytes and 16 % of dendritic cells 
(Tuckermann et al., 2007). Since only resident macrophages and skin DCs 
survive the conditioning regime, only these cell types are refractory to the 
repressive effects of endogenous GCs (Haniffa et al., 2009). Especially IL-6, 
TNFα and IFNγ are key pro-inflammatory cytokines in the context of aGvHD 
and high serum levels of IL-6 and TNFα are associated with aGvHD or even 
poor outcomes (Symington et al., 1992, Holler et al., 1990). According to this, 
by applying a neutralizing monoclonal antibody against TNFα in a CD4+ 
mediated aGvHD mouse model resulted in higher survival rates and moreover 
prevented the GvL effect (Korngold et al., 2003). In line, treatment with 
Infliximab, a chimeric antibody directed against the soluble and transmembrane 
forms of TNFα, was well tolerated by patients and showed an overall response 
rate of 82 % in steroid-resistant children, which suffered from aGvHD. However, 
while blocking of TNFα is useful to control aGvHD, its long-term outcome is 
poor and GvHD often relapses upon interruption of the therapy (Sleight et al., 
2007). Furthermore, antibody-mediated blockade of the IL-6 receptor (IL-6R) 
altered the pro-inflammatory milieu in an aGvHD mouse model and caused a 
strong reduction in mortality but it prevented also the GvL effect (Tawara et al., 
2011). Tocilizumab, a monoclonal antibody against the IL-6R, has been 
demonstrated to be beneficial in the context of steroid-refractory aGvHD and 
cGvHD in patients (Drobyski et al., 2018). While the roles of TNFα and IL-6 in 
aGvHD are well defined, the function of IFNγ remains controversial. Studies 
have shown, on the one hand, that IFNγ exacerbates gut GvHD while it acts 
synergistically with LPS, and on the other hand, that it has a protective role in 
the gut. Other work suggested that it may not even be required for the 
development of aGvHD (Wang and Yang, 2014). Our finding that the serum 
levels of IL-6 and TNFα were strongly increased in GRlysM mice at the peak of 
the disease, whereas the serum levels of IFNγ, a key cytokine produced by Th1 




highlighting an important role of IL-6 and TNFα but not IFNγ (Beilhack et al., 
2005, Chakraverty and Sykes, 2007). 
 
In contrast to systemic cytokine secretion, the gene expression profile of Il6, 
Tnfa, Ifng, Il1b, Ccl2, Il2 and Il10 in the jejunum and/ or the liver was similar in 
GRlysM and GRflox mice at all examined time points. Of note, the extent of 
cytokine regulation was more pronounced in the jejunum as compared to the 
liver. As a matter of fact, steroid administration seems to impact the expression 
of inflammatory mediators predominantly in the gastrointestinal tract rather than 
the liver (Kanojia et al., 1984, Weisdorf et al., 1990). Even though the mice in 
our experiments received no synthetic steroids, we assume that endogenous 
GC secretion is very high due to the strong ongoing inflammation, which might 
explain why the cytokine regulation was more pronounced in the jejunum than 
in the liver. Furthermore, we observed a “wavelike” gene expression pattern for 
many of the cytokines we analyzed, namely increasing levels from day 4 to 6 
and decreasing again until day 8. This might reflect the escalating inflammatory 
reactions within the mice during the first days of the HSCT and the ongoing 
disease, which is followed by a transient resolution (Beilhack et al., 2005). The 
pattern of the local cytokine production in the jejunum was similar to the gene 
expression profile though not that defined, but most importantly we could also 
barely detect any differences between both groups. As the gene expression 
pattern in both genotypes in aGvHD target organs was comparable it is not 
astonishing that the tissue destruction and the cellular infiltration of immune 
cells into the jejunum revealed no differences. The major conclusion from our 
data is that the systemic overshooting cytokine secretion of IL-6 and TNFα is 
responsible for the fulminant disease progression in GRlysM mice and that the 
local cytokine expression and secretion within the target organs jejunums and 
liver seems to be neglectable. In our view this situation can be explained as 
following. The majority of host APCs, including precursors are lost during the 
conditioning regime and their lack is filled by myeloid cells contained in the graft 
and differentiated ones from progenitor T cells therein, which eventually creates 
a chimeric repertoire of APCs within the mice (Haniffa et al., 2009). Wild type 




effects of endogenous GCs and preferentially migrate into inflamed tissues such 
as the jejunum and the liver. Hence, inflamed tissues are dominated by wild 
type monocytes/ macrophages whereas radioresistant GRlysM macrophages are 
mostly found in non-inflamed tissues. In turn, this explains why the cytokines 
are regulated on a systemic level rather than on a local level. Our experiments 
have impressively demonstrated the role of GC effects mediated by the GR in 
macrophages in the context of aGvHD. Therefore, targeted delivery of GCs to 
this cell type appears promising and has already been shown in a variety of 
other inflammatory diseases, such as EAE or arthritis. There it improved the 
disease course by a preferential delivery to target sites and/ or cells and had 
been shown to be superior in its effects compared to free GCs (Luhder and 
Reichardt, 2017). Targeted delivery of GCs was also successfully applied in an 
aGvHD mouse model. In this case, dexamethasone palmitates (DP) were 
engulfed by macrophages which attenuated the disease progression and 
reduced the mortality (Nishiwaki et al., 2014). This emphasizes the possibility to 
target macrophages with encapsulated GCs in order to treat aGvHD, which was 
also tested in this thesis. 
 
4.2 Interactions of IOH-NPs with selected cell types in vitro   
In the clinics, many inflammatory diseases are handled with GCs, if necessary 
with high doses and/ or for a long period of time, which often induces severe 
side-effects and resistance. In theory, targeted delivery of GCs could 
circumvent these issues (Vandewalle et al., 2018). The type of carrier system, 
however, is essential for the outcome. For example, PEG-LPs have the 
disadvantage to provoke an unwanted effect, namely the activation of the 
complement system (Sercombe et al., 2015). Moreover, the characteristics of 
NPs, with respect to shape, size or stability influence the interaction with the 
target cell and needs to be evaluated (Kuhn et al., 2014). Hence, we analyzed 
the cell type specificity, toxicity, cellular uptake mechanism and intracellular fate 
of IOH-NPs, which were available to us in this project.       
 
Due to their hydrophobic structure, GCs can easily pass the cell membrane, 




encapsulated in nanoparticles, like IOH-NPs, need to enter the cell via an active 
process called endocytosis. The endocytic capacities vary between cell types, 
thus contributing to the IOH-NPs cell-specificity (Behzadi et al., 2017). To get a 
good impression of the specificity of IOH-NPs, we selected cell lines 
representing macrophages, T and B lymphocytes, fibroblasts, epithelial cells 
and myoblasts. Longer incubation times increased the uptake in all cell lines, 
which indicates an increasing accumulation of IOH-NPs within all cells. MH-S 
cells, resembling macrophages, were most efficient in taking up IOH-NPs. 
Furthermore, L929, resembling fibroblasts were somewhat weaker on the    
long-run as MH-S cells while LA-4 cells and C2C12 cells, resembling epithelial 
cell and myoblasts, respectively, took up IOH-NPs with only moderate 
efficiency. In contrast, the cell lines WEHI7.1 and WEHI231, representing T and 
B lymphocytes hardly took up any IOH-NPs. The latter is in line with previous 
data from our group that were obtained in experiments in which primary 
lymphocytes were cultured in the presence of IOH-NPs (Montes-Cobos et al., 
2017). Further support comes from in vivo EAE studies where macrophages 
rather than T and B cells were the main target of IOH-NPs (Montes-Cobos et 
al., 2017). Given that cells found in solid tissues such as fibroblasts, and less 
efficiently epithelial cells and myoblasts engulf IOH-NP too, we assume that 
IOH-NPs are not completely cell type specific for macrophages. This needs to 
be considered with regard to the efficiency of GC therapy by IOH-NPs in 
aGvHD and moreover with respect to their ability to induce potential             
side-effects, such as myopathy or osteoporosis even though IOH-NP uptake by 
osteoblasts has not been tested yet.  
 
Another fundamental aspect of new nanoformulations is that they are being well 
tolerated, which can be tested for example by tetrazolium-based assays such 
as MTT (Bahadar et al., 2016). Our results indeed indicate that IOH-NPs, 
containing Zr are well tolerated by all cell lines. It is noteworthy that data from a 
recent study indicates that Zr activates the TLR 2, 3, 4 and 9 leading to the 
release of IL-6, TNFα and IL-1β, which was observed by culturing macrophages 




our IOH-NPs provoke the same reaction in the six cell lines needs to be 
evaluated in the future and should be tested on an mRNA level or via ELISA. 
 
A common way to study the entry route of nanomedicines is the application of 
pharmacological inhibitors although such a strategy involves disadvantages, for 
example that they can manipulate other entry routes and are therefore not 
entirely specific (Kou et al., 2013, Ivanov, 2008). Furthermore, the effects of the 
inhibitors can be cell line dependent (Vercauteren et al., 2010). However, 
pharmacological inhibitors are still attractive as their administration results 
immediately in blocking of individual pathways although it is suggested to obtain 
corroborating evidence for example from genetic manipulations of crucial 
proteins or the application of various inhibitors (Dutta and Donaldson, 2012). 
We applied three commonly used inhibitors in well-tolerated concentrations. 
CytoD successfully prevented the uptake of IOH-NPs in MH-S cells. This 
inhibitor caps actin filaments, thereby preventing their assembly and ultimately 
leading to actin filament disintegration. Actin polymerization is a crucial process 
for phagocytosis and macropinocytosis, but probably also for all other endocytic 
pathways though it plays no obligatory role in the formation of clathrin coated 
vesicles (Fujimoto et al., 2000). Interestingly, MDC had no effect on the uptake 
capacities of IOH-NPs in MH-S cells, which argues against their internalization 
via clathrin-mediated endocytosis. MDC is a rather specific inhibitor for   
clathrin-mediated endocytosis, even though some studies have implemented it 
in inhibiting macropinocytosis and phagocytosis, too, which however would not 
be compatible with our observation. Amiloride blocks macropinocytosis when 
applied at millimolar concentrations and we used it even at mircomolar 
concentrations (Ivanov, 2008). Indeed, Amiloride prevented the uptake of    
IOH-NPs in MH-S cells suggesting that internalization occurs mainly via 
macropinocytosis. Besides that, Amiloride induced cell death to some degree, 
but it is highly unlikely that the diminished uptake of IOH-NPs can be explained 
only by this fact. Macropinocytosis is an evolutionary conserved, non-selective 
form of endocytosis. It mediates the uptake of extracellular fluids and in primary 
immune cells, such as macrophages and dendritic cells, the uptake of soluble 




(>250 nm), a size which is also suitable for IOH-NPs (Canton, 2018, Palm, 
2019). Macrophages have a staggering rate of constant macropinocytosis 
internalizing their surface every 33 minutes (Steinman et al., 1976). However, 
the process of macropinocytosis itself is not restricted to primary immune cells, 
because it also occurs in other cell types such as fibroblasts or epithelial cells 
(Falcone et al., 2006). The fact that phagocytosis is restricted to professional 
adepts for example monocytes, macrophages, neutrophils and dendritic cells 
and in addition that it is initiated by the interaction of the respective receptor on 
the cellular surface of the particle supports our observed entry route of IOH-NPs 
(Kuhn et al., 2014). Worth mentioning, our experiments were performed in vitro 
and nanoparticles can have dynamic entities immediately after administration in 
vivo, probably unwanted entities, which represent biological obstacles. 
Generally, solely about 1 % of injected nanoformulations reach the target tissue, 
which makes it clear why the path towards clinical licensing is remarkable 
challenging (Li and Lane, 2019). The rapid removal of nanoformulations from 
the circulation can be explained by obstacles such as opsonization by plasma 
proteins, including complement components or antibodies. Subsequently 
nanoformulations are recognized by the respective receptors on the surface of 
phagocytes, which lead to their internalization and finally elimination, but most 
importantly influencing the entry route (Blanco et al., 2015). Whether IOH-NPs 
undergo opsonization within the blood circulation in vivo and whether this has 
any impact on the entry route needs to be studied in the future. So far, we 
observed IOH-NPs are internalized in MH-S cells via macropinocytosis, which 
occurs most likely via the same way in fibroblasts, epithelial cells and myoblasts 
in vitro.   
 
Macropinocytosis, more precisely the cargo trapped within the 
macropinosomes, can have two fates, either the cellular surface, where the 
cargo is released into the extracellular space, or the lysosomes, which contain 
enzymes for its degradation (Palm, 2019). Our results indicate that IOH-NPs are 
indeed travelling to lysosomes where the pharmacological agent 
betamethasone phosphate is released by hydrolysis of the phosphate-ester 




active. GCs promote an anti-inflammatory phenotype in macrophages, which 
involves the downregulation of surface expression markers such as MHCII or 
CD86, both are crucial for T cell activation (Roszer, 2015). This notion is in 
agreement with our data, which indicate a dose-dependent reduction of both 
surface markers in BMDMs when cultured in the presence of BMP-NPs. 
Moreover, these results are supported by earlier data from our group. The 
mRNA expression levels of pro- and anti-inflammatory genes in BMDMs were 
altered upon co-culturing them with BMP-NPs. As a consequence, Tnfa and Il1b 
were downregulated, whereas the expression of Cd163 and Ym1 was increased 
(Montes-Cobos et al., 2017). Recent studies by another group also examined 
effects of BMP-NPs on MH-S cells in vitro. To provoke an immune response, 
the cells were treated with LPS and cultured with BMP-NPs for 48 hours. 
Subsequently, IL-6 in the supernatant was reduced in a dose-dependent 
manner (Napp et al., 2018). Similar results were observed when TNFα secretion 
was analyzed (Heck et al., 2015). Collectively, betamethasone is efficiently 
released from IOH-NPs within the lysosomes and subsequently exerts  
immuno-modulatory actions in primary macrophages and MH-S cells. The 
efficiency of BMP-NPs, compared to the reference drug, is described to be 
similar or even more efficient (Montes-Cobos et al., 2017). 
 
4.3 Organ distribution of IOH-NPs in mice in vivo 
Intravenous (i.v.), subcutaneous (s.c.) and intramuscular (i.m.) injections are the 
most common routes for medical treatments in the clinics. The first route is 
chosen when rapid absorption is required and when the two other routes are not 
suitable, because the injected substances are too irritable for the tissue (Jin et 
al., 2015). In contrast, intraperitoneal injection (i.p.) is used in the clinics when 
regional therapy is needed for example for peritonitis or malignancies within the 
peritoneal cavity. This application route has the advantage to provide locally a 
longer half-life of the drug, while it takes longer until the drug reaches the 
circulation. It is thereby superior to i.v. injections under these circumstances. 
Nevertheless, i.p. injections are facing various challenges as it can have a 
negative impact on the target specificity of the drug and/ or the penetration into 




animal studies involve i.p. injections as it is technically easier when a drug is 
injected several times daily and/ or for longer periods of time. Furthermore, a 
study demonstrated that the commercially available anti-fungal drug 
amphotericin B is better tolerated when given i.p. at high dose rather than when 
given i.v. (Chang et al., 2010). With regard to the application route of 
nanoformulations, analysis of AmBisome®, a liposomal fungal drug formulation 
revealed major differences in the tissue distribution when administrated i.v. or 
i.p. as it was noted upon administration of nanoparticles with a size of about    
20 nm (Chang et al., 2010, Gao, 2017). In addition, also differences in the blood 
concentration were observed in another study depending on the application 
route when injecting iron-oxide nanoparticles labeled with high                
density-lipoproteins (Jung et al., 2014). Upon i.v. administration, the 
concentration of liposomes and iron-oxide NPs in the blood circulation was 
either highest 30 minutes after injection or had already declined at that time 
point, and thereafter further decreased due to the uptake into liver, spleen, lung 
and kidney. The uptake into other tissues such as heart, muscle or femur, 
however, was neglectable. In contrast after i.p. administration the 
concentrations within the blood slowly increased and peaked within 2 hours 
after the injection. This indicates a slow release from the peritoneal cavity into 
the lymph vessels, for example through the mesentery with its large absorbent 
surface, and afterwards via the thoracic duct into the blood (Chang et al., 2010, 
Jung et al., 2014, Gao, 2017). Within 4 hours after injection the level of NPs 
measured within the peritoneal cavity dropped again to control level. This 
indicates that the majority of NPs have been distributed within the body, 
absorbed into the blood stream and the pancreas, the latter by tissue-resident 
and peritoneal macrophages. NPs become cleared from the systemic circulation 
through the permeable endothelium and accumulate in liver, spleen, intestine, 
stomach, lung, kidney and bladder, but not in heart and brain (Pham et al., 
2018, Arvizo et al., 2011, Gao, 2017). Collectively, i.v. administration of NPs 
seems to accumulate quickly and predominantly in liver and spleen. In contrast, 
i.p. administration leads to the slow accumulation in further organs via the ability 
to cross the peritoneal barrier, is excreted mainly via the intestine and 




in the urine. Interestingly, i.p. injection causes a more rapid clearance than i.v. 
injection (Gao, 2017).  
 
Our own MRI and ICP-MS studies revealed i.p. injected IOH-NPs follow a 
similar path as described in the literature. We observed a slow release from the 
peritoneal cavity during the first two hours after injection until the signal here 
dropped to control levels. Meanwhile, IOH-NPs were detected within one hour 
after the injection in the liver, where they constantly accumulated over time. 
IOH-NPs have also been found in the stomach two hours after the injection, 
where the levels increased and remained constant three hours after the 
injection. Two hours after the injection the IOH-NPs also reached the small 
intestine and their concentration increased here from now on with fluctuations. 
Interestingly, IOH-NPs spared the kidney and the lung. 24 hours upon the 
injection, the signals in the liver and jejunum decreased again, arguing for an 
intestinal excretion of IOH-NPs. As we failed to prove the presence of IOH-NPs 
in the urine by MRI (data not shown) and since no IOH-NPs were found in the 
kidney, it is highly likely that indeed intestinal clearance dominates and might 
reach it through the stomach. Noteworthy, the IOH-NPs biodistribution after i.v. 
injection has been characterized before. Here, IOH-NPs were detected in the 
gall bladder, liver, lung and kidney, but not in the stomach. The studies 
suggested that i.v. injected IOH-NPs are predominantly excreted via the 
intestinal tract and a small fraction also via the kidney (Poß, 2017). 
Consequently, the application route strongly determines the fate of IOH-NPs in 
vivo after injection and results in a different organ distribution. Most importantly, 
our own results indicate that i.p. injection is favorable as it results in a slower 
release, a more even distribution between the organs and a lower risk of 
inducing nephrotoxicity due to its clearance route.  
 
It should be pointed out that our data concerning the biodistribution of IOH-NPs 
were obtained by using healthy mice. Since we mostly used IOH-NPs in the 
treatment of mice suffering from aGvHD in this thesis, it would be interesting 
whether the pharmacokinetics differs under such conditions from the healthy 




single systemic administration of copolymer-dexamethasone conjugate resulted 
in a higher influx in inflamed joints than healthy joints. This was achieved by the 
dynamic uptake by synoviocytes, which are a mixture of macrophage-like, 
fibroblast-like and dendritic cells, and by the enhanced vascular permeability in 
inflamed joints (Quan et al., 2010). In another study, polystyrene NPs loaded 
with a fluorescence dye were used for inhalation in a mouse model of allergic 
airway inflammation (AAI). Here, AAI lungs displayed a significantly stronger 
fluorescence signal as healthy lungs (Markus et al., 2015). The accumulation of 
BMP-NPs within inflamed tissue would also be desirable in aGvHD mice.   
 
4.4 IOH-NPs as a new therapeutic approach for GC therapy of aGvHD 
Each inflammatory disease has its distinct pathophysiology where different 
immune cell types are involved. Hence, the desired cell type specificity of GCs 
also differs. For instance, macrophages and neutrophils are the main target 
cells of GCs in the treatment of contact allergy (Tuckermann et al., 2007). In 
contrast, airway epithelial cells are crucial targets of GCs in an allergic asthma 
mouse model (Klassen et al., 2017). In the context of aGvHD, previous studies 
from our group highlighted a crucial role of GCs in T cells in a total MHC 
mismatched mouse model where GR deficiency of CD8+ cells aggravated 
clinical symptoms, histological features and reduced survival times (Theiss-
Suennemann et al., 2015). Furthermore, results presented in this thesis 
highlighted a crucial role of GCs also in radioresistant myeloid cells in a total 
MHC mismatched mouse model (Baake et al., 2018). In the initiation phase of 
aGvHD myeloid cells, more precisely macrophages, secrete pro-inflammatory 
cytokines and can induce tissue damage by the release of soluble mediators 
(Ghimire et al., 2017, Blazar et al., 2012). In contrast, GCs induce an M2 like 
phenotype in macrophages that contributes to wound healing, resolution of 
inflammation and suppress inflammatory responses (Desgeorges et al., 2019). 
Noteworthy, inhibiting the function of macrophages as well as expanding them 
has both been shown to prevent aGvHD in animal models (Hashimoto et al., 
2011, Shlomchik et al., 1999, Everse et al., 2001). However, simply eliminating 
resident host APCs can have major drawbacks such as infections, which 




innate immune system (Everse et al., 2001). Interestingly, targeted therapy of 
GCs can alter the mode of action as demonstrated in an EAE mouse model. 
Here, T cells were targeted by free GCs while GC-loaded LPs predominantly 
acted via macrophages. Nevertheless, both application forms improved the 
disease (Schweingruber et al., 2011). Hence, by modulating the macrophage 
phenotype by a cell type specific targeting of GCs, for example using IOH-NPs, 
which are taken up not exclusively, but dominantly by macrophages in vitro, 
might be a successful strategy to treat aGvHD. The results presented in this 
thesis provide good evidence that this is indeed the case.    
 
Initially we explored the treatment efficiency of GC-loaded IOH-NPs (BMP-NPs) 
compared to free GC (BMX) in a long-term experiment. To mimic the situation in 
the clinics, mice received the drugs when first symptoms appeared. Notably, 
mice treated with EP-NPs, not containing any drug, were comparable to mice 
receiving only PBS in most experiments indicating that in this experimental 
setting IOH-NPs are well tolerated, which is in line with our in vitro studies as 
well as previous in vivo studies conducted in an EAE mouse model (Montes-
Cobos et al., 2017). BMP-NP and BMX treatment extended the survival in 
aGvHD mice with similar efficiencies, although GC-treated mice still died in the 
second critical phase of aGvHD at around day 20 to 30. BMP-NPs were slightly 
superior to free BMX which might be explained by the better long-term 
availability of BMP-NPs in contrast to BMX. 
 
In the short-term experiments both GC formulations were similar in efficiency 
and resulted in lower clinical scores, higher body weight values and prevented 
the drop in body temperature at the peak of the disease. Previous reports also 
showed an improvement of aGvHD in mice by frequently used GCs in free form, 
such as prednisolone or dexamethasone (Bouazzaoui et al., 2011, Theiss-
Suennemann et al., 2015, Nishiwaki et al., 2014). Noteworthy, the experimental 
setups partially differ in the drug dose, treatment duration, conditioning regime 
intensity, mouse strain, number of cells transferred within the graft or grading 
system used, which is why the disease course may vary between the studies 




Nishiwaki et al. applied a dexamethasone palmitate emulsion (DP), a 
liposteroid, which is engulfed by macrophages via phagocytosis, vs. 
dexamethasone sodium phosphate (DSP), which is a free GC, in an aGvHD 
mouse model. Here, DP was slightly more effective than DSP concerning the 
survival rate (Nishiwaki et al., 2014). Collectively, our data revealed that BMP-
NP treatment has an overall similar, although not dramatically better efficiency 
than BMX.  
 
The mode of action of BMP-NPs vs. BMX was studied in the early phase of 
aGvHD, which is the time when the inflammatory processes start and strongly 
increase, and when high-dose GCs would have to be applied in the clinics 
(Ferrara et al., 2009, Svennilson, 2005). Histological analysis revealed that the 
tissue destruction in the jejunum was similarly reduced in BMP-NP and BMX 
treated mice. Also the number of goblet cells was increased to the same extent. 
Surprisingly, BMX reduced CD3+ T cells and CD68+ myeloid cells in the gut, 
whereas BMP-NPs had no such an effect. Recent studies demonstrated the 
ability of a targeted GC therapy to reduce the number of macrophages. F4/80+ 
cells were strongly reduced in the skin, which is one of the most commonly 
affected organs in aGvHD (Nishiwaki et al., 2014, Strong Rodrigues et al., 
2018). Our pharmacokinetic studies of IOH-NPs in healthy mice further let us 
assume that IOH-NPs accumulate in the jejunum and thereby have the potential 
to influence the phenotype of cells in this aGvHD target organ. However,    
BMP-NPs neither affected the composition of T cells in the jejunum nor the 
proportion of inflammatory and resting non-inflammatory macrophages and 
monocytes, which is fundamentally different from mice treated with BMX. GCs 
in general are well known to induce apoptosis in T cells, but analyses by our 
group indicated that T cell survival was barely effected by BMP-NPs 
(Tuckermann et al., 2005, Montes-Cobos et al., 2017). These data are in line 
with our findings that IOH-NPs are hardly taken up by T cells and explain why 
the number of infiltrating T cells is reduced in the gut of BMX treated mice but 
not in BMP-NP treated mice. In contrast to our model, BMP-NP treatment 
reduced the infiltration of monocytes/ macrophages into the target region of the 




specifically on this cell type in vivo (Montes-Cobos et al., 2017). In another EAE 
study, the application of GC-loaded liposomes reduced the infiltration of 
macrophages/ monocytes into the CNS too, but not as efficiently as free 
dexamethasone (Schweingruber et al., 2011). The fact that the number of 
infiltrating CD3+ and CD68+ cells in BMP-NP treated mice was unmodified in the 
jejunum combined with the observation of a barely effected abundance of 
different subpopulations of these cells, let us draw the conclusion, that other 
mechanisms than the repression of immune cell infiltration into the small 
intestine must be responsible for the ameliorating effect of BMP-NPs in aGvHD. 
 
Our in vitro analysis of the cell type specific uptake of IOH-NPs indicated that 
myeloid cells were the most important target of this nanoformulation. This 
conclusion could also be confirmed in vivo for our aGvHD mouse model. The 
therapeutic effect of BMP-NPs was fully abrogated in GRlysM mice, lacking the 
GR in macrophages/ monocytes, suggesting that GC effects in these cells were 
indeed essential to ameliorate aGvHD. BMP-NP treatment failed to reduce 
clinical symptoms and to prevent the drop in body temperature. Furthermore, 
the tissue destruction in the jejunum of GRlysM mice and the reduction in goblet 
cell numbers normally seen after BMX treatment were also abrogated. Hence, 
GCs delivered with the help of IOH-NPs ameliorate aGvHD by modulating 
myeloid cell function. 
 
Since our previous work had revealed that GRlysM mice succumbed to early 
death because of a systemic hypersecretion of pro-inflammatory cytokines, we 
considered it likely that BMP-NPs might act by suppressing systemic cytokine 
secretion in aGvHD wild type mice, too (Baake et al., 2018). However, systemic 
levels of IL-6, TNFα and IFNγ were elevated in aGvHD mice regardless of their 
treatment. From this finding we must conclude that therapeutically applied GCs, 
both free BMX and BMP-NPs do not act by preventing a systemic cytokine 
release syndrome but rather exert their function locally within the target organs. 
This notion was supported by our gene expression analyses of relevant 
cytokines in the jejunum. mRNA levels of Tnfa and Il6, which are primarily 




Ifng were reduced in BMX treated mice, which is in agreement with a study 
conducted in an aGvHD mouse model treated with prednisolone (Bouazzaoui et 
al., 2011). BMP-NPs reduced the expression of Tnfa, Il2, Ifng and Il6, too. Both, 
IFNγ and TNFα have been reported to induce direct damage to the GI tract and 
thus their reduced expression would be beneficial in aGvHD (Hill et al., 1997, 
Brown et al., 2003, Burman et al., 2007, Bouazzaoui et al., 2009, Korngold et 
al., 2003). IL-2 is a key cytokine of T cell dependent immune responses and is 
primarily produced by activated CD4+ T cells (Shin et al., 2011). The humanized 
monoclonal antibody daclizumab against the IL-2 receptor α-chain (CD25) has 
shown substantial activity in the treatment of aGvHD in patients and proven 
safety in phase I-III clinical trial studies (Przepiorka et al., 2000). Basiliximab, 
another IL-2 antibody has also been reported to be effective in a substantial 
portion of patients with steroid-refractory aGvHD (Massenkeil et al., 2002). On 
the other hand, IL-2 has immune modulatory functions, as it leads to the 
expansion of T effector cells (Teffs) and at the same time increases Tregs. 
Tregs are more resistant to Dex-induced cell death than Teffs due to higher 
expression of the GR and Bcl-2. Therefore, a combined therapy of IL-2 and 
dexamethasone was hypothesized to expand selectively Tregs in vivo, which 
has been tested in an aGvHD MHC mismatched mouse model and EAE. 
Indeed, both models showed promising results characterized by longer survival 
times and greater suppression of aGvHD as well as inhibited the development 
of EAE (Xie et al., 2009, Chen et al., 2006). In contrast, a study testing a 
combined therapy with corticosteroids and daclizumab in aGvHD patients 
evoked concerns as serious infections and relapses occurred in the patients 
contributing to an increased mortality (Lee et al., 2004). Currently it is unknown 
whether BMP-NP treatment has any effect on Tregs. In our analysis, the 
expression of the anti-inflammatory cytokine Il10 in the gut was significantly 
reduced in BMX and BMP-NP treated mice. A significant lower mRNA level of 
Il10 upon dexamethasone treatment in vivo was also noted previously in 
peritoneal macrophages (Schweingruber et al., 2011). In contrast, Il10 mRNA 
levels of PBMCs from the majority of multiple sclerosis patients increased upon 
steroid treatment (Gayo et al., 1998). Moreover, ex vivo pre-treatment of human 




increased Il10 expression indicating a selective mechanism of GCs (Mozo et al., 
2004). Generally, IL-10 seems to have a protective role in aGvHD as high 
frequencies of donor cells, producing this cytokine, coincides with the absence 
of aGvHD, and vice versa low levels coincide with increased rates of GvHD 
(Weston et al., 2006, Holler et al., 2000). Of note, endogenous IL-10 is often 
produced as a reaction to cope with strong inflammation, which might be the 
case in the control groups in our setting. Nevertheless, high levels of IL-10 can 
also act as a growth factor for CD4+ and CD8+ T cells (Blazar et al., 1998). Ccl2 
mRNA levels in the gut were also reduced in both GC-treated groups. An earlier 
study revealed increased levels of CCL-2 in the intestine of mice suffering from 
aGvHD similar to our mice (Castor et al., 2011). Another study indicated that 
high levels of CCL-2 recruiting monocytes and macrophages to the lung, the 
target organ in idiopathic pneumonia syndrome (IPS), another severe 
complication of HSCT, resulted in a stronger IPS severity. Interestingly, 
neutralizing CCL-2 or the infusion of CCL-2 receptor (CCR2) deficient donor 
cells reduced the cellular infiltration and improved IPS (Hildebrandt et al., 2004). 
Collectively, our data indicate that BMP-NPs are predominantly incorporated by 
macrophages in vivo and act on a local level rather than on a systemic one, 
which let us to conclude that BMP-NPs localize in target organs. Furthermore, 
BMP-NP treatment is efficient but not superior to BMX. Nevertheless, the 
apparently different mechanisms by which BMP-NPs ameliorate aGvHD might 
still be an advantage in the treatment of this disease.      
 
4.5 GC-induced side-effects after BMP-NP treatment                         
A major drawback of GC treatment of inflammatory diseases such as aGvHD is 
the frequent induction of sometimes even life-threatening side-effects (Petta et 
al., 2019). For a long time, it was believed that side-effects are induced by 
dimer-mediated transactivation, while anti-inflammatory effects evoke from 
monomer-mediated transrepression. The distinction of both effects turned out to 
be difficult, but several SEGRAs (selective GR antagonists) are still currently 
tested. Another possible way to overcome side-effects is the targeting of GCs to 




2018). Theoretically, this can be realized by the encapsulation of GCs into   
IOH-NPs that we found to target mainly macrophages.  
 
In this thesis we investigated three common metabolic side-effects that 
frequently occur in patients during chronic application of GCs, namely an 
impaired liver metabolism, myopathy and osteoporosis. Induction of these   
side-effects in inbred mouse strains is difficult to achieve, for which reason we 
treated them for 14 consecutive days although using the same concentration as 
in our aGvHD experiments. The expression of genes encoding liver proteins 
and enzymes, known to be controlled by GCs, such as Fkbp51, Tat and Pepck 
were significantly increased in both GC-treated groups. Not surprisingly, as a 
consequence, the blood glucose level was also increased, even though lacking 
significance. All three analyzed genes are regulated on a transcriptional level 
through GR binding sites within the promotor region (Vander Kooi et al., 2005, 
Imai et al., 1993, Vermeer et al., 2003, Alexandrova, 1994). Our data are in 
agreement with other studies showing an upregulation of the analyzed genes in 
the liver by other GCs such as prednisolone or dexamethasone, even though 
lower concentrations have been applied there (Frijters et al., 2010, Opherk et 
al., 2004). Notably, our data on the in vivo biodistribution of IOH-NPs indicated 
that BMP-NPs accumulate in the liver, which we observed both in MRI and   
ICP-MS studies. Possibly, they are then taken up by hepatocytes and regulate 
their function similarly to BMX. Whether IOH-NPs are taken up by Kupffer cells, 
which are tissue resident macrophages in the liver and constitute their largest 
reservoir in the body has not yet been tested (Dixon et al., 2013). Interestingly, 
alternatively activated M2 Kupffer cells can counteract systemic insulin 
resistance by impacting the lipid metabolism in the liver and theoretically 
thereby influence the blood glucose level (Odegaard et al., 2008, Odegaard and 
Chawla, 2011). In fact, insulin intolerance has been tested after the injection of 
both GC application forms but the results revealed to be inconclusive (data not 
shown). Taken together, the use of IOH-NPs for GC delivery does not allow to 





BMP-NP and BMX treatment similarly regulated also key myopathy genes in the 
M. gastrocnemius on a genetic level that are involved in protein degradation 
and synthesis. In detail, Mt2 and Foxo1 were significantly elevated in both    
GC-treated groups. Foxo1 is a transcription factor containing up to eight GREs 
in the proximal promotor and believed to control in turn a variety of genes 
involved in myopathy, including E3 ligases (Schakman et al., 2008, Qin et al., 
2014, Sato et al., 2017, Waddell et al., 2008). Mt2 contains two GREs within the 
proximal promotor and is an important zinc buffering protein, which influences 
signaling pathways involved in protein synthesis, such as mTOR (Kelly et al., 
1997). A recent study indicated that the loss of MT2 protects against             
GC-induced myopathy (Summermatter et al., 2017). Our results are in 
agreement with another study in which the mRNA levels of both genes were 
elevated after treatment with dexamethasone, even though the authors 
analyzed the M. triceps surae, which compromises amongst others the            
M. gastrocnemius (Watson et al., 2012). GCs are also known to induce 
myopathy by secondary effects, for example by acting on other non-related 
muscle cells such as fibroblasts, thereby reducing the extracellular matrix as the 
collagen production is diminished. Indeed, both GC application forms resulted in 
lower mRNA levels of Col1a1 as associated with dexamethasone treatment 
which is also shown by other studies (Riso et al., 2008, Watson et al., 2012). 
Most importantly, the similar regulation of myopathy related genes by both 
BMP-NPs and BMX also resulted in a similar loss of muscle mass. The weight 
of the M. gastrocnemius, but also the total body weight, were reduced after     
14 days of GC treatment, regardless of whether the free drug was applied or   
BMP-NPs were used for delivery. Noteworthy, the efficient regulation of genes 
in the muscle and extracellular matrix, leading to the induction of myopathy by 
BMP-NPs, is in agreement with our in vitro studies, in which we observed a 
moderate and even better uptake of IOH-NP in myo- and fibroblasts, 
respectively. Collectively, these data argue that the application of GCs by using 
IOH-NPs will not allow to prevent the induction of myopathy, which is one of the 





GC-induced osteoporosis is also a major adverse side-effect observed in the 
clinics. A previous study in an arthritis mouse model showed equal therapeutic 
efficiencies of free dexamethasone and a copolymer-dexamethasone-conjugate 
(P-dex) while P-dex did not induce bone resorption in contrast to free 
dexamethasone as determined by µCT analysis examining morphometric 
parameters of the bone (Quan et al., 2016). We used another method to assess 
the induction of osteoporosis, namely by studying bone resorption markers in 
serum samples, which is a common practice in the clinics to determine ongoing 
processes within the bone. C-terminal telopeptide of type I collagen (CTX-1) is a 
collagen degradation product and a byproduct of osteoclast activity, which 
serves as bone resorption marker. In contrast, pro-collagen type 1 N-terminal 
peptide (P1NP) serves as bone formation marker and is a byproduct of collagen 
synthesis resulting from osteoblast activity (Shetty et al., 2016). CTX-1 was 
elevated in both GC-treated groups compared to their respective control group 
although lacking significance, whereas P1NP was significantly reduced in both 
GC-treated groups. Osteoclasts are differentiated tissue-resident macrophages 
within the bone, hence, they should theoretically be prone to incorporate      
IOH-NPs (Desgeorges et al., 2019). Surprisingly, our data indicate that they are 
rather taken up by osteoblasts than osteoclasts. Notably, Rauch et al. showed 
that the GR in osteoblasts was more important for the induction of osteoporosis 
by GCs than in osteoclasts (Rauch et al., 2010). Whether IOH-NPs are indeed 
taken up by both cell types and with which efficiency their functions are 
regulated is currently under investigation. In any case, the initial serum analysis 
of bone markers strongly suggests that also osteoporosis will not be 
circumvented by using IOH-NPs. Collectively, our data indicate that BMP-NPs 
act on hepatocytes, myoblasts and bone cells with similar efficacy as free BMX, 
and thereby manipulate the gene expression profiles that can trigger 
hyperglycemia, myopathy and osteoporosis. It remains unknown whether the 
induction of these side-effects could be reduced by lowering the dose of      
IOH-NPs. However, our results suggest, that the goal to have a GC therapy at 
hand that lacks major side-effects of traditional GC therapy, can probably not be 




4.6 Conclusions and future directions 
Despite the many findings we made concerning the role of macrophages in 
aGvHD and the mechanisms of IOH-NPs, many questions remain. For instance, 
it is unclear to which extent BMP-NPs act on the many different cell types found 
in vivo in mice and humans. BMP-NP treatment of aGvHD induced in GR
lysM
 
mice suggests that macrophages are efficiently targeted, whereas this is not the 
case for T cells, being in line with the in vitro experiments. However, the three 
side-effects tested in this thesis all still occur, arguing that many cell types are 
capable of taking up the IOH-NPs, though with different efficiencies. Another 
issue is that BMP-NPs, when cultured under physiological conditions for          
48 hours in vitro, are intact to 90 - 95 % (Heck et al., 2015). Nevertheless, we 
observed an aggregation of IOH-NPs within the intraperitoneal puncture area 
upon multiple injections. This raises the questions of how much of the IOH-NPs 
are indeed taken up by the lymphatic system and whether the amount should 
be increased. However, it could also mean that the IOH-NP form a depot that 
releases the drug over longer periods of time, which could explain the 
occurrence of GC-side-effects in mice treated with the nanoformulation. 
Peritoneal adhesion is a common risk after i.p. injections (Bajaj and Yeo, 2010). 
Analyzing aGvHD mice via MRI studies that receive multiple injections of    
GAP-NPs would provide insights into the pharmacokinetic. A crucial question 
related to the possible future application in humans is, what happens to the 
remaining Zr when IOH-NPs are hydrolyzed. Is it released via exocytosis and 
excreted via the GI tract? This could be investigated by analyzing urine samples 
by using ICP-MS as MRI studies were not sensitive enough for this purpose.  
Zr-based NPs were previously found to be moderately toxic in a human 
macrophage and alveolar type II cell line, THP-1 and A549 respectively, and 
also in the mouse osteoblast cell line 3T3-E1 at high concentrations (Ye and 
Shi, 2018). In addition, Zr triggers pro-inflammatory cytokine secretion in 
macrophages (Obando-Pereda et al., 2014). Neither toxicity nor cytokine 
secretion has been observed in our experimental setups but need to be further 





Taken together, BMP-NPs were successfully applied in the treatment of EAE, 
AAI and now also aGvHD in mouse models (Montes-Cobos et al., 2017). In all 
cases the efficiency was comparable to free GCs but not dramatically improved. 
The advantage is the preferential targeting of macrophages compared to T cells 
but the hope to circumvent metabolic side-effects did not hold true. Still, it is 
possible that unwanted activities of GCs on T cells such as the repression of the 
beneficial GvL effect in HSCT are avoided after application of BMP-NPs. 
Hence, further work is required to ultimately decide whether there is a benefit 





ALAVI, M., KARIMI, N. & SAFAEI, M. 2017. Application of Various Types of 
Liposomes in Drug Delivery Systems. Adv Pharm Bull, 7, 3-9. 
ALEXANDROVA, M. 1994. Stress induced tyrosine aminotransferase activity 
via glucocorticoid receptor. Horm Metab Res, 26, 97-9. 
ALMAWI, W. Y., BEYHUM, H. N., RAHME, A. A. & RIEDER, M. J. 1996. 
Regulation of cytokine and cytokine receptor expression by 
glucocorticoids. J Leukoc Biol, 60, 563-72. 
ANDERSON, B. E., MCNIFF, J. M., JAIN, D., BLAZAR, B. R., SHLOMCHIK, W. 
D. & SHLOMCHIK, M. J. 2005. Distinct roles for donor- and host-derived 
antigen-presenting cells and costimulatory molecules in murine chronic 
graft-versus-host disease: requirements depend on target organ. Blood, 
105, 2227-34. 
ANTIN, J. H., CHEN, A. R., COURIEL, D. R., HO, V. T., NASH, R. A. & 
WEISDORF, D. 2004. Novel approaches to the therapy of steroid-
resistant acute graft-versus-host disease. Biol Blood Marrow Transplant, 
10, 655-68. 
ARVIZO, R. R., MIRANDA, O. R., MOYANO, D. F., WALDEN, C. A., GIRI, K., 
BHATTACHARYA, R., ROBERTSON, J. D., ROTELLO, V. M., REID, J. 
M. & MUKHERJEE, P. 2011. Modulating pharmacokinetics, tumor uptake 
and biodistribution by engineered nanoparticles. PLoS One, 6, e24374. 
ARYA, S. K., WONG-STAAL, F. & GALLO, R. C. 1984. Dexamethasone-
mediated inhibition of human T cell growth factor and gamma-interferon 
messenger RNA. J Immunol, 133, 273-6. 
ASAVAROENGCHAI, W., WANG, H., WANG, S., WANG, L., BRONSON, R., 
SYKES, M. & YANG, Y. G. 2007. An essential role for IFN-gamma in 
regulation of alloreactive CD8 T cells following allogeneic hematopoietic 
cell transplantation. Biol Blood Marrow Transplant, 13, 46-55. 
ASHWELL, J. D., LU, F. W. & VACCHIO, M. S. 2000. Glucocorticoids in T cell 
development and function*. Annu Rev Immunol, 18, 309-45. 
AYROLDI, E., CANNARILE, L., MIGLIORATI, G., NOCENTINI, G., DELFINO, 
D. V. & RICCARDI, C. 2012. Mechanisms of the anti-inflammatory 
effects of glucocorticoids: genomic and nongenomic interference with 
MAPK signaling pathways. FASEB J, 26, 4805-20. 
BAAKE, T., JORSS, K., SUENNEMANN, J., ROSSMANN, L., 
BOHNENBERGER, H., TUCKERMANN, J. P., REICHARDT, H. M., 
FISCHER, H. J. & REICHARDT, S. D. 2018. The glucocorticoid receptor 
in recipient cells keeps cytokine secretion in acute graft-versus-host 
disease at bay. Oncotarget, 9, 15437-15450. 
BAHADAR, H., MAQBOOL, F., NIAZ, K. & ABDOLLAHI, M. 2016. Toxicity of 
Nanoparticles and an Overview of Current Experimental Models. Iran 
Biomed J, 20, 1-11. 
BAJAJ, G. & YEO, Y. 2010. Drug delivery systems for intraperitoneal therapy. 
Pharm Res, 27, 735-8. 
BAKER, K. S., RONCAROLO, M. G., PETERS, C., BIGLER, M., DEFOR, T. & 
BLAZAR, B. R. 1999. High spontaneous IL-10 production in unrelated 




related complications and early deaths. Bone Marrow Transplant, 23, 
1123-9. 
BALL, L. M., EGELER, R. M. & PARTY, E. P. W. 2008. Acute GvHD: 
pathogenesis and classification. Bone Marrow Transplant, 41 Suppl 2, 
S58-64. 
BANUELOS, J., SHIN, S., CAO, Y., BOCHNER, B. S., MORALES-NEBREDA, 
L., BUDINGER, G. R., ZHOU, L., LI, S., XIN, J., LINGEN, M. W., DONG, 
C., SCHLEIMER, R. P. & LU, N. Z. 2016. BCL-2 protects human and 
mouse Th17 cells from glucocorticoid-induced apoptosis. Allergy, 71, 
640-50. 
BARCZYK, K., EHRCHEN, J., TENBROCK, K., AHLMANN, M., KNEIDL, J., 
VIEMANN, D. & ROTH, J. 2010. Glucocorticoids promote survival of anti-
inflammatory macrophages via stimulation of adenosine receptor A3. 
Blood, 116, 446-55. 
BARNES, P. J. 2011. Glucocorticosteroids: current and future directions. Br J 
Pharmacol, 163, 29-43. 
BASCHANT, U. & TUCKERMANN, J. 2010. The role of the glucocorticoid 
receptor in inflammation and immunity. J Steroid Biochem Mol Biol, 120, 
69-75. 
BEHZADI, S., SERPOOSHAN, V., TAO, W., HAMALY, M. A., ALKAWAREEK, 
M. Y., DREADEN, E. C., BROWN, D., ALKILANY, A. M., FAROKHZAD, 
O. C. & MAHMOUDI, M. 2017. Cellular uptake of nanoparticles: journey 
inside the cell. Chem Soc Rev, 46, 4218-4244. 
BEILHACK, A., SCHULZ, S., BAKER, J., BEILHACK, G. F., WIELAND, C. B., 
HERMAN, E. I., BAKER, E. M., CAO, Y. A., CONTAG, C. H. & NEGRIN, 
R. S. 2005. In vivo analyses of early events in acute graft-versus-host 
disease reveal sequential infiltration of T-cell subsets. Blood, 106, 1113-
22. 
BILLINGHAM, R. E. 1958. Studies on the reaction of injected homologous 
lymphoid tissue cells against the host. Ann N Y Acad Sci, 73, 782-8. 
BILLINGHAM, R. E. 1966. The biology of graft-versus-host reactions. Harvey 
Lect, 62, 21-78. 
BLANCO, E., SHEN, H. & FERRARI, M. 2015. Principles of nanoparticle design 
for overcoming biological barriers to drug delivery. Nat Biotechnol, 33, 
941-51. 
BLAZAR, B. R. & MURPHY, W. J. 2005. Bone marrow transplantation and 
approaches to avoid graft-versus-host disease (GVHD). Philos Trans R 
Soc Lond B Biol Sci, 360, 1747-67. 
BLAZAR, B. R., MURPHY, W. J. & ABEDI, M. 2012. Advances in graft-versus-
host disease biology and therapy. Nat Rev Immunol, 12, 443-58. 
BLAZAR, B. R., SHARPE, A. H., TAYLOR, P. A., PANOSKALTSIS-MORTARI, 
A., GRAY, G. S., KORNGOLD, R. & VALLERA, D. A. 1996. Infusion of 
anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits 
murine graft-versus-host disease lethality in part via direct effects on 
CD4+ and CD8+ T cells. J Immunol, 157, 3250-9. 
BLAZAR, B. R., TAYLOR, P. A., PANOSKALTSIS-MORTARI, A., NARULA, S. 
K., SMITH, S. R., RONCAROLO, M. G. & VALLERA, D. A. 1998. 
Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-




BLOTTA, M. H., DEKRUYFF, R. H. & UMETSU, D. T. 1997. Corticosteroids 
inhibit IL-12 production in human monocytes and enhance their capacity 
to induce IL-4 synthesis in CD4+ lymphocytes. J Immunol, 158, 5589-95. 
BOIERI, M., SHAH, P., DRESSEL, R. & INNGJERDINGEN, M. 2016. The Role 
of Animal Models in the Study of Hematopoietic Stem Cell 
Transplantation and GvHD: A Historical Overview. Front Immunol, 7, 
333. 
BOUAZZAOUI, A., SPACENKO, E., MUELLER, G., HUBER, E., SCHUBERT, 
T., HOLLER, E., ANDREESEN, R. & HILDEBRANDT, G. C. 2011. 
Steroid treatment alters adhesion molecule and chemokine expression in 
experimental acute graft-vs.-host disease of the intestinal tract. Exp 
Hematol, 39, 238-249 e1. 
BOUAZZAOUI, A., SPACENKO, E., MUELLER, G., MIKLOS, S., HUBER, E., 
HOLLER, E., ANDREESEN, R. & HILDEBRANDT, G. C. 2009. 
Chemokine and chemokine receptor expression analysis in target organs 
of acute graft-versus-host disease. Genes Immun, 10, 687-701. 
BRAUN, M. Y., LOWIN, B., FRENCH, L., ACHA-ORBEA, H. & TSCHOPP, J. 
1996. Cytotoxic T cells deficient in both functional fas ligand and perforin 
show residual cytolytic activity yet lose their capacity to induce lethal 
acute graft-versus-host disease. J Exp Med, 183, 657-61. 
BROWN, G. R., LEE, E. L. & THIELE, D. L. 2003. TNF enhances CD4+ T cell 
alloproliferation, IFN-gamma responses, and intestinal graft-versus-host 
disease by IL-12-independent mechanisms. J Immunol, 170, 5082-8. 
BULBAKE, U., DOPPALAPUDI, S., KOMMINENI, N. & KHAN, W. 2017. 
Liposomal Formulations in Clinical Use: An Updated Review. 
Pharmaceutics, 9. 
BURMAN, A. C., BANOVIC, T., KUNS, R. D., CLOUSTON, A. D., STANLEY, A. 
C., MORRIS, E. S., ROWE, V., BOFINGER, H., SKOCZYLAS, R., 
RAFFELT, N., FAHY, O., MCCOLL, S. R., ENGWERDA, C. R., 
MCDONALD, K. P. & HILL, G. R. 2007. IFNgamma differentially controls 
the development of idiopathic pneumonia syndrome and GVHD of the 
gastrointestinal tract. Blood, 110, 1064-72. 
BUTTGEREIT, F. & SCHEFFOLD, A. 2002. Rapid glucocorticoid effects on 
immune cells. Steroids, 67, 529-34. 
BUTTS, C. L., SHUKAIR, S. A., DUNCAN, K. M., HARRIS, C. W., 
BELYAVSKAYA, E. & STERNBERG, E. M. 2007. Effects of 
dexamethasone on rat dendritic cell function. Horm Metab Res, 39, 404-
12. 
CAIN, D. W. & CIDLOWSKI, J. A. 2017. Immune regulation by glucocorticoids. 
Nat Rev Immunol, 17, 233-247. 
CANALIS, E. 2005. Mechanisms of glucocorticoid action in bone. Curr 
Osteoporos Rep, 3, 98-102. 
CANALIS, E., MAZZIOTTI, G., GIUSTINA, A. & BILEZIKIAN, J. P. 2007. 
Glucocorticoid-induced osteoporosis: pathophysiology and therapy. 
Osteoporos Int, 18, 1319-28. 
CANTON, J. 2018. Macropinocytosis: New Insights Into Its Underappreciated 
Role in Innate Immune Cell Surveillance. Front Immunol, 9, 2286. 
CAO, Y., BENDER, I. K., KONSTANTINIDIS, A. K., SHIN, S. C., JEWELL, C. 
M., CIDLOWSKI, J. A., SCHLEIMER, R. P. & LU, N. Z. 2013. 




stage-specific glucocorticoid sensitivities of dendritic cells in mice and 
humans. Blood, 121, 1553-62. 
CARLSON, M. J., WEST, M. L., COGHILL, J. M., PANOSKALTSIS-MORTARI, 
A., BLAZAR, B. R. & SERODY, J. S. 2009. In vitro-differentiated TH17 
cells mediate lethal acute graft-versus-host disease with severe 
cutaneous and pulmonary pathologic manifestations. Blood, 113, 1365-
74. 
CASTILLO, P. M., JIMENEZ-RUIZ, A., CARNERERO, J. M. & PRADO-
GOTOR, R. 2018. Exploring Factors for the Design of Nanoparticles as 
Drug Delivery Vectors. Chemphyschem, 19, 2810-2828. 
CASTOR, M. G., PINHO, V. & TEIXEIRA, M. M. 2012. The role of chemokines 
in mediating graft versus host disease: opportunities for novel 
therapeutics. Front Pharmacol, 3, 23. 
CASTOR, M. G., REZENDE, B. M., BERNARDES, P. T., VIEIRA, A. T., 
VIEIRA, E. L., ARANTES, R. M., SOUZA, D. G., SILVA, T. A., 
TEIXEIRA, M. M. & PINHO, V. 2011. PI3Kgamma controls leukocyte 
recruitment, tissue injury, and lethality in a model of graft-versus-host 
disease in mice. J Leukoc Biol, 89, 955-64. 
CAVET, J., DICKINSON, A. M., NORDEN, J., TAYLOR, P. R., JACKSON, G. H. 
& MIDDLETON, P. G. 2001. Interferon-gamma and interleukin-6 gene 
polymorphisms associate with graft-versus-host disease in HLA-matched 
sibling bone marrow transplantation. Blood, 98, 1594-600. 
CHAKRAVERTY, R. & SYKES, M. 2007. The role of antigen-presenting cells in 
triggering graft-versus-host disease and graft-versus-leukemia. Blood, 
110, 9-17. 
CHANG, T., OLSON, J. A., PROFFITT, R. T. & ADLER-MOORE, J. P. 2010. 
Differences in tissue drug concentrations following intravenous versus 
intraperitoneal treatment with amphotericin B deoxycholate or liposomal 
amphotericin B. Med Mycol, 48, 430-5. 
CHAO, N. J. & CHEN, B. J. 2006. Prophylaxis and treatment of acute graft-
versus-host disease. Semin Hematol, 43, 32-41. 
CHEN, L., JONDAL, M. & YAKIMCHUK, K. 2018. Regulatory effects of 
dexamethasone on NK and T cell immunity. Inflammopharmacology, 26, 
1331-1338. 
CHEN, X., DAS, R., KOMOROWSKI, R., BERES, A., HESSNER, M. J., 
MIHARA, M. & DROBYSKI, W. R. 2009. Blockade of interleukin-6 
signaling augments regulatory T-cell reconstitution and attenuates the 
severity of graft-versus-host disease. Blood, 114, 891-900. 
CHEN, X., MURAKAMI, T., OPPENHEIM, J. J. & HOWARD, O. M. Z. 2004. 
Differential response of murine CD4+CD25+ and CD4+CD25- T cells to 
dexamethasone-induced cell death. Eur J Immunol, 34, 859-869. 
CHEN, X., OPPENHEIM, J. J., WINKLER-PICKETT, R. T., ORTALDO, J. R. & 
HOWARD, O. M. 2006. Glucocorticoid amplifies IL-2-dependent 
expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in 
vivo and enhances their capacity to suppress EAE. Eur J Immunol, 36, 
2139-49. 
CHEUK, D. K. 2013. Optimal stem cell source for allogeneic stem cell 





COHEN, J. J. & DUKE, R. C. 1984. Glucocorticoid activation of a calcium-
dependent endonuclease in thymocyte nuclei leads to cell death. J 
Immunol, 132, 38-42. 
COHEN, J. L., TRENADO, A., VASEY, D., KLATZMANN, D. & SALOMON, B. 
L. 2002. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for 
graft-versus-host disease. J Exp Med, 196, 401-6. 
CONNER, S. D. & SCHMID, S. L. 2003. Regulated portals of entry into the cell. 
Nature, 422, 37-44. 
COOKE, K. R., KOBZIK, L., MARTIN, T. R., BREWER, J., DELMONTE, J., JR., 
CRAWFORD, J. M. & FERRARA, J. L. 1996. An experimental model of 
idiopathic pneumonia syndrome after bone marrow transplantation: I. 
The roles of minor H antigens and endotoxin. Blood, 88, 3230-9. 
COPELAN, E. A. 2006. Hematopoietic stem-cell transplantation. N Engl J Med, 
354, 1813-26. 
CRUZ-TOPETE, D. & CIDLOWSKI, J. A. 2015. One hormone, two actions: anti- 
and pro-inflammatory effects of glucocorticoids. 
Neuroimmunomodulation, 22, 20-32. 
DEEG, H. J. 2007. How I treat refractory acute GVHD. Blood, 109, 4119-26. 
DEKHUIJZEN, P. N., GAYAN-RAMIREZ, G., BISSCHOP, A., DE BOCK, V., 
DOM, R. & DECRAMER, M. 1995. Corticosteroid treatment and 
nutritional deprivation cause a different pattern of atrophy in rat 
diaphragm. J Appl Physiol (1985), 78, 629-37. 
DELANY, A. M., GABBITAS, B. Y. & CANALIS, E. 1995. Cortisol downregulates 
osteoblast alpha 1 (I) procollagen mRNA by transcriptional and 
posttranscriptional mechanisms. J Cell Biochem, 57, 488-94. 
DESGEORGES, T., CARATTI, G., MOUNIER, R., TUCKERMANN, J. & 
CHAZAUD, B. 2019. Glucocorticoids Shape Macrophage Phenotype for 
Tissue Repair. Front Immunol, 10, 1591. 
DESHMANE, S. L., KREMLEV, S., AMINI, S. & SAWAYA, B. E. 2009. 
Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon 
Cytokine Res, 29, 313-26. 
DIXON, L. J., BARNES, M., TANG, H., PRITCHARD, M. T. & NAGY, L. E. 
2013. Kupffer cells in the liver. Compr Physiol, 3, 785-97. 
DOHERTY, G. J. & MCMAHON, H. T. 2009. Mechanisms of endocytosis. Annu 
Rev Biochem, 78, 857-902. 
DROBYSKI, W. R., SZABO, A., ZHU, F., KEEVER-TAYLOR, C., HEBERT, K. 
M., DUNN, R., YIM, S., JOHNSON, B., D'SOUZA, A., EAPEN, M., 
FENSKE, T. S., HARI, P., HAMADANI, M., HOROWITZ, M. M., RIZZO, 
J. D., SABER, W., SHAH, N., SHAW, B. & PASQUINI, M. 2018. 
Tocilizumab, tacrolimus and methotrexate for the prevention of acute 
graft-versus-host disease: low incidence of lower gastrointestinal tract 
disease. Haematologica, 103, 717-727. 
DUFFNER, U. A., MAEDA, Y., COOKE, K. R., REDDY, P., ORDEMANN, R., 
LIU, C., FERRARA, J. L. & TESHIMA, T. 2004. Host dendritic cells alone 
are sufficient to initiate acute graft-versus-host disease. J Immunol, 172, 
7393-8. 
DUMA, D., JEWELL, C. M. & CIDLOWSKI, J. A. 2006. Multiple glucocorticoid 
receptor isoforms and mechanisms of post-translational modification. J 




DUNN, A. J. 2000. Cytokine activation of the HPA axis. Ann N Y Acad Sci, 917, 
608-17. 
DUTTA, D. & DONALDSON, J. G. 2012. Search for inhibitors of endocytosis: 
Intended specificity and unintended consequences. Cell Logist, 2, 203-
208. 
EGDAHL, R. H., ROLLER, F. R., SWANSON, R. L. & VARCO, R. L. 1958. 
Acquired tolerance to homografts and heterografts in the rat. Ann N Y 
Acad Sci, 73, 842-7. 
EHRCHEN, J., STEINMULLER, L., BARCZYK, K., TENBROCK, K., NACKEN, 
W., EISENACHER, M., NORDHUES, U., SORG, C., SUNDERKOTTER, 
C. & ROTH, J. 2007. Glucocorticoids induce differentiation of a 
specifically activated, anti-inflammatory subtype of human monocytes. 
Blood, 109, 1265-74. 
ELENKOV, I. J. 2004. Glucocorticoids and the Th1/Th2 balance. Ann N Y Acad 
Sci, 1024, 138-46. 
EMMER, P. M., VAN DER VLAG, J., ADEMA, G. J. & HILBRANDS, L. B. 2006. 
Dendritic cells activated by lipopolysaccharide after dexamethasone 
treatment induce donor-specific allograft hyporesponsiveness. 
Transplantation, 81, 1451-9. 
EVERSE, L. A., ANDERSON, L. D., JR., VAN ROOIJEN, N. & MULLEN, C. A. 
2001. Bone marrow transplant conditioning intensified with liposomal 
clodronate to eliminate residual host antigen presenting cells fails to 
ameliorate GVHD and increases PERI-BMT mortality. Transplantation, 
71, 611-8. 
EVERSON, G. T., TROUILLOT, T., WACHS, M., BAK, T., STEINBERG, T., 
KAM, I., SHRESTHA, R. & STEGALL, M. 1999. Early steroid withdrawal 
in liver transplantation is safe and beneficial. Liver Transpl Surg, 5, S48-
57. 
FAHEY, A. J., ROBINS, R. A., KINDLE, K. B., HEERY, D. M. & 
CONSTANTINESCU, C. S. 2006. Effects of glucocorticoids on STAT4 
activation in human T cells are stimulus-dependent. J Leukoc Biol, 80, 
133-44. 
FALCONE, S., COCUCCI, E., PODINI, P., KIRCHHAUSEN, T., CLEMENTI, E. 
& MELDOLESI, J. 2006. Macropinocytosis: regulated coordination of 
endocytic and exocytic membrane traffic events. J Cell Sci, 119, 4758-
69. 
FERRARA, J. L. 1993. Cytokine dysregulation as a mechanism of graft versus 
host disease. Curr Opin Immunol, 5, 794-9. 
FERRARA, J. L., LEVINE, J. E., REDDY, P. & HOLLER, E. 2009. Graft-versus-
host disease. Lancet, 373, 1550-61. 
FINERTY, J. C. 1952. Parabiosis in physiological studies. Physiol Rev, 32, 277-
302. 
FOURNIER, M., HUANG, Z. S., LI, H., DA, X., CERCEK, B. & LEWIS, M. I. 
2003. Insulin-like growth factor I prevents corticosteroid-induced 
diaphragm muscle atrophy in emphysematous hamsters. Am J Physiol 
Regul Integr Comp Physiol, 285, R34-43. 
FOWLER, D. H., KURASAWA, K., SMITH, R., ECKHAUS, M. A. & GRESS, R. 
E. 1994. Donor CD4-enriched cells of Th2 cytokine phenotype regulate 
graft-versus-host disease without impairing allogeneic engraftment in 




FRANCHIMONT, D. 2004. Overview of the actions of glucocorticoids on the 
immune response: a good model to characterize new pathways of 
immunosuppression for new treatment strategies. Ann N Y Acad Sci, 
1024, 124-37. 
FRANCO, L. M., GADKARI, M., HOWE, K. N., SUN, J., KARDAVA, L., KUMAR, 
P., KUMARI, S., HU, Z., FRASER, I. D. C., MOIR, S., TSANG, J. S. & 
GERMAIN, R. N. 2019. Immune regulation by glucocorticoids can be 
linked to cell type-dependent transcriptional responses. J Exp Med, 216, 
384-406. 
FRIJTERS, R., FLEUREN, W., TOONEN, E. J., TUCKERMANN, J. P., 
REICHARDT, H. M., VAN DER MAADEN, H., VAN ELSAS, A., VAN 
LIEROP, M. J., DOKTER, W., DE VLIEG, J. & ALKEMA, W. 2010. 
Prednisolone-induced differential gene expression in mouse liver 
carrying wild type or a dimerization-defective glucocorticoid receptor. 
BMC Genomics, 11, 359. 
FUJIMOTO, L. M., ROTH, R., HEUSER, J. E. & SCHMID, S. L. 2000. Actin 
assembly plays a variable, but not obligatory role in receptor-mediated 
endocytosis in mammalian cells. Traffic, 1, 161-71. 
GAO, Y. Z., X; ZHANG, Y; CHEN, X; WANG, L; FENG, W; HUANG, C; LI, F, 
2017. In vivo biodistribution and passive accumulation of upconversion 
nanoparticles in colorectal cancer models via intraperitoneal injection. 
RSC Advances, 7. 
GARNETT, C., APPERLEY, J. F. & PAVLU, J. 2013. Treatment and 
management of graft-versus-host disease: improving response and 
survival. Ther Adv Hematol, 4, 366-78. 
GAYO, A., MOZO, L., SUAREZ, A., TUNON, A., LAHOZ, C. & GUTIERREZ, C. 
1998. Glucocorticoids increase IL-10 expression in multiple sclerosis 
patients with acute relapse. J Neuroimmunol, 85, 122-30. 
GHIMIRE, S., WEBER, D., MAVIN, E., WANG, X. N., DICKINSON, A. M. & 
HOLLER, E. 2017. Pathophysiology of GvHD and Other HSCT-Related 
Major Complications. Front Immunol, 8, 79. 
GILES, K. M., ROSS, K., ROSSI, A. G., HOTCHIN, N. A., HASLETT, C. & 
DRANSFIELD, I. 2001. Glucocorticoid augmentation of macrophage 
capacity for phagocytosis of apoptotic cells is associated with reduced 
p130Cas expression, loss of paxillin/pyk2 phosphorylation, and high 
levels of active Rac. J Immunol, 167, 976-86. 
GIVON, T., REVEL, M. & SLAVIN, S. 1994. Potential use of interleukin-6 in 
bone marrow transplantation: effects of recombinant human interleukin-6 
after syngeneic and semiallogeneic bone marrow transplantation in mice. 
Blood, 83, 1690-7. 
GOKER, H., HAZNEDAROGLU, I. C. & CHAO, N. J. 2001. Acute graft-vs-host 
disease: pathobiology and management. Exp Hematol, 29, 259-77. 
GRATWOHL, A., BALDOMERO, H., GRATWOHL, M., ALJURF, M., BOUZAS, 
L. F., HOROWITZ, M., KODERA, Y., LIPTON, J., IIDA, M., PASQUINI, 
M. C., PASSWEG, J., SZER, J., MADRIGAL, A., FRAUENDORFER, K., 
NIEDERWIESER, D., WORLDWIDE NETWORK OF, B. & MARROW, T. 
2013. Quantitative and qualitative differences in use and trends of 
hematopoietic stem cell transplantation: a Global Observational Study. 




GRAUBERT, T. A., DIPERSIO, J. F., RUSSELL, J. H. & LEY, T. J. 1997. 
Perforin/granzyme-dependent and independent mechanisms are both 
important for the development of graft-versus-host disease after murine 
bone marrow transplantation. J Clin Invest, 100, 904-11. 
GRUBER, J., SGONC, R., HU, Y. H., BEUG, H. & WICK, G. 1994. Thymocyte 
apoptosis induced by elevated endogenous corticosterone levels. Eur J 
Immunol, 24, 1115-21. 
GUO, S., ZHANG, X., ZHENG, M., ZHANG, X., MIN, C., WANG, Z., CHEON, S. 
H., OAK, M. H., NAH, S. Y. & KIM, K. M. 2015. Selectivity of commonly 
used inhibitors of clathrin-mediated and caveolae-dependent endocytosis 
of G protein-coupled receptors. Biochim Biophys Acta, 1848, 2101-10. 
HANIFFA, M., GINHOUX, F., WANG, X. N., BIGLEY, V., ABEL, M., DIMMICK, 
I., BULLOCK, S., GRISOTTO, M., BOOTH, T., TAUB, P., HILKENS, C., 
MERAD, M. & COLLIN, M. 2009. Differential rates of replacement of 
human dermal dendritic cells and macrophages during hematopoietic 
stem cell transplantation. J Exp Med, 206, 371-85. 
HANNON, M., LECHANTEUR, C., LUCAS, S., SOMJA, J., SEIDEL, L., BELLE, 
L., BRUCK, F., BAUDOUX, E., GIET, O., CHANTILLON, A. M., 
DELVENNE, P., DRION, P., BEGUIN, Y., HUMBLET-BARON, S. & 
BARON, F. 2014. Infusion of clinical-grade enriched regulatory T cells 
delays experimental xenogeneic graft-versus-host disease. Transfusion, 
54, 353-63. 
HASHIMOTO, D., CHOW, A., GRETER, M., SAENGER, Y., KWAN, W. H., 
LEBOEUF, M., GINHOUX, F., OCHANDO, J. C., KUNISAKI, Y., VAN 
ROOIJEN, N., LIU, C., TESHIMA, T., HEEGER, P. S., STANLEY, E. R., 
FRENETTE, P. S. & MERAD, M. 2011. Pretransplant CSF-1 therapy 
expands recipient macrophages and ameliorates GVHD after allogeneic 
hematopoietic cell transplantation. J Exp Med, 208, 1069-82. 
HECK, J. G., NAPP, J., SIMONATO, S., MOLLMER, J., LANGE, M., 
REICHARDT, H. M., STAUDT, R., ALVES, F. & FELDMANN, C. 2015. 
Multifunctional phosphate-based inorganic-organic hybrid nanoparticles. 
J Am Chem Soc, 137, 7329-36. 
HEIDEVELD, E., HAMPTON-O'NEIL, L. A., CROSS, S. J., VAN ALPHEN, F. P. 
J., VAN DEN BIGGELAAR, M., TOYE, A. M. & VAN DEN AKKER, E. 
2018. Glucocorticoids induce differentiation of monocytes towards 
macrophages that share functional and phenotypical aspects with 
erythroblastic island macrophages. Haematologica, 103, 395-405. 
HIGAKI, M., ISHIHARA, T., IZUMO, N., TAKATSU, M. & MIZUSHIMA, Y. 2005. 
Treatment of experimental arthritis with poly(D, L-lactic/glycolic acid) 
nanoparticles encapsulating betamethasone sodium phosphate. Ann 
Rheum Dis, 64, 1132-6. 
HILDEBRANDT, G. C., DUFFNER, U. A., OLKIEWICZ, K. M., CORRION, L. A., 
WILLMARTH, N. E., WILLIAMS, D. L., CLOUTHIER, S. G., 
HOGABOAM, C. M., REDDY, P. R., MOORE, B. B., KUZIEL, W. A., LIU, 
C., YANIK, G. & COOKE, K. R. 2004. A critical role for CCR2/MCP-1 
interactions in the development of idiopathic pneumonia syndrome after 
allogeneic bone marrow transplantation. Blood, 103, 2417-26. 
HILL, G. R., CRAWFORD, J. M., COOKE, K. R., BRINSON, Y. S., PAN, L. & 




disease: the role of gastrointestinal damage and inflammatory cytokines. 
Blood, 90, 3204-13. 
HILL, G. R. & FERRARA, J. L. 2000. The primacy of the gastrointestinal tract as 
a target organ of acute graft-versus-host disease: rationale for the use of 
cytokine shields in allogeneic bone marrow transplantation. Blood, 95, 
2754-9. 
HILLIER, S. G. 2007. Diamonds are forever: the cortisone legacy. J Endocrinol, 
195, 1-6. 
HO, V. T. & CUTLER, C. 2008. Current and novel therapies in acute GVHD. 
Best Pract Res Clin Haematol, 21, 223-37. 
HOCKENBERY, D. M., ZUTTER, M., HICKEY, W., NAHM, M. & KORSMEYER, 
S. J. 1991. BCL2 protein is topographically restricted in tissues 
characterized by apoptotic cell death. Proc Natl Acad Sci U S A, 88, 
6961-5. 
HOFER, T., KRICHEVSKY, O. & ALTAN-BONNET, G. 2012. Competition for IL-
2 between Regulatory and Effector T Cells to Chisel Immune Responses. 
Front Immunol, 3, 268. 
HOGGER, P., DREIER, J., DROSTE, A., BUCK, F. & SORG, C. 1998. 
Identification of the integral membrane protein RM3/1 on human 
monocytes as a glucocorticoid-inducible member of the scavenger 
receptor cysteine-rich family (CD163). J Immunol, 161, 1883-90. 
HOLLER, E., BUTZHAMMER, P., SCHMID, K., HUNDSRUCKER, C., 
KOESTLER, J., PETER, K., ZHU, W., SPORRER, D., HEHLGANS, T., 
KREUTZ, M., HOLLER, B., WOLFF, D., EDINGER, M., ANDREESEN, 
R., LEVINE, J. E., FERRARA, J. L., GESSNER, A., SPANG, R. & 
OEFNER, P. J. 2014. Metagenomic analysis of the stool microbiome in 
patients receiving allogeneic stem cell transplantation: loss of diversity is 
associated with use of systemic antibiotics and more pronounced in 
gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant, 
20, 640-5. 
HOLLER, E., KOLB, H. J., MOLLER, A., KEMPENI, J., LIESENFELD, S., 
PECHUMER, H., LEHMACHER, W., RUCKDESCHEL, G., GLEIXNER, 
B., RIEDNER, C. & ET AL. 1990. Increased serum levels of tumor 
necrosis factor alpha precede major complications of bone marrow 
transplantation. Blood, 75, 1011-6. 
HOLLER, E., RONCAROLO, M. G., HINTERMEIER-KNABE, R., EISSNER, G., 
ERTL, B., SCHULZ, U., KNABE, H., KOLB, H. J., ANDREESEN, R. & 
WILMANNS, W. 2000. Prognostic significance of increased IL-10 
production in patients prior to allogeneic bone marrow transplantation. 
Bone Marrow Transplant, 25, 237-41. 
HOROWITZ, M. M., GALE, R. P., SONDEL, P. M., GOLDMAN, J. M., KERSEY, 
J., KOLB, H. J., RIMM, A. A., RINGDEN, O., ROZMAN, C., SPECK, B. & 
ET AL. 1990. Graft-versus-leukemia reactions after bone marrow 
transplantation. Blood, 75, 555-62. 
ICLOZAN, C., YU, Y., LIU, C., LIANG, Y., YI, T., ANASETTI, C. & YU, X. Z. 
2010. T helper17 cells are sufficient but not necessary to induce acute 
graft-versus-host disease. Biol Blood Marrow Transplant, 16, 170-8. 
IMAI, E., MINER, J. N., MITCHELL, J. A., YAMAMOTO, K. R. & GRANNER, D. 




interaction and the response of the phosphoenolpyruvate carboxykinase 
gene to glucocorticoids. J Biol Chem, 268, 5353-6. 
IVANOV, A. I. 2008. Pharmacological inhibition of endocytic pathways: is it 
specific enough to be useful? Methods Mol Biol, 440, 15-33. 
JACOBSOHN, D. A. & VOGELSANG, G. B. 2007. Acute graft versus host 
disease. Orphanet J Rare Dis, 2, 35. 
JAKSCH, M. & MATTSSON, J. 2005. The pathophysiology of acute graft-
versus-host disease. Scand J Immunol, 61, 398-409. 
JIA, D., O'BRIEN, C. A., STEWART, S. A., MANOLAGAS, S. C. & WEINSTEIN, 
R. S. 2006. Glucocorticoids act directly on osteoclasts to increase their 
life span and reduce bone density. Endocrinology, 147, 5592-9. 
JIN, J. F., ZHU, L. L., CHEN, M., XU, H. M., WANG, H. F., FENG, X. Q., ZHU, 
X. P. & ZHOU, Q. 2015. The optimal choice of medication administration 
route regarding intravenous, intramuscular, and subcutaneous injection. 
Patient Prefer Adherence, 9, 923-42. 
JOHNSON, B. D. & TRUITT, R. L. 1995. Delayed infusion of immunocompetent 
donor cells after bone marrow transplantation breaks graft-host tolerance 
allows for persistent antileukemic reactivity without severe graft-versus-
host disease. Blood, 85, 3302-12. 
JUNG, C., KAUL, M. G., BRUNS, O. T., DUCIC, T., FREUND, B., HEINE, M., 
REIMER, R., MEENTS, A., SALMEN, S. C., WELLER, H., NIELSEN, P., 
ADAM, G., HEEREN, J. & ITTRICH, H. 2014. Intraperitoneal injection 
improves the uptake of nanoparticle-labeled high-density lipoprotein to 
atherosclerotic plaques compared with intravenous injection: a 
multimodal imaging study in ApoE knockout mice. Circ Cardiovasc 
Imaging, 7, 303-11. 
KADMIEL, M. & CIDLOWSKI, J. A. 2013. Glucocorticoid receptor signaling in 
health and disease. Trends Pharmacol Sci, 34, 518-30. 
KANDA, J. 2013. Effect of HLA mismatch on acute graft-versus-host disease. 
Int J Hematol, 98, 300-8. 
KANOJIA, M. D., ANAGNOSTOU, A. A., ZANDER, A. R., VELLEKOOP, L., 
SPITZER, G., VERMA, D. S., JAGANNATH, S. & DICKE, K. A. 1984. 
High-dose methylprednisolone treatment for acute graft-versus-host 
disease after bone marrow transplantation in adults. Transplantation, 37, 
246-9. 
KAPPEL, L. W., GOLDBERG, G. L., KING, C. G., SUH, D. Y., SMITH, O. M., 
LIGH, C., HOLLAND, A. M., GRUBIN, J., MARK, N. M., LIU, C., 
IWAKURA, Y., HELLER, G. & VAN DEN BRINK, M. R. 2009. IL-17 
contributes to CD4-mediated graft-versus-host disease. Blood, 113, 945-
52. 
KARAGIANNIDIS, C., AKDIS, M., HOLOPAINEN, P., WOOLLEY, N. J., 
HENSE, G., RUCKERT, B., MANTEL, P. Y., MENZ, G., AKDIS, C. A., 
BLASER, K. & SCHMIDT-WEBER, C. B. 2004. Glucocorticoids 
upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy 
Clin Immunol, 114, 1425-33. 
KELLY, E. J., SANDGREN, E. P., BRINSTER, R. L. & PALMITER, R. D. 1997. 
A pair of adjacent glucocorticoid response elements regulate expression 





KIM, S. W., RHEE, H. J., KO, J., KIM, Y. J., KIM, H. G., YANG, J. M., CHOI, E. 
C. & NA, D. S. 2001. Inhibition of cytosolic phospholipase A2 by annexin 
I. Specific interaction model and mapping of the interaction site. J Biol 
Chem, 276, 15712-9. 
KITAJIMA, T., ARIIZUMI, K., BERGSTRESSER, P. R. & TAKASHIMA, A. 1996. 
A novel mechanism of glucocorticoid-induced immune suppression: the 
inhibiton of T cell-mediated terminal maturation of a murine dendritic cell 
line. J Clin Invest, 98, 142-7. 
KLASSEN, C., KARABINSKAYA, A., DEJAGER, L., VETTORAZZI, S., VAN 
MOORLEGHEM, J., LUHDER, F., MEIJSING, S. H., TUCKERMANN, J. 
P., BOHNENBERGER, H., LIBERT, C. & REICHARDT, H. M. 2017. 
Airway Epithelial Cells Are Crucial Targets of Glucocorticoids in a Mouse 
Model of Allergic Asthma. J Immunol, 199, 48-61. 
KLEIMAN, A., HUBNER, S., RODRIGUEZ PARKITNA, J. M., NEUMANN, A., 
HOFER, S., WEIGAND, M. A., BAUER, M., SCHMID, W., SCHUTZ, G., 
LIBERT, C., REICHARDT, H. M. & TUCKERMANN, J. P. 2012. 
Glucocorticoid receptor dimerization is required for survival in septic 
shock via suppression of interleukin-1 in macrophages. FASEB J, 26, 
722-9. 
KLEIN, G. L. 2015. The Effect of Glucocorticoids on Bone and Muscle. 
Osteoporos Sarcopenia, 1, 39-45. 
KORNGOLD, R., MARINI, J. C., DE BACA, M. E., MURPHY, G. F. & GILES-
KOMAR, J. 2003. Role of tumor necrosis factor-alpha in graft-versus-
host disease and graft-versus-leukemia responses. Biol Blood Marrow 
Transplant, 9, 292-303. 
KORNGOLD, R. & SPRENT, J. 1978. Lethal graft-versus-host disease after 
bone marrow transplantation across minor histocompatibility barriers in 
mice. Prevention by removing mature T cells from marrow. J Exp Med, 
148, 1687-98. 
KORNGOLD, R. & SPRENT, J. 1987. T cell subsets and graft-versus-host 
disease. Transplantation, 44, 335-9. 
KOU, L., SUN, J., ZHAI, Y. & HE, Z. 2013. The endocytosis and intracellular 
fate of nanomedicines: Implication for rational design. Asian Journal of 
Pharmaceutical Sciences, 8, 1-10. 
KUHN, D. A., VANHECKE, D., MICHEN, B., BLANK, F., GEHR, P., PETRI-
FINK, A. & ROTHEN-RUTISHAUSER, B. 2014. Different endocytotic 
uptake mechanisms for nanoparticles in epithelial cells and 
macrophages. Beilstein J Nanotechnol, 5, 1625-36. 
LASKIN, D. L. 2009. Macrophages and inflammatory mediators in chemical 
toxicity: a battle of forces. Chem Res Toxicol, 22, 1376-85. 
LEE, S. J., ZAHRIEH, D., AGURA, E., MACMILLAN, M. L., MAZIARZ, R. T., 
MCCARTHY, P. L., JR., HO, V. T., CUTLER, C., ALYEA, E. P., ANTIN, 
J. H. & SOIFFER, R. J. 2004. Effect of up-front daclizumab when 
combined with steroids for the treatment of acute graft-versus-host 
disease: results of a randomized trial. Blood, 104, 1559-64. 
LI, B. & LANE, L. A. 2019. Probing the biological obstacles of nanomedicine 
with gold nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 
11, e1542. 
LI, C. C., MUNITIC, I., MITTELSTADT, P. R., CASTRO, E. & ASHWELL, J. D. 




Glucocorticoids Is Protective in LPS-Induced Sepsis. PLoS Biol, 13, 
e1002269. 
LIBERMAN, A. C., DRUKER, J., REFOJO, D., HOLSBOER, F. & ARZT, E. 
2009. Glucocorticoids inhibit GATA-3 phosphorylation and activity in T 
cells. FASEB J, 23, 1558-71. 
LINKER, R. A., WELLER, C., LUHDER, F., MOHR, A., SCHMIDT, J., KNAUTH, 
M., METSELAAR, J. M. & GOLD, R. 2008. Liposomal 
glucocorticosteroids in treatment of chronic autoimmune demyelination: 
long-term protective effects and enhanced efficacy of methylprednisolone 
formulations. Exp Neurol, 211, 397-406. 
LIU, Y., COUSIN, J. M., HUGHES, J., VAN DAMME, J., SECKL, J. R., 
HASLETT, C., DRANSFIELD, I., SAVILL, J. & ROSSI, A. G. 1999. 
Glucocorticoids promote nonphlogistic phagocytosis of apoptotic 
leukocytes. J Immunol, 162, 3639-46. 
LU, Y. & WALLER, E. K. 2009. Dichotomous role of interferon-gamma in 
allogeneic bone marrow transplant. Biol Blood Marrow Transplant, 15, 
1347-53. 
LUHDER, F. & REICHARDT, H. M. 2017. Novel Drug Delivery Systems 
Tailored for Improved Administration of Glucocorticoids. Int J Mol Sci, 18. 
MACMILLAN, M. L., WEISDORF, D. J., WAGNER, J. E., DEFOR, T. E., 
BURNS, L. J., RAMSAY, N. K., DAVIES, S. M. & BLAZAR, B. R. 2002. 
Response of 443 patients to steroids as primary therapy for acute graft-
versus-host disease: comparison of grading systems. Biol Blood Marrow 
Transplant, 8, 387-94. 
MAEDA, Y., LEVY, R. B., REDDY, P., LIU, C., CLOUTHIER, S. G., TESHIMA, 
T. & FERRARA, J. L. 2005. Both perforin and Fas ligand are required for 
the regulation of alloreactive CD8+ T cells during acute graft-versus-host 
disease. Blood, 105, 2023-7. 
MAPARA, M. Y., KIM, Y. M., WANG, S. P., BRONSON, R., SACHS, D. H. & 
SYKES, M. 2002. Donor lymphocyte infusions mediate superior graft-
versus-leukemia effects in mixed compared to fully allogeneic chimeras: 
a critical role for host antigen-presenting cells. Blood, 100, 1903-9. 
MAPARA, M. Y., LENG, C., KIM, Y. M., BRONSON, R., LOKSHIN, A., 
LUSTER, A. & SYKES, M. 2006. Expression of chemokines in GVHD 
target organs is influenced by conditioning and genetic factors and 
amplified by GVHR. Biol Blood Marrow Transplant, 12, 623-34. 
MARKUS, M. A., NAPP, J., BEHNKE, T., MITKOVSKI, M., MONECKE, S., 
DULLIN, C., KILFEATHER, S., DRESSEL, R., RESCH-GENGER, U. & 
ALVES, F. 2015. Tracking of Inhaled Near-Infrared Fluorescent 
Nanoparticles in Lungs of SKH-1 Mice with Allergic Airway Inflammation. 
ACS Nano, 9, 11642-57. 
MARQUES, A. H., SILVERMAN, M. N. & STERNBERG, E. M. 2009. 
Glucocorticoid dysregulations and their clinical correlates. From 
receptors to therapeutics. Ann N Y Acad Sci, 1179, 1-18. 
MARTINEZ, F. O., SICA, A., MANTOVANI, A. & LOCATI, M. 2008. Macrophage 
activation and polarization. Front Biosci, 13, 453-61. 
MASSENKEIL, G., RACKWITZ, S., GENVRESSE, I., ROSEN, O., DORKEN, B. 
& ARNOLD, R. 2002. Basiliximab is well tolerated and effective in the 




allogeneic stem cell transplantation. Bone Marrow Transplant, 30, 899-
903. 
MATTE, C. C., LIU, J., CORMIER, J., ANDERSON, B. E., ATHANASIADIS, I., 
JAIN, D., MCNIFF, J. & SHLOMCHIK, W. D. 2004. Donor APCs are 
required for maximal GVHD but not for GVL. Nat Med, 10, 987-92. 
MATYSZAK, M. K., CITTERIO, S., RESCIGNO, M. & RICCIARDI-
CASTAGNOLI, P. 2000. Differential effects of corticosteroids during 
different stages of dendritic cell maturation. Eur J Immunol, 30, 1233-42. 
METSELAAR, J. M., WAUBEN, M. H., WAGENAAR-HILBERS, J. P., 
BOERMAN, O. C. & STORM, G. 2003. Complete remission of 
experimental arthritis by joint targeting of glucocorticoids with long-
circulating liposomes. Arthritis Rheum, 48, 2059-66. 
MIN, C. K., LEE, W. Y., MIN, D. J., LEE, D. G., KIM, Y. J., PARK, Y. H., KIM, H. 
J., LEE, S., KIM, D. W., LEE, J. W., MIN, W. S. & KIM, C. C. 2001. The 
kinetics of circulating cytokines including IL-6, TNF-alpha, IL-8 and IL-10 
following allogeneic hematopoietic stem cell transplantation. Bone 
Marrow Transplant, 28, 935-40. 
MONTES-COBOS, E., RING, S., FISCHER, H. J., HECK, J., STRAUSS, J., 
SCHWANINGER, M., REICHARDT, S. D., FELDMANN, C., LUHDER, F. 
& REICHARDT, H. M. 2017. Targeted delivery of glucocorticoids to 
macrophages in a mouse model of multiple sclerosis using inorganic-
organic hybrid nanoparticles. J Control Release, 245, 157-169. 
MORISHIMA, S., KASHIWASE, K., MATSUO, K., AZUMA, F., YABE, T., SATO-
OTSUBO, A., OGAWA, S., SHIINA, T., SATAKE, M., SAJI, H., KATO, S., 
KODERA, Y., SASAZUKI, T., MORISHIMA, Y. & JAPAN MARROW 
DONOR, P. 2016. High-risk HLA alleles for severe acute graft-versus-
host disease and mortality in unrelated donor bone marrow 
transplantation. Haematologica, 101, 491-8. 
MOSER, M., DE SMEDT, T., SORNASSE, T., TIELEMANS, F., CHENTOUFI, 
A. A., MURAILLE, E., VAN MECHELEN, M., URBAIN, J. & LEO, O. 
1995. Glucocorticoids down-regulate dendritic cell function in vitro and in 
vivo. Eur J Immunol, 25, 2818-24. 
MOUTSATSOU, P., KASSI, E. & PAPAVASSILIOU, A. G. 2012. Glucocorticoid 
receptor signaling in bone cells. Trends Mol Med, 18, 348-59. 
MOZO, L., SUAREZ, A. & GUTIERREZ, C. 2004. Glucocorticoids up-regulate 
constitutive interleukin-10 production by human monocytes. Clin Exp 
Allergy, 34, 406-12. 
MURRAY, P. J., ALLEN, J. E., BISWAS, S. K., FISHER, E. A., GILROY, D. W., 
GOERDT, S., GORDON, S., HAMILTON, J. A., IVASHKIV, L. B., 
LAWRENCE, T., LOCATI, M., MANTOVANI, A., MARTINEZ, F. O., 
MEGE, J. L., MOSSER, D. M., NATOLI, G., SAEIJ, J. P., SCHULTZE, J. 
L., SHIREY, K. A., SICA, A., SUTTLES, J., UDALOVA, I., VAN 
GINDERACHTER, J. A., VOGEL, S. N. & WYNN, T. A. 2014. 
Macrophage activation and polarization: nomenclature and experimental 
guidelines. Immunity, 41, 14-20. 
NAKIC, B. & SILOBRCIC, V. 1958. Tolerance of skin homografts related to fatal 
disease in separated rat parabionts. Nature, 182, 264-5. 
NAPP, J., MARKUS, M. A., HECK, J. G., DULLIN, C., MOBIUS, W., GORPAS, 




Nanoparticles for Traceable Delivery of Glucocorticoids to Inflammatory 
Sites. Theranostics, 8, 6367-6383. 
NASERIAN, S., LECLERC, M., THIOLAT, A., PILON, C., LE BRET, C., 
BELKACEMI, Y., MAURY, S., CHARLOTTE, F. & COHEN, J. L. 2018. 
Simple, Reproducible, and Efficient Clinical Grading System for Murine 
Models of Acute Graft-versus-Host Disease. Front Immunol, 9, 10. 
NASSEREDDINE, S., RAFEI, H., ELBAHESH, E. & TABBARA, I. 2017. Acute 
Graft Versus Host Disease: A Comprehensive Review. Anticancer Res, 
37, 1547-1555. 
NELSON, T., BEHFAR, A. & TERZIC, A. 2008. Stem cells: biologics for 
regeneration. Clin Pharmacol Ther, 84, 620-3. 
NESTEL, F. P., PRICE, K. S., SEEMAYER, T. A. & LAPP, W. S. 1992. 
Macrophage priming and lipopolysaccharide-triggered release of tumor 
necrosis factor alpha during graft-versus-host disease. J Exp Med, 175, 
405-13. 
NIKOLIC, B., LEE, S., BRONSON, R. T., GRUSBY, M. J. & SYKES, M. 2000. 
Th1 and Th2 mediate acute graft-versus-host disease, each with distinct 
end-organ targets. J Clin Invest, 105, 1289-98. 
NISHIMOTO, N. & KISHIMOTO, T. 2006. Interleukin 6: from bench to bedside. 
Nat Clin Pract Rheumatol, 2, 619-26. 
NISHIWAKI, S., NAKAYAMA, T., MURATA, M., NISHIDA, T., TERAKURA, S., 
SAITO, S., KATO, T., MIZUNO, H., IMAHASHI, N., SETO, A., OZAWA, 
Y., MIYAMURA, K., ITO, M., TAKESHITA, K., KATO, H., TOYOKUNI, S., 
NAGAO, K., UEDA, R. & NAOE, T. 2014. Dexamethasone palmitate 
ameliorates macrophages-rich graft-versus-host disease by inhibiting 
macrophage functions. PLoS One, 9, e96252. 
O'BRIEN, C. A., JIA, D., PLOTKIN, L. I., BELLIDO, T., POWERS, C. C., 
STEWART, S. A., MANOLAGAS, S. C. & WEINSTEIN, R. S. 2004. 
Glucocorticoids act directly on osteoblasts and osteocytes to induce their 
apoptosis and reduce bone formation and strength. Endocrinology, 145, 
1835-41. 
OAKLEY, R. H. & CIDLOWSKI, J. A. 2013. The biology of the glucocorticoid 
receptor: new signaling mechanisms in health and disease. J Allergy Clin 
Immunol, 132, 1033-44. 
OBANDO-PEREDA, G. A., FISCHER, L. & STACH-MACHADO, D. R. 2014. 
Titanium and zirconia particle-induced pro-inflammatory gene expression 
in cultured macrophages and osteolysis, inflammatory hyperalgesia and 
edema in vivo. Life Sci, 97, 96-106. 
ODEGAARD, J. I. & CHAWLA, A. 2011. Alternative macrophage activation and 
metabolism. Annu Rev Pathol, 6, 275-97. 
ODEGAARD, J. I., RICARDO-GONZALEZ, R. R., RED EAGLE, A., VATS, D., 
MOREL, C. R., GOFORTH, M. H., SUBRAMANIAN, V., MUKUNDAN, L., 
FERRANTE, A. W. & CHAWLA, A. 2008. Alternative M2 activation of 
Kupffer cells by PPARdelta ameliorates obesity-induced insulin 
resistance. Cell Metab, 7, 496-507. 
OKAMOTO, S. 2017. Current indication for hematopoietic cell transplantation in 
adults. Hematol Oncol Stem Cell Ther, 10, 178-183. 
ONWUBALILI, J. K. & OBINECHE, E. N. 1992. High incidence of post-
transplant diabetes mellitus in a single-centre study. Nephrol Dial 




OPHERK, C., TRONCHE, F., KELLENDONK, C., KOHLMULLER, D., 
SCHULZE, A., SCHMID, W. & SCHUTZ, G. 2004. Inactivation of the 
glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and 
ameliorates hyperglycemia in streptozotocin-induced diabetes mellitus. 
Mol Endocrinol, 18, 1346-53. 
ORAY, M., ABU SAMRA, K., EBRAHIMIADIB, N., MEESE, H. & FOSTER, C. S. 
2016. Long-term side effects of glucocorticoids. Expert Opin Drug Saf, 
15, 457-65. 
PACHOT, A., CAZALIS, M. A., VENET, F., TURREL, F., FAUDOT, C., VOIRIN, 
N., DIASPARRA, J., BOURGOIN, N., POITEVIN, F., MOUGIN, B., 
LEPAPE, A. & MONNERET, G. 2008. Decreased expression of the 
fractalkine receptor CX3CR1 on circulating monocytes as new feature of 
sepsis-induced immunosuppression. J Immunol, 180, 6421-9. 
PALM, W. 2019. Metabolic functions of macropinocytosis. Philos Trans R Soc 
Lond B Biol Sci, 374, 20180285. 
PASIEKA, A. M. & RAFACHO, A. 2016. Impact of Glucocorticoid Excess on 
Glucose Tolerance: Clinical and Preclinical Evidence. Metabolites, 6. 
PEMBERTON, P. A., STEIN, P. E., PEPYS, M. B., POTTER, J. M. & 
CARRELL, R. W. 1988. Hormone binding globulins undergo serpin 
conformational change in inflammation. Nature, 336, 257-8. 
PEMMARI, A., PAUKKERI, E. L., HAMALAINEN, M., LEPPANEN, T., 
KORHONEN, R. & MOILANEN, E. 2019. MKP-1 promotes anti-
inflammatory M(IL-4/IL-13) macrophage phenotype and mediates the 
anti-inflammatory effects of glucocorticoids. Basic Clin Pharmacol 
Toxicol, 124, 404-415. 
PEREZ-SIMON, J. A., DIEZ-CAMPELO, M., MARTINO, R., BRUNET, S., 
URBANO, A., CABALLERO, M. D., DE LEON, A., VALCARCEL, D., 
CARRERAS, E., DEL CANIZO, M. C., LOPEZ-FIDALGO, J., SIERRA, J. 
& SAN MIGUEL, J. F. 2005. Influence of the intensity of the conditioning 
regimen on the characteristics of acute and chronic graft-versus-host 
disease after allogeneic transplantation. Br J Haematol, 130, 394-403. 
PETTA, I., PEENE, I., ELEWAUT, D., VEREECKE, L. & DE BOSSCHER, K. 
2019. Risks and benefits of corticosteroids in arthritic diseases in the 
clinic. Biochem Pharmacol. 
PHAM, B. T. T., COLVIN, E. K., PHAM, N. T. H., KIM, B. J., FULLER, E. S., 
MOON, E. A., BARBEY, R., YUEN, S., RICKMAN, B. H., BRYCE, N. S., 
BICKLEY, S., TANUDJI, M., JONES, S. K., HOWELL, V. M. & 
HAWKETT, B. S. 2018. Biodistribution and Clearance of Stable 
Superparamagnetic Maghemite Iron Oxide Nanoparticles in Mice 
Following Intraperitoneal Administration. Int J Mol Sci, 19. 
PIEMONTI, L., MONTI, P., ALLAVENA, P., LEONE, B. E., CAPUTO, A. & DI 
CARLO, V. 1999a. Glucocorticoids increase the endocytic activity of 
human dendritic cells. Int Immunol, 11, 1519-26. 
PIEMONTI, L., MONTI, P., ALLAVENA, P., SIRONI, M., SOLDINI, L., LEONE, 
B. E., SOCCI, C. & DI CARLO, V. 1999b. Glucocorticoids affect human 
dendritic cell differentiation and maturation. J Immunol, 162, 6473-81. 
POBER, J. S. 1987. Effects of tumour necrosis factor and related cytokines on 
vascular endothelial cells. Ciba Found Symp, 131, 170-84. 
POß, M., ; TOWER, R, J; NAPP, J,; APPOLD, L, C,; LAMMERS, T,; ALVES, F,; 




[GdO]+[ICG]- Nanoparticles for Optical, Photoacousticm and Magnetic 
Resonance Imaging. Chemistry of Materials, 29, 3547-3554. 
PRZEPIORKA, D., KERNAN, N. A., IPPOLITI, C., PAPADOPOULOS, E. B., 
GIRALT, S., KHOURI, I., LU, J. G., GAJEWSKI, J., DURETT, A., 
CLEARY, K., CHAMPLIN, R., ANDERSSON, B. S. & LIGHT, S. 2000. 
Daclizumab, a humanized anti-interleukin-2 receptor alpha chain 
antibody, for treatment of acute graft-versus-host disease. Blood, 95, 83-
9. 
PRZEPIORKA, D., WEISDORF, D., MARTIN, P., KLINGEMANN, H. G., 
BEATTY, P., HOWS, J. & THOMAS, E. D. 1995. 1994 Consensus 
Conference on Acute GVHD Grading. Bone Marrow Transplant, 15, 825-
8. 
QIN, W., PAN, J., QIN, Y., LEE, D. N., BAUMAN, W. A. & CARDOZO, C. 2014. 
Identification of functional glucocorticoid response elements in the mouse 
FoxO1 promoter. Biochem Biophys Res Commun, 450, 979-83. 
QUAN, L., ZHANG, Y., DUSAD, A., REN, K., PURDUE, P. E., GOLDRING, S. 
R. & WANG, D. 2016. The Evaluation of the Therapeutic Efficacy and 
Side Effects of a Macromolecular Dexamethasone Prodrug in the 
Collagen-Induced Arthritis Mouse Model. Pharm Res, 33, 186-93. 
QUAN, L. D., PURDUE, P. E., LIU, X. M., BOSKA, M. D., LELE, S. M., THIELE, 
G. M., MIKULS, T. R., DOU, H., GOLDRING, S. R. & WANG, D. 2010. 
Development of a macromolecular prodrug for the treatment of 
inflammatory arthritis: mechanisms involved in arthrotropism and 
sustained therapeutic efficacy. Arthritis Res Ther, 12, R170. 
RAMIREZ, F., FOWELL, D. J., PUKLAVEC, M., SIMMONDS, S. & MASON, D. 
1996. Glucocorticoids promote a TH2 cytokine response by CD4+ T cells 
in vitro. J Immunol, 156, 2406-12. 
RATANATHARATHORN, V., AYASH, L., LAZARUS, H. M., FU, J. & UBERTI, J. 
P. 2001. Chronic graft-versus-host disease: clinical manifestation and 
therapy. Bone Marrow Transplant, 28, 121-9. 
RAUCH, A., SEITZ, S., BASCHANT, U., SCHILLING, A. F., ILLING, A., 
STRIDE, B., KIRILOV, M., MANDIC, V., TAKACZ, A., SCHMIDT-
ULLRICH, R., OSTERMAY, S., SCHINKE, T., SPANBROEK, R., ZAISS, 
M. M., ANGEL, P. E., LERNER, U. H., DAVID, J. P., REICHARDT, H. M., 
AMLING, M., SCHUTZ, G. & TUCKERMANN, J. P. 2010. 
Glucocorticoids suppress bone formation by attenuating osteoblast 
differentiation via the monomeric glucocorticoid receptor. Cell Metab, 11, 
517-31. 
REA, D., VAN KOOTEN, C., VAN MEIJGAARDEN, K. E., OTTENHOFF, T. H., 
MELIEF, C. J. & OFFRINGA, R. 2000. Glucocorticoids transform CD40-
triggering of dendritic cells into an alternative activation pathway resulting 
in antigen-presenting cells that secrete IL-10. Blood, 95, 3162-7. 
REICHARDT, H. M., KAESTNER, K. H., TUCKERMANN, J., KRETZ, O., 
WESSELY, O., BOCK, R., GASS, P., SCHMID, W., HERRLICH, P., 
ANGEL, P. & SCHUTZ, G. 1998. DNA binding of the glucocorticoid 
receptor is not essential for survival. Cell, 93, 531-41. 
REICHARDT, H. M. & SCHUTZ, G. 1998. Glucocorticoid signalling--multiple 




RHEN, T. & CIDLOWSKI, J. A. 2005. Antiinflammatory action of 
glucocorticoids--new mechanisms for old drugs. N Engl J Med, 353, 
1711-23. 
RISO, E. M., AHTIKOSKI, A., ALEV, K., KAASIK, P., PEHME, A. & SEENE, T. 
2008. Relationship between extracellular matrix, contractile apparatus, 
muscle mass and strength in case of glucocorticoid myopathy. J Steroid 
Biochem Mol Biol, 108, 117-20. 
ROSZER, T. 2015. Understanding the Mysterious M2 Macrophage through 
Activation Markers and Effector Mechanisms. Mediators Inflamm, 2015, 
816460. 
ROWE, V., BANOVIC, T., MACDONALD, K. P., KUNS, R., DON, A. L., 
MORRIS, E. S., BURMAN, A. C., BOFINGER, H. M., CLOUSTON, A. D. 
& HILL, G. R. 2006. Host B cells produce IL-10 following TBI and 
attenuate acute GVHD after allogeneic bone marrow transplantation. 
Blood, 108, 2485-92. 
ROZKOVA, D., HORVATH, R., BARTUNKOVA, J. & SPISEK, R. 2006. 
Glucocorticoids severely impair differentiation and antigen presenting 
function of dendritic cells despite upregulation of Toll-like receptors. Clin 
Immunol, 120, 260-71. 
SALOMAO, M., DORRITIE, K., MAPARA, M. Y. & SEPULVEDA, A. 2016. 
Histopathology of Graft-vs-Host Disease of Gastrointestinal Tract and 
Liver: An Update. Am J Clin Pathol, 145, 591-603. 
SATO, A. Y., RICHARDSON, D., CREGOR, M., DAVIS, H. M., AU, E. D., 
MCANDREWS, K., ZIMMERS, T. A., ORGAN, J. M., PEACOCK, M., 
PLOTKIN, L. I. & BELLIDO, T. 2017. Glucocorticoids Induce Bone and 
Muscle Atrophy by Tissue-Specific Mechanisms Upstream of E3 
Ubiquitin Ligases. Endocrinology, 158, 664-677. 
SCHACKE, H., DOCKE, W. D. & ASADULLAH, K. 2002. Mechanisms involved 
in the side effects of glucocorticoids. Pharmacol Ther, 96, 23-43. 
SCHAKMAN, O., GILSON, H. & THISSEN, J. P. 2008. Mechanisms of 
glucocorticoid-induced myopathy. J Endocrinol, 197, 1-10. 
SCHAKMAN, O., KALISTA, S., BARBE, C., LOUMAYE, A. & THISSEN, J. P. 
2013. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell 
Biol, 45, 2163-72. 
SCHMIDT, J., METSELAAR, J. M., WAUBEN, M. H., TOYKA, K. V., STORM, 
G. & GOLD, R. 2003. Drug targeting by long-circulating liposomal 
glucocorticosteroids increases therapeutic efficacy in a model of multiple 
sclerosis. Brain, 126, 1895-904. 
SCHROEDER, M. A. & DIPERSIO, J. F. 2011. Mouse models of graft-versus-
host disease: advances and limitations. Dis Model Mech, 4, 318-33. 
SCHWEINGRUBER, N., HAINE, A., TIEDE, K., KARABINSKAYA, A., VAN 
DEN BRANDT, J., WUST, S., METSELAAR, J. M., GOLD, R., 
TUCKERMANN, J. P., REICHARDT, H. M. & LUHDER, F. 2011. 
Liposomal encapsulation of glucocorticoids alters their mode of action in 
the treatment of experimental autoimmune encephalomyelitis. J 
Immunol, 187, 4310-8. 
SERCOMBE, L., VEERATI, T., MOHEIMANI, F., WU, S. Y., SOOD, A. K. & 
HUA, S. 2015. Advances and Challenges of Liposome Assisted Drug 




SHANG, L., NIENHAUS, K. & NIENHAUS, G. U. 2014. Engineered 
nanoparticles interacting with cells: size matters. J Nanobiotechnology, 
12, 5. 
SHETTY, S., KAPOOR, N., BONDU, J. D., THOMAS, N. & PAUL, T. V. 2016. 
Bone turnover markers: Emerging tool in the management of 
osteoporosis. Indian J Endocrinol Metab, 20, 846-852. 
SHIN, H. J., BAKER, J., LEVESON-GOWER, D. B., SMITH, A. T., SEGA, E. I. 
& NEGRIN, R. S. 2011. Rapamycin and IL-2 reduce lethal acute graft-
versus-host disease associated with increased expansion of donor type 
CD4+CD25+Foxp3+ regulatory T cells. Blood, 118, 2342-50. 
SHLOMCHIK, W. D. 2007. Graft-versus-host disease. Nat Rev Immunol, 7, 
340-52. 
SHLOMCHIK, W. D., COUZENS, M. S., TANG, C. B., MCNIFF, J., ROBERT, 
M. E., LIU, J., SHLOMCHIK, M. J. & EMERSON, S. G. 1999. Prevention 
of graft versus host disease by inactivation of host antigen-presenting 
cells. Science, 285, 412-5. 
SIMONSEN, M. 1957. The impact on the developing embryo and newborn 
animal of adult homologous cells. Acta Pathol Microbiol Scand, 40, 480-
500. 
SLEIGHT, B. S., CHAN, K. W., BRAUN, T. M., SERRANO, A. & GILMAN, A. L. 
2007. Infliximab for GVHD therapy in children. Bone Marrow Transplant, 
40, 473-80. 
SOCIE, G. & BLAZAR, B. R. 2009. Acute graft-versus-host disease: from the 
bench to the bedside. Blood, 114, 4327-36. 
SPRENT, J., SCHAEFER, M., GAO, E. K. & KORNGOLD, R. 1988. Role of T 
cell subsets in lethal graft-versus-host disease (GVHD) directed to class I 
versus class II H-2 differences. I. L3T4+ cells can either augment or 
retard GVHD elicited by Lyt-2+ cells in class I different hosts. J Exp Med, 
167, 556-69. 
STAHN, C. & BUTTGEREIT, F. 2008. Genomic and nongenomic effects of 
glucocorticoids. Nat Clin Pract Rheumatol, 4, 525-33. 
STEINMAN, R. M., BRODIE, S. E. & COHN, Z. A. 1976. Membrane flow during 
pinocytosis. A stereologic analysis. J Cell Biol, 68, 665-87. 
STORB, R., DEEG, H. J., WHITEHEAD, J., APPELBAUM, F., BEATTY, P., 
BENSINGER, W., BUCKNER, C. D., CLIFT, R., DONEY, K., 
FAREWELL, V. & ET AL. 1986. Methotrexate and cyclosporine 
compared with cyclosporine alone for prophylaxis of acute graft versus 
host disease after marrow transplantation for leukemia. N Engl J Med, 
314, 729-35. 
STREHL, C. & BUTTGEREIT, F. 2013. Optimized glucocorticoid therapy: 
teaching old drugs new tricks. Mol Cell Endocrinol, 380, 32-40. 
STRONG RODRIGUES, K., OLIVEIRA-RIBEIRO, C., DE ABREU FIUZA 
GOMES, S. & KNOBLER, R. 2018. Cutaneous Graft-Versus-Host 
Disease: Diagnosis and Treatment. Am J Clin Dermatol, 19, 33-50. 
SUMMERMATTER, S., BOUZAN, A., PIERREL, E., MELLY, S., STAUFFER, 
D., GUTZWILLER, S., NOLIN, E., DORNELAS, C., FRYER, C., 
LEIGHTON-DAVIES, J., GLASS, D. J. & FOURNIER, B. 2017. Blockade 
of Metallothioneins 1 and 2 Increases Skeletal Muscle Mass and 




SURJIT, M., GANTI, K. P., MUKHERJI, A., YE, T., HUA, G., METZGER, D., LI, 
M. & CHAMBON, P. 2011. Widespread negative response elements 
mediate direct repression by agonist-liganded glucocorticoid receptor. 
Cell, 145, 224-41. 
SVENNILSON, J. 2005. Novel approaches in GVHD therapy. Bone Marrow 
Transplant, 35 Suppl 1, S65-7. 
SYMINGTON, F. W., SYMINGTON, B. E., LIU, P. Y., VIGUET, H., 
SANTHANAM, U. & SEHGAL, P. B. 1992. The relationship of serum IL-6 
levels to acute graft-versus-host disease and hepatorenal disease after 
human bone marrow transplantation. Transplantation, 54, 457-62. 
SZYSKA, M. & NA, I. K. 2016. Bone Marrow GvHD after Allogeneic 
Hematopoietic Stem Cell Transplantation. Front Immunol, 7, 118. 
TALABER, G., JONDAL, M. & OKRET, S. 2013. Extra-adrenal glucocorticoid 
synthesis: immune regulation and aspects on local organ homeostasis. 
Mol Cell Endocrinol, 380, 89-98. 
TAWARA, I., KOYAMA, M., LIU, C., TOUBAI, T., THOMAS, D., EVERS, R., 
CHOCKLEY, P., NIEVES, E., SUN, Y., LOWLER, K. P., MALTER, C., 
NISHIMOTO, N., HILL, G. R. & REDDY, P. 2011. Interleukin-6 
modulates graft-versus-host responses after experimental allogeneic 
bone marrow transplantation. Clin Cancer Res, 17, 77-88. 
TERWEY, T. H., KIM, T. D., KOCHMAN, A. A., HUBBARD, V. M., LU, S., 
ZAKRZEWSKI, J. L., RAMIREZ-MONTAGUT, T., ENG, J. M., 
MURIGLAN, S. J., HELLER, G., MURPHY, G. F., LIU, C., BUDAK-
ALPDOGAN, T., ALPDOGAN, O. & VAN DEN BRINK, M. R. 2005. 
CCR2 is required for CD8-induced graft-versus-host disease. Blood, 106, 
3322-30. 
TESHIMA, T., ORDEMANN, R., REDDY, P., GAGIN, S., LIU, C., COOKE, K. R. 
& FERRARA, J. L. 2002. Acute graft-versus-host disease does not 
require alloantigen expression on host epithelium. Nat Med, 8, 575-81. 
THEISS-SUENNEMANN, J., JORSS, K., MESSMANN, J. J., REICHARDT, S. 
D., MONTES-COBOS, E., LUHDER, F., TUCKERMANN, J. P., H, A. W., 
DRESSEL, R., GRONE, H. J., STRAUSS, G. & REICHARDT, H. M. 
2015. Glucocorticoids attenuate acute graft-versus-host disease by 
suppressing the cytotoxic capacity of CD8(+) T cells. J Pathol, 235, 646-
55. 
TUCKERMANN, J. P., KLEIMAN, A., MCPHERSON, K. G. & REICHARDT, H. 
M. 2005. Molecular mechanisms of glucocorticoids in the control of 
inflammation and lymphocyte apoptosis. Crit Rev Clin Lab Sci, 42, 71-
104. 
TUCKERMANN, J. P., KLEIMAN, A., MORIGGL, R., SPANBROEK, R., 
NEUMANN, A., ILLING, A., CLAUSEN, B. E., STRIDE, B., FORSTER, I., 
HABENICHT, A. J., REICHARDT, H. M., TRONCHE, F., SCHMID, W. & 
SCHUTZ, G. 2007. Macrophages and neutrophils are the targets for 
immune suppression by glucocorticoids in contact allergy. J Clin Invest, 
117, 1381-90. 
UNGER, W. W., LABAN, S., KLEIJWEGT, F. S., VAN DER SLIK, A. R. & 
ROEP, B. O. 2009. Induction of Treg by monocyte-derived DC 
modulated by vitamin D3 or dexamethasone: differential role for PD-L1. 




VAN DIJK, A. M., KESSLER, F. L., STADHOUDERS-KEET, S. A., 
VERDONCK, L. F., DE GAST, G. C. & OTTEN, H. G. 1999. Selective 
depletion of major and minor histocompatibility antigen reactive T cells: 
towards prevention of acute graft-versus-host disease. Br J Haematol, 
107, 169-75. 
VANDER KOOI, B. T., ONUMA, H., OESER, J. K., SVITEK, C. A., ALLEN, S. 
R., VANDER KOOI, C. W., CHAZIN, W. J. & O'BRIEN, R. M. 2005. The 
glucose-6-phosphatase catalytic subunit gene promoter contains both 
positive and negative glucocorticoid response elements. Mol Endocrinol, 
19, 3001-22. 
VANDEVYVER, S., DEJAGER, L., TUCKERMANN, J. & LIBERT, C. 2013. New 
insights into the anti-inflammatory mechanisms of glucocorticoids: an 
emerging role for glucocorticoid-receptor-mediated transactivation. 
Endocrinology, 154, 993-1007. 
VANDEVYVER, S., DEJAGER, L., VAN BOGAERT, T., KLEYMAN, A., LIU, Y., 
TUCKERMANN, J. & LIBERT, C. 2012. Glucocorticoid receptor 
dimerization induces MKP1 to protect against TNF-induced inflammation. 
J Clin Invest, 122, 2130-40. 
VANDEWALLE, J., LUYPAERT, A., DE BOSSCHER, K. & LIBERT, C. 2018. 
Therapeutic Mechanisms of Glucocorticoids. Trends Endocrinol Metab, 
29, 42-54. 
VERCAUTEREN, D., VANDENBROUCKE, R. E., JONES, A. T., REJMAN, J., 
DEMEESTER, J., DE SMEDT, S. C., SANDERS, N. N. & 
BRAECKMANS, K. 2010. The use of inhibitors to study endocytic 
pathways of gene carriers: optimization and pitfalls. Mol Ther, 18, 561-9. 
VERMEER, H., HENDRIKS-STEGEMAN, B. I., VAN DER BURG, B., VAN 
BUUL-OFFERS, S. C. & JANSEN, M. 2003. Glucocorticoid-induced 
increase in lymphocytic FKBP51 messenger ribonucleic acid expression: 
a potential marker for glucocorticoid sensitivity, potency, and 
bioavailability. J Clin Endocrinol Metab, 88, 277-84. 
VETTORAZZI, S., BODE, C., DEJAGER, L., FRAPPART, L., SHELEST, E., 
KLASSEN, C., TASDOGAN, A., REICHARDT, H. M., LIBERT, C., 
SCHNEIDER, M., WEIH, F., HENRIETTE UHLENHAUT, N., DAVID, J. 
P., GRALER, M., KLEIMAN, A. & TUCKERMANN, J. P. 2015. 
Glucocorticoids limit acute lung inflammation in concert with inflammatory 
stimuli by induction of SphK1. Nat Commun, 6, 7796. 
VIA, C. S. & FINKELMAN, F. D. 1993. Critical role of interleukin-2 in the 
development of acute graft-versus-host disease. Int Immunol, 5, 565-72. 
VIZZARDELLI, C., PAVELKA, N., LUCHINI, A., ZANONI, I., BENDICKSON, L., 
PELIZZOLA, M., BERETTA, O., FOTI, M., GRANUCCI, F., NILSEN-
HAMILTON, M. & RICCIARDI-CASTAGNOLI, P. 2006. Effects of 
dexamethazone on LPS-induced activationand migration of mouse 
dendritic cells revealed by a genome-wide transcriptional analysis. Eur J 
Immunol, 36, 1504-15. 
WADDELL, D. S., BAEHR, L. M., VAN DEN BRANDT, J., JOHNSEN, S. A., 
REICHARDT, H. M., FURLOW, J. D. & BODINE, S. C. 2008. The 
glucocorticoid receptor and FOXO1 synergistically activate the skeletal 
muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol 




WAGNER, D. H., JR., HAGMAN, J., LINSLEY, P. S., HODSDON, W., FREED, 
J. H. & NEWELL, M. K. 1996. Rescue of thymocytes from glucocorticoid-
induced cell death mediated by CD28/CTLA-4 costimulatory interactions 
with B7-1/B7-2. J Exp Med, 184, 1631-8. 
WAGNER, J. E., THOMPSON, J. S., CARTER, S. L., KERNAN, N. A. & 
UNRELATED DONOR MARROW TRANSPLANTATION, T. 2005. Effect 
of graft-versus-host disease prophylaxis on 3-year disease-free survival 
in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a 
multi-centre, randomised phase II-III trial. Lancet, 366, 733-41. 
WANG, D., MULLER, N., MCPHERSON, K. G. & REICHARDT, H. M. 2006. 
Glucocorticoids engage different signal transduction pathways to induce 
apoptosis in thymocytes and mature T cells. J Immunol, 176, 1695-702. 
WANG, H., ASAVAROENGCHAI, W., YEAP, B. Y., WANG, M. G., WANG, S., 
SYKES, M. & YANG, Y. G. 2009. Paradoxical effects of IFN-gamma in 
graft-versus-host disease reflect promotion of lymphohematopoietic graft-
versus-host reactions and inhibition of epithelial tissue injury. Blood, 113, 
3612-9. 
WANG, H. & YANG, Y. G. 2014. The complex and central role of interferon-
gamma in graft-versus-host disease and graft-versus-tumor activity. 
Immunol Rev, 258, 30-44. 
WATSON, M. L., BAEHR, L. M., REICHARDT, H. M., TUCKERMANN, J. P., 
BODINE, S. C. & FURLOW, J. D. 2012. A cell-autonomous role for the 
glucocorticoid receptor in skeletal muscle atrophy induced by systemic 
glucocorticoid exposure. Am J Physiol Endocrinol Metab, 302, E1210-20. 
WEISDORF, D., HAAKE, R., BLAZAR, B., MILLER, W., MCGLAVE, P., 
RAMSAY, N., KERSEY, J. & FILIPOVICH, A. 1990. Treatment of 
moderate/severe acute graft-versus-host disease after allogeneic bone 
marrow transplantation: an analysis of clinical risk features and outcome. 
Blood, 75, 1024-30. 
WEISSLEDER, R., NAHRENDORF, M. & PITTET, M. J. 2014. Imaging 
macrophages with nanoparticles. Nat Mater, 13, 125-38. 
WESTON, L. E., GECZY, A. F. & BRISCOE, H. 2006. Production of IL-10 by 
alloreactive sibling donor cells and its influence on the development of 
acute GVHD. Bone Marrow Transplant, 37, 207-12. 
WILLIAMSON, E., GARSIDE, P., BRADLEY, J. A., MORE, I. A. & MOWAT, A. 
M. 1997. Neutralizing IL-12 during induction of murine acute graft-versus-
host disease polarizes the cytokine profile toward a Th2-type alloimmune 
response and confers long term protection from disease. J Immunol, 159, 
1208-15. 
XIE, Y., WU, M., SONG, R., MA, J., SHI, Y., QIN, W. & JIN, Y. 2009. A 
glucocorticoid amplifies IL-2-induced selective expansion of 
CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses 
graft-versus-host disease after allogeneic lymphocyte transplantation. 
Acta Biochim Biophys Sin (Shanghai), 41, 781-91. 
YANG, J., ZHANG, L., YU, C., YANG, X. F. & WANG, H. 2014. Monocyte and 
macrophage differentiation: circulation inflammatory monocyte as 
biomarker for inflammatory diseases. Biomark Res, 2, 1. 
YANG, Y. G., DEY, B. R., SERGIO, J. J., PEARSON, D. A. & SYKES, M. 1998. 
Donor-derived interferon gamma is required for inhibition of acute graft-




YE, M. & SHI, B. 2018. Zirconia Nanoparticles-Induced Toxic Effects in 
Osteoblast-Like 3T3-E1 Cells. Nanoscale Res Lett, 13, 353. 
YI, T., ZHAO, D., LIN, C. L., ZHANG, C., CHEN, Y., TODOROV, I., LEBON, T., 
KANDEEL, F., FORMAN, S. & ZENG, D. 2008. Absence of donor Th17 
leads to augmented Th1 differentiation and exacerbated acute graft-
versus-host disease. Blood, 112, 2101-10. 
YU, Y., WANG, D., LIU, C., KAOSAARD, K., SEMPLE, K., ANASETTI, C. & YU, 
X. Z. 2011. Prevention of GVHD while sparing GVL effect by targeting 
Th1 and Th17 transcription factor T-bet and RORgammat in mice. Blood, 
118, 5011-20. 
ZEISER, R. & BLAZAR, B. R. 2016. Preclinical models of acute and chronic 
graft-versus-host disease: how predictive are they for a successful 
clinical translation? Blood, 127, 3117-26. 
ZEISER, R. & BLAZAR, B. R. 2017. Acute Graft-versus-Host Disease - Biologic 
Process, Prevention, and Therapy. N Engl J Med, 377, 2167-2179. 
ZEISER, R., SOCIE, G. & BLAZAR, B. R. 2016. Pathogenesis of acute graft-
versus-host disease: from intestinal microbiota alterations to donor T cell 
activation. Br J Haematol, 175, 191-207. 
ZHANG, L., YU, J. & WEI, W. 2018. Advance in Targeted Immunotherapy for 
Graft-Versus-Host Disease. Front Immunol, 9, 1087. 
ZHANG, Y., LOUBOUTIN, J. P., ZHU, J., RIVERA, A. J. & EMERSON, S. G. 
2002a. Preterminal host dendritic cells in irradiated mice prime CD8+ T 
cell-mediated acute graft-versus-host disease. J Clin Invest, 109, 1335-
44. 
ZHANG, Y., SHLOMCHIK, W. D., JOE, G., LOUBOUTIN, J. P., ZHU, J., 
RIVERA, A., GIANNOLA, D. & EMERSON, S. G. 2002b. APCs in the 
liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic 
graft-versus-host disease. J Immunol, 169, 7111-8. 
ZUBIAGA, A. M., MUNOZ, E. & HUBER, B. T. 1992. IL-4 and IL-2 selectively 
rescue Th cell subsets from glucocorticoid-induced apoptosis. J 







6.1 Acknowledgements  
At this point of my thesis, I would to give my thanks to many people who 
distributed to this work in different ways. 
 
At first I sincerely dedicate my thanks to my supervisor Prof. Dr. Holger 
Reichardt for his everlasting and kind openness for questions and discussions. I 
appreciated that he gladly shared his outstanding analytical scientific skills with 
me as well as for providing helpful suggestions throughout the time of my PhD 
from all I learned much.  
 
Next, I would like to thank the members of my thesis committee Prof. Dr. Lutz 
Walter and Prof. Dr. Matthias Dobbelstein for their interest in my project and 
encouraging discussions during my thesis committee meetings. 
 
Furthermore, I am thankful for the successful, pleasant and honest collaboration 
with Dr. Hanibal Bohnenberger, Jennifer Appelhans, Prof. Dr. Susann Boretius, 
Dr. Amir Moussavi, Kristin Kötz, Prof. Dr. Jan Tuckermann, Yasmine Hachemi 
and Dr. Michael Engelke. I would also like to give my thanks to our collaborators 
in the Institute for Technology in Karlsruhe for providing us with IOH-NPs, which 
have been partially modified for our needs. 
 
Moreover, I was very grateful for the enjoyable and helpful atmosphere in our 
lab/ office created by the cordial current and former lab members of our 
research group. I would also like to express my special thanks to those who 
assisted me during the last months of my PhD as well as various students I 
supervised with pleasure, especially to those who distributed to this work, in 
particular Katrin Ciupka, Bhakti Irene Seth and Lara Gentemann.   
 
Finally, I very much thank my family for supporting me in so many ways at any 





BAAKE, T., JORSS, K., SUENNEMANN, J., ROSSMANN, L., 
BOHNENBERGER, H., TUCKERMANN, J. P., REICHARDT, H. M., FISCHER, 
H. J. & REICHARDT, S. D. 2018. The glucocorticoid receptor in recipient cells 
keeps cytokine secretion in acute graft-versus-host-disease at bay. Oncotarget, 
9, 15437-15450. 
 
LI, H., KAISER, T. K., BORSCHIWER, M., BOHNENBERGER, H., LÜHDER, 
F., WALTER, L., DRESSEL, R., MEIJSING, S. H. & REICHARDT, H. M. 
submitted. Glucocorticoid resistance of allogeneic T cells alters the gene 
expression profile in the inflamed small intestine of mice suffering from acute 
graft-versus-host disease. J. Steroid Biochem. Mol. Biol. 
 
KAISER, T. K., KHORENKO, M., MOUSSAVI, A., ENGELKE, M., BORETIUS, 
S., FELDMANN, C. & REICHARDT, H. M. submitted. Highly selective organ 
distribution and cellular uptake of inorganic-organic hybrid nanoparticles 
customized for the targeted delivery of glucocorticoids. Journal of Controlled 
Release. 
